

# CITATION REPORT

List of articles citing

Multidrug resistance in cancer: role of ATP-dependent transp

DOI: 10.1038/nrc706

Nature Reviews Cancer, 2002, 2, 48-58.

**Source:** <https://exaly.com/paper-pdf/34733414/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2267	Plastid Genes Encoding the Transcription/Translation Apparatus Are Differentially Transcribed Early in Barley ( <i>Hordeum vulgare</i> ) Chloroplast Development (Evidence for Selective Stabilization of psbA mRNA). <b>1993</b> , 101, 781-791		148
2266	Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. <b>1994</b> , 20, 731		0
2265	Requirement of the N-terminal extension for vacuolar trafficking and transport activity of yeast Ycf1p, an ATP-binding cassette transporter. <b>2002</b> , 13, 4443-55		53
2264	MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. <b>2002</b> , 99, 6997-7002		104
2263	Proteolytic Cleavage of the Linker Region of the Human P-glycoprotein Modulates Its ATPase Function. <b>2002</b> , 277, 29417-23		15
2262	The emergence of resistance to targeted cancer therapeutics. <b>2002</b> , 3, 603-23		21
2261	Overcoming multidrug resistance in taxane chemotherapy. <b>2002</b> , 40, 918-25		63
2260	Evidence for the locations of distinct steroid and Vinca alkaloid interaction domains within the murine mdr1b P-glycoprotein. <b>2002</b> , 62, 1238-48		14
2259	Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. <b>2002</b> , 368, 325-32		28
2258	Multidrug Resistance I: P-Glycoprotein. <b>2002</b> , 247-254		
2257	Gene targets of antisense therapies in breast cancer. <b>2002</b> , 6, 375-85		15
2256	Physical state changes of membrane lipids in human lung adenocarcinoma A(549) cells and their resistance to cisplatin. <b>2002</b> , 34, 1248-55		29
2255	Molecular imaging of gene expression and protein function in vivo with PET and SPECT. <b>2002</b> , 16, 336-51		113
2254	Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. <b>2002</b> , 9, 579-86		42
2253	Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. <i>Nature Reviews Cancer</i> , <b>2002</b> , 2, 431-41	31.3	63
2252	Similarity based SAR (SIBAR) as tool for early ADME profiling. <b>2002</b> , 16, 785-93		27
2251	Effect of valsopodar on the pharmacokinetics of unbound paclitaxel. <b>2003</b> , 21, 291-8		9

2250	Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization. <b>2003</b> , 82, 125-41	29
2249	Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human intestines. <b>2003</b> , 20, 3-15	42
2248	Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. <b>2003</b> , 20, 351-9	77
2247	Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. <b>2003</b> , 17, 103-14	166
2246	Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. <b>2003</b> , 30, 879-87	27
2245	Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes. <b>2003</b> , 30, 1024-31	21
2244	Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach. <b>2003</b> , 8, 356-63	40
2243	Multidrug resistance-1 (MDR-1) in autoimmune disorders III: increased P-glycoprotein activity in lymphocytes from immune thrombocytopenic purpura patients. <b>2003</b> , 31, 483-7	20
2242	Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. <b>2003</b> , 66, 2381-95	27
2241	Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix Peucedani. <b>2003</b> , 473, 9-17	164
2240	In silico screening with benzofurane- and benzopyrane-type MDR-modulators. <b>2003</b> , 58, 185-91	12
2239	Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. <b>2003</b> , 55, 133-50	103
2238	Xenobiotic transporter expression and function in the human mammary gland. <b>2003</b> , 55, 653-65	44
2237	A new science-business paradigm in anticancer drug development. <b>2003</b> , 21, 103-6	27
2236	Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells. <b>2003</b> , 103, 752-8	10
2235	Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. <b>2003</b> , 106, 108-15	61
2234	Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. <b>2003</b> , 107, 721-8	88
2233	Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype. <b>2003</b> , 27, 413-23	20

2232	Overview of the clinical efficacy of investigational anticancer drugs. <b>2003</b> , 253, 46-75	67
2231	Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. <b>2003</b> , 1, 105-12	24
2230	Quantitative real-time reverse transcription-polymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiation. <b>2003</b> , 121, 390-8	42
2229	Side population keratinocytes resembling bone marrow side population stem cells are distinct from label-retaining keratinocyte stem cells. <b>2003</b> , 121, 1095-103	85
2228	Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. <b>2003</b> , 4, 338-45	35
2227	Importance of P-glycoprotein for drug disposition in humans. <b>2003</b> , 33 Suppl 2, 6-9	108
2226	DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. <b>2003</b> , 94, 459-66	71
2225	Cancer gene therapy: an awkward adolescence. <b>2003</b> , 10, 501-8	57
2224	Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. <b>2003</b> , 22, 7396-402	164
2223	P-glycoprotein: from genomics to mechanism. <b>2003</b> , 22, 7468-85	847
2222	Pharmacogenetics goes genomic. <b>2003</b> , 4, 937-47	249
2221	P-glycoprotein in autoimmune diseases. <b>2003</b> , 3, 188-188	
2220	Communication between the nucleotide binding domains of P-glycoprotein occurs via conformational changes that involve residue 508. <b>2003</b> , 42, 7780-9	12
2219	Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. <b>2003</b> , 348, 1442-8	611
2218	Clinical relevance of P-glycoprotein in drug therapy. <b>2003</b> , 35, 417-54	153
2217	ABC-transporters: implications on drug resistance from microorganisms to human cancers. <b>2003</b> , 22, 188-99	201
2216	Screening for effectors that modify multidrug resistance in yeast. <b>2003</b> , 22, 284-90	8
2215	Affinity labeling of highly hydrophobic integral membrane proteins for proteome-wide analysis. <b>2003</b> , 2, 153-61	72

2214	Analysis of catalytic carboxylate mutants E552Q and E1197Q suggests asymmetric ATP hydrolysis by the two nucleotide-binding domains of P-glycoprotein. <b>2003</b> , 42, 12875-85	31
2213	Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. <b>2003</b> , 42, 9989-10000	33
2212	Classification analysis of P-glycoprotein substrate specificity. <b>2003</b> , 11, 391-406	204
2211	Crystal structures of the ATPase subunit of the glucose ABC transporter from <i>Sulfolobus solfataricus</i> : nucleotide-free and nucleotide-bound conformations. <b>2003</b> , 330, 343-58	137
2210	Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). <b>2003</b> , 545, 144-50	147
2209	Mechanisms of anticancer drug resistance. <b>2003</b> , 33, 651-67	29
2208	Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. <b>2003</b> , 29, 31-44	37
2207	Drug resistance reversal--are we getting closer?. <b>2003</b> , 39, 2450-61	116
2206	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. <b>2003</b> , 6, 71-84	181
2205	Targeting cancer cells by exploiting their resistance. <b>2003</b> , 9, 307-12	46
2204	Canalicular multispecific organic anion transporter ABCC2. <b>2003</b> , 263-289	2
2203	Drug delivery systems for cancer drugs. <b>2003</b> , 13, 1801-1807	7
2202	Structure of the substrate binding pocket of the multidrug transporter EmrE: site-directed spin labeling of transmembrane segment 1. <b>2003</b> , 42, 6099-105	42
2201	Anticancer Agents from Unique Natural Products Sources. <b>2003</b> , 41, 15-38	18
2200	The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. <b>2003</b> , 3, 291-301	26
2199	Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. <b>2003</b> , 32, 325-36	219
2198	Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. <b>2003</b> , 32, 381-387	
2197	Regulation of multidrug resistance in cancer cells by hyaluronan. <b>2003</b> , 278, 25285-8	176

2196	Chemoembolization in the management of liver tumors. <b>2003</b> , 8, 425-37	85
2195	The distribution of Abcc6 in normal mouse tissues suggests multiple functions for this ABC transporter. <b>2003</b> , 51, 887-902	295
2194	The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models. <b>2003</b> , 89, 1581-9	43
2193	P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. <b>2003</b> , 278, 10344-52	102
2192	Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. <b>2003</b> , 278, 39706-10	146
2191	Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. <b>2003</b> , 22, 1117	3
2190	Molecular analysis of therapy resistance in gastric cancer. <b>2003</b> , 21, 326-38	24
2189	Is CFTR dysfunction in cystic fibrosis compensated by MRPs?. <b>2003</b> , 54, 625-6	2
2188	Pharmacogenomics in the treatment of epilepsy. <b>2003</b> , 4, 747-51	8
2187	Mechanisms of antiepileptic drug resistance. <b>2003</b> , 16, 197-201	122
2186	Assessment of the P-glycoprotein expression by 99mTc-MIBI bone marrow imaging in patients with untreated leukaemia. <b>2003</b> , 24, 397-402	10
2185	Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. <b>2003</b> , 10, 159-65	750
2184	Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. <b>2003</b> , 101, 4589-97	63
2183	Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. <b>2003</b> , 102, 1202-10	75
2182	Renal Cancer Treatment: A Review of the Literature. <b>2003</b> , 89, 476-484	13
2181	The Role of Hyaluronan in Cancer. <b>2004</b> , 285-305	1
2180	. <b>2004</b> ,	7
2179	Identification of Cytoskeletal [14C]Carboplatin-Binding Proteins Reveals Reduced Expression and Disorganization of Actin and Filamin in Cisplatin-Resistant Cell Lines. <b>2004</b> , 66, 789-793	27

2178	Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. <b>2004</b> , 4, 1-17	79
2177	Novel approaches for targeted cancer therapy. <b>2004</b> , 4, 313-26	71
2176	Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. <b>2004</b> , 10, 647-57	71
2175	Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. <b>2004</b> , 4, 1385-98	74
2174	Principles of Molecular Oncology. <b>2004</b> ,	6
2173	Functional imaging of multidrug resistant phenotype by <sup>99m</sup> Tc-MIBI scan in patients with multiple myeloma. <b>2004</b> , 19, 165-70	20
2172	Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. <b>2004</b> , 64, 8987-93	190
2171	Properties of P-glycoprotein with mutations in the "catalytic carboxylate" glutamate residues. <b>2004</b> , 279, 46518-26	53
2170	Synergy between conserved ABC signature Ser residues in P-glycoprotein catalysis. <b>2004</b> , 279, 5363-73	45
2169	Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. <b>2004</b> , 64, 4294-301	244
2168	Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. <b>2004</b> , 279, 46706-14	74
2167	Cancer Stem Cells Persist in Many Cancer Cell Lines. <b>2004</b> , 3, 412-413	100
2166	'Side Population' cells in adult mouse testis express Bcrp1 gene and are enriched in spermatogonia and germinal stem cells. <b>2004</b> , 131, 479-87	117
2165	ydaG and ydbA of <i>Lactococcus lactis</i> encode a heterodimeric ATP-binding cassette-type multidrug transporter. <b>2004</b> , 279, 34449-55	44
2164	A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. <b>2004</b> , 10, 4724-33	62
2163	Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells. <b>2004</b> , 65, 1217-24	14
2162	Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. <b>2004</b> , 279, 19781-9	204
2161	Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. <b>2004</b> , 64, 8708-14	40

2160	VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. <b>2004</b> , 10, 1826-34	147
2159	Mitochondria in tumor cells studied by laser scanning confocal microscopy. <b>2004</b> , 9, 385-94	34
2158	Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. <b>2004</b> , 66, 1332-9	106
2157	The intracellular pharmacology of antiretroviral protease inhibitors. <b>2004</b> , 54, 982-90	89
2156	Conformational transitions induced by the binding of MgATP to the vitamin B12 ATP-binding cassette (ABC) transporter BtuCD. <b>2004</b> , 279, 45013-9	76
2155	Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state. <b>2004</b> , 279, 48855-64	41
2154	The role of ABC transporters in drug resistance, metabolism and toxicity. <b>2004</b> , 1, 27-42	435
2153	Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma. <b>2004</b> , 24, 635	4
2152	Sensitization of multidrug resistant human osteosarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. <b>2004</b> , 25, 1599	2
2151	Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. <b>2004</b> , 24, 365	1
2150	Molecular modeling correctly predicts the functional importance of Phe594 in transmembrane helix 11 of the multidrug resistance protein, MRP1 (ABCC1). <b>2004</b> , 279, 463-8	53
2149	A comparison of signaling activities induced by Taxol and desoxyepothilone B. <b>2004</b> , 16, 563-76	10
2148	The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance. <b>2004</b> , 3, 382-4	14
2147	Regulation of the stability of P-glycoprotein by ubiquitination. <b>2004</b> , 66, 395-403	92
2146	CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. <b>2004</b> , 10, 7599-606	27
2145	Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. <b>2004</b> , 101, 1702-7	123
2144	Combined mutation of catalytic glutamate residues in the two nucleotide binding domains of P-glycoprotein generates a conformation that binds ATP and ADP tightly. <b>2004</b> , 279, 31212-20	70
2143	Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. <b>2004</b> , 65, 897-905	63



2142	Strategies for inhibition of MDR1 gene expression. <b>2004</b> , 66, 268-75		52
2141	Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. <b>2004</b> , 64, 7562-9		72
2140	Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. <b>2004</b> , 14, 1333-44		94
2139	High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. <b>2004</b> , 65, 1485-95		290
2138	Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. <b>2004</b> , 66, 1397-405		73
2137	Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. <b>2004</b> , 63, 131-7		31
2136	Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. <b>2004</b> , 63, 138-43		65
2135	Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. <b>2004</b> ,		7
2134	The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors. <b>2004</b> , 127, 26-33		28
2133	Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. <b>2004</b> , 127, 392-8		44
2132	Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. <b>2004</b> , 18, 413-22		25
2131	Functional interaction of intestinal CYP3A4 and P-glycoprotein. <b>2004</b> , 18, 621-6		89
2130	Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. <b>2004</b> , 45, 441-51		175
2129	The potential of positron-emission tomography to study anticancer-drug resistance. <i>Nature Reviews Cancer</i> , <b>2004</b> , 4, 457-69	31.3	32
2128	Hyaluronan: from extracellular glue to pericellular cue. <i>Nature Reviews Cancer</i> , <b>2004</b> , 4, 528-39	31.3	1586
2127	ABCs of drug resistance. <i>Nature Reviews Cancer</i> , <b>2004</b> , 4, 755-755	31.3	
2126	ABCs of drug resistance. <b>2004</b> , 3, 828-828		
2125	Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. <b>2004</b> , 11 Suppl 1, S45-55		256

2124	Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. <b>2004</b> , 11, 1170-4	81
2123	P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. <b>2004</b> , 18, 401-8	269
2122	MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. <b>2004</b> , 23, 753-62	68
2121	Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. <b>2004</b> , 23, 945-55	27
2120	Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. <b>2004</b> , 23, 3613-21	53
2119	Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. <b>2004</b> , 91, 270-6	43
2118	Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin. <b>2004</b> , 91, 1405-13	21
2117	3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility. <b>2004</b> , 141, 415-22	22
2116	Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. <b>2004</b> , 21, 17-24	55
2115	Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. <b>2004</b> , 21, 69-75	63
2114	P-glycoprotein in autoimmune diseases. <b>2004</b> , 3, 188-92	42
2113	Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06. <b>2004</b> , 68, 911-21	33
2112	Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. <b>2004</b> , 68, 2043-52	194
2111	Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. <b>2004</b> , 101, 781-6	850
2110	Microtubule inhibitory effects of various SJ compounds on tissue culture cells. <b>2004</b> , 27, 436-41	4
2109	P-glycoprotein-based drug-drug interactions: preclinical methods and relevance to clinical observations. <b>2004</b> , 27, 127-35	12
2108	Synthesis and biological evaluation of taxinine analogues as orally active multidrug resistance reversal agents in cancer. <b>2004</b> , 14, 4767-70	18
2107	Three ATP-binding cassette transporter genes, Abca14, Abca15, and Abca16, form a cluster on mouse Chromosome 7F3. <b>2004</b> , 15, 335-43	15

2106	99mTc-MIBI in the evaluation of breast cancer biology. <b>2004</b> , 31 Suppl 1, S88-96	51
2105	Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and TRA96023. <b>2004</b> , 53, 363-9	49
2104	In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. <b>2004</b> , 54, 131-8	51
2103	Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. <b>2004</b> , 54, 283-9	7
2102	Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines. <b>2004</b> , 31, 521-7	20
2101	Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies. <b>2004</b> , 68, 563-73	27
2100	Application of expression genomics in drug development and genomic medicine. <b>2004</b> , 62, 124-133	4
2099	Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: Implications in multidrug resistance in cancer. <b>2004</b> , 109, 174-81	56
2098	Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. <b>2004</b> , 109, 238-46	291
2097	Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line. <b>2004</b> , 110, 627-32	16
2096	ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. <b>2004</b> , 109, 848-54	134
2095	Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. <b>2004</b> , 200, 223-34	48
2094	Analogues of tetramethylrosamine as transport molecules for and inhibitors of P-glycoprotein-mediated multidrug resistance. <b>2004</b> , 12, 4625-31	17
2093	Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. <b>2004</b> , 28, 973-7	38
2092	Caveolin-1 and cancer multidrug resistance: coordinate regulation of pro-survival proteins?. <b>2004</b> , 28, 907-8	26
2091	Prognostic factors in soft tissue sarcoma Tissue microarray for immunostaining, the importance of whole-tumor sections and time-dependence. <b>2004</b> , 75, 1-52	8
2090	Pheophorbide a is a specific probe for ABCG2 function and inhibition. <b>2004</b> , 64, 1242-6	292
2089	Efflux of sphingoid bases by P-glycoprotein in human intestinal Caco-2 cells. <b>2004</b> , 68, 2541-6	42

2088	Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. <b>2004</b> , 43, 13944-54	59
2087	HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. <b>2004</b> , 64, 7426-31	91
2086	Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. <b>2004</b> , 1, 426-33	51
2085	The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium. <b>2004</b> , 43, 12081-9	50
2084	System dynamics of subcellular transport. <b>2004</b> , 1, 414-25	15
2083	The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). <b>2004</b> , 65, 675-84	73
2082	Clinical molecular imaging. <b>2004</b> , 1, 4-23	46
2081	Chemoembolization for hepatocellular carcinoma. <b>2004</b> , 127, S179-88	434
2080	Mechanisms of cancer: multidrug resistance. <b>2004</b> , 1, 229-234	49
2079	In silico antitarget screening. <b>2004</b> , 1, 209-15	15
2078	Breast cancer resistance protein (BCRP) in acute leukemia. <b>2004</b> , 45, 649-54	32
2077	Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy. <b>2004</b> , 43, 2262-71	56
2076	Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. <b>2004</b> , 3, 403-9	34
2075	Mutational analysis of ABCG2: role of the GXXXG motif. <b>2004</b> , 43, 9448-56	89
2074	Role of a conserved membrane-embedded acidic residue in the multidrug transporter MdfA. <b>2004</b> , 43, 518-25	45
2073	Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity. <b>2004</b> , 15, 1464-74	55
2072	Structural understanding of efflux-mediated drug resistance: potential routes to efflux inhibition. <b>2004</b> , 4, 479-86	33
2071	Therapeutic implications of cancer stem cells. <b>2004</b> , 14, 43-7	466

2070	Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients. <b>2004</b> , 58, 320-4	15
2069	Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. <b>2004</b> , 7, 245-55	28
2068	Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. <b>2004</b> , 40, 594-605	90
2067	Cholesterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells. <b>2004</b> , 316, 705-11	38
2066	Stable suppression of MDR1 gene expression and function by RNAi in Caco-2 cells. <b>2004</b> , 324, 365-71	32
2065	Importance of P-glycoprotein at blood-tissue barriers. <b>2004</b> , 25, 423-9	421
2064	Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. <b>2004</b> , 129, 349-60	299
2063	Expression of lung resistance-related protein in transitional cell carcinoma of bladder. <b>2004</b> , 63, 694-8	5
2062	Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. <b>2004</b> , 64, 7130-8	66
2061	Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. <b>2004</b> , 5, 409-18	136
2060	Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein. <b>2004</b> , 279, 18232-8	50
2059	Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane. <b>2004</b> , 279, 7692-7	61
2058	Tumour-selective drug delivery via folate receptor-targeted liposomes. <b>2004</b> , 1, 7-17	54
2057	Herbal modulation of P-glycoprotein. <b>2004</b> , 36, 57-104	316
2056	Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. <b>2004</b> , 6, 129-37	432
2055	Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?. <b>2004</b> , 30, 37-51	59
2054	Pharmacogenomics of MDR and MRP subfamilies. <b>2004</b> , 1, 85-104	18
2053	Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. <b>2004</b> , 17, 641-651	29

2052	Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance. <b>2004</b> , 15, 303-9	16
2051	Ex vivo reversal of chemoresistance by tariquidar (XR9576). <b>2004</b> , 15, 861-9	19
2050	Co-administration of simvastatin and cytotoxic drugs is advantageous in myeloma cell lines. <b>2004</b> , 15, 79-84	13
2049	MEN15658: a new promising anti-tumoral drug active on resistant tumor cells. <b>2004</b> , 15, 151-6	
2048	New Drug Development. <b>2004</b> ,	11
2047	Strong linkage disequilibrium at the nucleotide analogue transporter ABCC5 gene locus. <b>2005</b> , 15, 91-104	7
2046	High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation. <b>2005</b> , 16, 393-9	28
2045	Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. <b>2005</b> , 106, 1355-61	25
2044	PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. <b>2005</b> , 106, 3584-93	47
2043	A proposal for the physiological significance of mdr1 and Bcrp1/Abcg2 gene expression in normal tissue regeneration and after cancer therapy. <b>2005</b> , 232, 41-5	22
2042	Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. <b>2005</b> , 29, 1425-34	77
2041	Structure-activity studies of uptake and phototoxicity with heavy-chalcogen analogues of tetramethylrosamine in vitro in chemosensitive and multidrug-resistant cells. <b>2005</b> , 13, 6394-403	23
2040	Synthesis of (-)-5?-methoxyhydnocarpin-D, an inhibitor of the Staphylococcus aureus multidrug resistance pump. <b>2005</b> , 61, 4149-4156	7
2039	Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. <b>2005</b> , 78, 619-26	62
2038	Preparations of vitamin D analogs, spirostanols and furostanols from diosgenin and their cytotoxic activities. <b>2005</b> , 40, 662-73	21
2037	Application of expression genomics for predicting treatment response in cancer. <b>2005</b> , 1058, 186-95	9
2036	GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. <b>2005</b> , 81, 39-44	44
2035	Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. <b>2005</b> , 6, 115-38	100

2034	Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. <b>2005</b> , 46, 643-7	176
2033	Drug resistance in brain diseases and the role of drug efflux transporters. <b>2005</b> , 6, 591-602	695
2032	Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. <b>2005</b> , 92, 259-64	48
2031	Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. <b>2005</b> , 93, 46-53	20
2030	Tumour stem cells and drug resistance. <i>Nature Reviews Cancer</i> , <b>2005</b> , 5, 275-84	31.3 2947
2029	RNA interference and potential therapeutic applications of short interfering RNAs. <b>2005</b> , 12, 787-95	100
2028	Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. <b>2005</b> , 24, 7542-51	62
2027	Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells. <b>2005</b> , 85, 664-74	33
2026	Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). <b>2005</b> , 272, 4725-40	120
2025	Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. <b>2005</b> , 18, 102-12	65
2024	Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. <b>2005</b> , 46, 224-35	220
2023	Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells. <b>2005</b> , 160, 126-33	24
2022	Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. <b>2005</b> , 32, S9-15	112
2021	Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). <b>2005</b> , 32, S3-8	84
2020	Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. <b>2005</b> , 32, S16-21	25
2019	Introduction: chemotherapies in the treatment of breast cancer. <b>2005</b> , 32, S1-2	
2018	Pharmacogenetics for individualized cancer chemotherapy. <b>2005</b> , 107, 155-76	114
2017	Natural selection in neoplastic progression of Barrett's esophagus. <b>2005</b> , 15, 474-83	38

2016	Anthracyclines, proteasome activity and multi-drug-resistance. <b>2005</b> , 5, 114	35
2015	Cancer cell adaptation to chemotherapy. <b>2005</b> , 5, 78	95
2014	Differentiation and drug resistance relationships in leukemia cells. <b>2005</b> , 94, 98-108	9
2013	Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. <b>2005</b> , 113, 229-40	64
2012	Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). <b>2005</b> , 113, 568-74	19
2011	Na <sup>+</sup> /H <sup>+</sup> exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. <b>2005</b> , 115, 924-9	60
2010	Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. <b>2005</b> , 117, 670-82	53
2009	Probing ATP-dependent conformational changes in the multidrug resistance protein 1 (MRP1/ABCC1) in live tumor cells with a novel recombinant single-chain Fv antibody targeted to the extracellular N-terminus. <b>2005</b> , 116, 703-9	7
2008	Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. <b>2005</b> , 104, 682-91	232
2007	Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. <b>2005</b> , 25, 453-72	127
2006	EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. <b>2005</b> , 55, 461-5	32
2005	Single nucleotide polymorphisms modify the transporter activity of ABCG2. <b>2005</b> , 56, 161-72	200
2004	Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). <b>2005</b> , 56, 344-50	61
2003	Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. <b>2005</b> , 92, 451-63	44
2002	Analysis of ABCC6 (MRP6) in normal human tissues. <b>2005</b> , 123, 517-28	64
2001	Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. <b>2005</b> , 131, 355-63	112
2000	Increased resistance to anthelmintics of <i>Haemonchus contortus</i> eggs associated with changes in membrane fluidity of eggshells during embryonation. <b>2005</b> , 95, 266-72	10
1999	Investigation of multidrug resistance in cultured human renal cell carcinoma cells by <sup>31</sup> P-NMR spectroscopy and treatment survival assays. <b>2005</b> , 18, 144-61	8



1998	Gene expression profiling of primary breast cancer. <b>2005</b> , 7, 38-44	15
1997	Stem/progenitor cells in mouse mammary gland development and breast cancer. <b>2005</b> , 10, 17-24	64
1996	Similarity-based descriptors (SIBAR)--a tool for safe exchange of chemical information?. <b>2005</b> , 19, 687-92	8
1995	Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids. <b>2005</b> , 5, 20	21
1994	An ETP model (exclusion-tolerance-progression) for multi drug resistance. <b>2005</b> , 2, 17	2
1993	Molecular mechanisms of drug resistance. <b>2005</b> , 205, 275-92	1044
1992	Application of RNAi to cancer research and therapy. <b>2005</b> , 10, 1946-60	19
1991	The Relationship betweenMDR1Polymorphisms and the Response to Etoposide/Cisplatin Combination Chemotherapy in Small Cell Lung Cancer. <b>2005</b> , 58, 135	
1990	Imaging Multidrug Resistance P-glycoprotein Transport Function Using MicroPET with Technetium-94m-Sestamibi. <b>2005</b> , 4, 153535002005041	17
1989	In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. <b>2005</b> , 11, 4487-94	91
1988	Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents. <b>2005</b> , 68, 625-34	25
1987	Gene expression profiling of the irinotecan pathway in colorectal cancer. <b>2005</b> , 11, 2053-62	52
1986	Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. <b>2005</b> , 11, 1719-33	55
1985	Regulation of hepatic transporters by xenobiotic receptors. <b>2005</b> , 6, 309-28	149
1984	Dihydro-beta-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania. <b>2005</b> , 11, 3125-39	41
1983	A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. <b>2005</b> , 14, 2075-87	52
1982	MDR1 genotype-related pharmacokinetics: fact or fiction?. <b>2005</b> , 20, 391-414	117
1981	Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance. <b>2005</b> , 65, 10952-8	77

1980	Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an antiproliferative cytokine. <b>2005</b> , 65, 1631-4	16
1979	Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. <b>2005</b> , 65, 6593-600	30
1978	Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation. <b>2005</b> , 67, 1349-59	35
1977	Identification of a missense mutation in the bovine ABCG2 gene with a major effect on the QTL on chromosome 6 affecting milk yield and composition in Holstein cattle. <b>2005</b> , 15, 936-44	273
1976	ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. <b>2005</b> , 65, 11419-28	235
1975	Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. <b>2005</b> , 67, 902-11	57
1974	Characterization of a new antibody raised against the NH2 terminus of P-glycoprotein. <b>2005</b> , 11, 5833-9	14
1973	Isolation and enrichment of murine spermatogonial stem cells using rhodamine 123 mitochondrial dye. <b>2005</b> , 72, 767-71	44
1972	Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. <b>2005</b> , 280, 20310-5	191
1971	Targeting microtubules for cancer chemotherapy. <b>2005</b> , 5, 65-71	317
1970	Proteomic approaches for studying chemoresistance in cancer. <b>2005</b> , 2, 215-28	18
1969	Inhibitors of p-glycoprotein--lead identification and optimisation. <b>2005</b> , 5, 153-63	35
1968	Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. <b>2005</b> , 1, 595-611	36
1967	Structural basis of energy transduction in the transport cycle of MsbA. <b>2005</b> , 308, 1023-8	126
1966	Tumoral drug metabolism: overview and its implications for cancer therapy. <b>2005</b> , 23, 205-29	123
1965	Trimers of N-alkylglycines are potent modulators of the multidrug resistance phenotype. <b>2005</b> , 313, 112-20	9
1964	Interruption of homologous desensitization in cyclic guanosine 3',5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. <b>2005</b> , 65, 11129-35	30
1963	Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. <b>2005</b> , 280, 6950-9	73

1962	Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. <b>2005</b> , 23, 1161-8	93
1961	P-glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone]. <b>2005</b> , 314, 355-62	30
1960	The dileucine motif at the COOH terminus of human multidrug resistance P-glycoprotein is important for folding but not activity. <b>2005</b> , 280, 2522-8	21
1959	Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. <b>2005</b> , 280, 11569-77	138
1958	Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. <b>2005</b> , 26, 968-75	102
1957	Integration/Interaction of Oncologic Growth. <b>2005</b> ,	3
1956	YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. <b>2005</b> , 65, 4078-87	119
1955	Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A). <b>2005</b> , 312, 281-9	72
1954	Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. <b>2005</b> , 65, 3861-7	142
1953	Musculin/MyoR is expressed in kidney side population cells and can regulate their function. <b>2005</b> , 169, 921-8	110
1952	Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy. <b>2005</b> , 19, 158-9	20
1951	Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. <b>2005</b> , 4, 1693-8	91
1950	Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone. <b>2005</b> , 17, 215-23	36
1949	P-glycoprotein expression influences the result of 99mTc-MIBI scintigraphy in tertiary hyperparathyroidism. <b>2005</b> , 16, 215	0
1948	The effect of 6-mercaptopurine on early human placental explants. <b>2005</b> , 20, 1390-7	18
1947	Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression. <b>2005</b> , 4, 1325-30	5
1946	Inhibition of P-glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy. <b>2005</b> , 4, 313-7	14
1945	Chapter 18 P-glycoproteins and xenobiotic efflux transport in fish. <b>2005</b> , 6, 495-533	18

1944	Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. <b>2005</b> , 44, 14020-9	76
1943	A naive bayes classifier for prediction of multidrug resistance reversal activity on the basis of atom typing. <b>2005</b> , 48, 4031-9	75
1942	Mechanisms Involved in Chemoresistance in Ovarian Cancer. <b>2005</b> , 44, 209-217	10
1941	ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. <b>2005</b> , 65, 4320-33	473
1940	Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. <b>2005</b> , 65, 7446-54	224
1939	Knocking down transport: applications of RNA interference in the study of drug transport proteins. <b>2005</b> , 37, 705-23	11
1938	Predictive markers in breast and other cancers: a review. <b>2005</b> , 51, 494-503	128
1937	Are MTT assays the right tool to analyze drug resistance caused by ABC-transporters in patient samples?. <b>2005</b> , 46, 1357-63	5
1936	Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. <b>2005</b> , 5, 123-31	45
1935	Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. <b>2005</b> , 65, 9388-97	45
1934	Reversion of human Pgp-dependent multidrug resistance by new sesquiterpenes from <i>Zinowiewia costaricensis</i> . <b>2005</b> , 48, 4266-75	30
1933	The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. <b>2005</b> , 389, 517-26	130
1932	Involvement of the "occluded nucleotide conformation" of P-glycoprotein in the catalytic pathway. <b>2005</b> , 44, 12879-86	66
1931	Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. <b>2005</b> , 1, 127-34	78
1930	Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers. <b>2005</b> , 44, 10893-904	66
1929	Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents. <b>2005</b> , 48, 2218-28	34
1928	Neoplastic growth: the consequence of evolutionary malignant resistance to chronic damage for survival of cells (review of a new theory of the origin of cancer). <b>2005</b> , 65, 595-604	11
1927	Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. <b>2005</b> , 333, 754-62	110

1926	Schisandrin B--a novel inhibitor of P-glycoprotein. <b>2005</b> , 335, 406-11	58
1925	The ABC transporter PGP-2 from <i>Caenorhabditis elegans</i> is expressed in the sensory neuron pair AWA and contributes to lysosome formation and lipid storage within the intestine. <b>2005</b> , 338, 862-71	18
1924	4'-O-Alkyaloenin derivatives and their sulfates directed toward overcoming multidrug resistance in tumor cells. <b>2005</b> , 218, 15-20	12
1923	Targeting senescence pathways to reverse drug resistance in cancer. <b>2005</b> , 219, 1-13	32
1922	Mechanisms of platinum drug resistance. <b>2005</b> , 26, 113-6	111
1921	A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1). <b>2005</b> , 26, 385-7	73
1920	ATP-binding cassette (ABC) transporters in normal and pathological lung. <b>2005</b> , 6, 59	132
1919	Unbiased examination of changes in plasma membrane proteins in drug resistant cancer cells. <b>2005</b> , 4, 2148-53	47
1918	Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models. <b>2005</b> , 48, 7426-36	34
1917	Mechanisms of drug resistance in cancer chemotherapy. <b>2005</b> , 14 Suppl 1, 35-48	411
1916	The genetics of ATP-binding cassette transporters. <b>2005</b> , 400, 409-29	120
1915	Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. <b>2005</b> , 68, 430-8	47
1914	Daily rhythms of P-glycoprotein expression in mice. <b>2005</b> , 22, 655-65	62
1913	Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. <b>2005</b> , 7, R862-70	61
1912	Arylmethoxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. <b>2006</b> , 49, 6607-13	18
1911	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1043-1051	
1910	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1240-1240	
1909	Reversal of ABC Transporter-Dependent Multidrug Resistance in Cancer. <b>2006</b> , 5, 285-297	9

1908	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1053-1058	
1907	Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. <b>2006</b> , 5, 270-8	125
1906	Cancer Drug Resistance. <b>2006</b> ,	17
1905	The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. <b>2006</b> , 45, 8940-51	85
1904	Antiprotease therapy in cancer: hot or not?. <b>2006</b> , 6, 257-79	75
1903	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1160-1174	7
1902	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1002-1008	
1901	Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. <b>2006</b> , 3, 205-16	268
1900	The conserved tyrosine residues 401 and 1044 in ATP sites of human P-glycoprotein are critical for ATP binding and hydrolysis: evidence for a conserved subdomain, the A-loop in the ATP-binding cassette. <b>2006</b> , 45, 7605-16	53
1899	Phase I and Pharmacokinetic Evaluation of the Combination of Orally Administered Docetaxel and Cyclosporin A in Tumor-Bearing Cats. <b>2006</b> , 20, 1370-1375	7
1898	Bivalent probes of the human multidrug transporter P-glycoprotein. <b>2006</b> , 45, 11695-702	33
1897	Expresi3n de prote3nas relacionadas con resistencia a M3ltiples Drogas (MDR-Prote3nas) y resistencia a la quimioterapia en el c3ncer de pulm3n.. <b>2006</b> , 103, 105-117	
1896	Expresi3n de Prote3nas Relacionadas con Resistencia a M3ltiples Drogas (MDR-Prote3nas) en tumores s3lidos. <b>2006</b> , 103, 163-175	
1895	Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. <b>2006</b> , 5, 1995-2006	96
1894	Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. <b>2006</b> , 45, 253-85	121
1893	Pharmacokinetic considerations in the treatment of CNS tumours. <b>2006</b> , 45, 871-903	53
1892	Glutathione in cancer biology and therapy. <b>2006</b> , 43, 143-81	719
1891	Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein. <b>2006</b> , 45, 2739-51	17

1890	Multipotent, dedifferentiated cancer stem-like cells from brain gliomas. <b>2006</b> , 15, 423-35	45
1889	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1160-1160	
1888	Intracellular chemiluminescence activates targeted photodynamic destruction of leukaemic cells. <b>2006</b> , 95, 189-96	42
1887	Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein--monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease. <b>2006</b> , 16, 575-89, viii	16
1886	Stimulation of P-glycoprotein ATPase by analogues of tetramethylrosamine: coupling of drug binding at the "R" site to the ATP hydrolysis transition state. <b>2006</b> , 45, 8034-47	26
1885	Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance. <b>2006</b> , 49, 932-41	45
1884	Expression, purification, and characterization of cysteine-free mouse P-glycoprotein. <b>2006</b> , 445, 124-8	18
1883	Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates. <b>2006</b> , 450, 100-12	9
1882	Insight in eukaryotic ABC transporter function by mutation analysis. <b>2006</b> , 580, 1064-84	62
1881	Mechanisms and strategies to overcome multiple drug resistance in cancer. <b>2006</b> , 580, 2903-9	293
1880	Insights into the molecular mechanism of action of Celastraceae sesquiterpenes as specific, non-transported inhibitors of human P-glycoprotein. <b>2006</b> , 1758, 98-110	12
1879	Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. <b>2006</b> , 349, 303-9	46
1878	The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. <b>2006</b> , 234, 62-72	36
1877	Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. <b>2006</b> , 235, 84-92	141
1876	Role of pharmacogenetics in irinotecan therapy. <b>2006</b> , 234, 90-106	78
1875	Fluoxetine and reversal of multidrug resistance. <b>2006</b> , 237, 180-7	54
1874	Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response. <b>2006</b> , 234, 40-50	36
1873	Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. <b>2006</b> , 239, 168-82	167

1872	Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. <b>2006</b> , 243, 274-80	80
1871	Brain cancer stem-like cells. <b>2006</b> , 42, 1237-42	39
1870	Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. <b>2006</b> , 62, 44-51	29
1869	Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell). <b>2006</b> , 49, 6908-16	41
1868	Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial. <b>2006</b> , 1, 594-600	84
1867	The livestock photosensitizer, phytoporphyryn (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2. <b>2006</b> , 81, 345-9	18
1866	Evolution of the vertebrate ABC gene family: analysis of gene birth and death. <b>2006</b> , 88, 1-11	127
1865	Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies. <b>2006</b> , 33, 831-40	33
1864	Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor $\beta$ negative fulvestrant-resistant MCF-7 cells. <b>2006</b> , 29, 1237	4
1863	Polymer Genomics. 173-198	7
1862	Short interfering RNA (siRNA): tool or therapeutic?. <b>2006</b> , 110, 47-58	78
1861	Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. <b>2006</b> , 107, 2486-92	59
1860	OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. <b>2006</b> , 108, 697-704	370
1859	Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. <b>2006</b> , 108, 1370-3	140
1858	Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives. <b>2006</b> , 7, 949-59	25
1857	Cellular functions of vaults and their involvement in multidrug resistance. <b>2006</b> , 7, 923-34	81
1856	Multidrug transporters as drug targets. <b>2006</b> , 7, 911-21	46
1855	The blood-brain barrier: Its implications in neurological disease and treatment. <b>2006</b> , 2, 18-25	3



1854	Plasma membrane calcium ATPase (PMCA4): a housekeeper for RT-PCR relative quantification of polytopic membrane proteins. <b>2006</b> , 7, 29	20
1853	Free radical theory of autoimmunity. <b>2006</b> , 3, 22	27
1852	Differential partitioning of Galphai1 with the cellular microtubules: a possible mechanism of development of Taxol resistance in human ovarian carcinoma cells. <b>2006</b> , 1, 3	3
1851	Metabolism of a new P-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/electrospray mass spectrometry. <b>2006</b> , 20, 1457-62	10
1850	Role of cyclic GMP signaling in the melanocyte response to hypergravity. <b>2006</b> , 6, 406-413	3
1849	ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression. <b>2006</b> , 47, 757-64	13
1848	Functional imaging of multidrug resistance in breast cancer. <b>2006</b> , 21 Suppl 1, 24-7	5
1847	Modulation of p-glycoprotein function by caveolin-1 phosphorylation. <b>2007</b> , 101, 1-8	55
1846	LmrCD is a major multidrug resistance transporter in <i>Lactococcus lactis</i> . <b>2006</b> , 61, 771-81	80
1845	Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. <b>2006</b> , 9, 487-8	131
1844	Topoisomerase I inhibitors: camptothecins and beyond. <i>Nature Reviews Cancer</i> , <b>2006</b> , 6, 789-802	31.3 1510
1843	Targeting multidrug resistance in cancer. <b>2006</b> , 5, 219-34	2649
1842	Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells. <b>2006</b> , 71, 146-54	15
1841	The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. <b>2006</b> , 149, 250-60	56
1840	Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. <b>2006</b> , 149, 506-15	88
1839	The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. <b>2006</b> , 25, 1743-52	95
1838	The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. <b>2006</b> , 25, 3186-95	36
1837	Design, synthesis and evaluation of naphthalene-2-carboxamides as reversal agents in MDR cancer. <b>2006</b> , 14, 6022-6	13

1836	(+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells. <b>2006</b> , 14, 7138-45	39
1835	A cationic chalcogenoxanthylum photosensitizer effective in vitro in chemosensitive and multidrug-resistant cells. <b>2006</b> , 14, 8635-43	20
1834	Inhibition of P-glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins. <b>2006</b> , 16, 5700-3	10
1833	Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. <b>2006</b> , 68, 213-28	111
1832	Sorcina, an important gene associated with multidrug-resistance in human leukemia cells. <b>2006</b> , 30, 469-76	45
1831	Intracellular delivery of oligonucleotide conjugates and dendrimer complexes. <b>2006</b> , 1082, 18-26	37
1830	Genes of multidrug resistance in haematological malignancies. <b>2006</b> , 61, 247-256	3
1829	The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. <b>2006</b> , 15, 1597-607	58
1828	Cancer stem cells. <b>2006</b> , 355, 1253-61	1256
1827	Pharmacophore-based discovery of ligands for drug transporters. <b>2006</b> , 58, 1431-50	92
1826	Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. <b>2006</b> , 58, 1597-621	177
1825	The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. <b>2007</b> , 25, 115-22	11
1824	Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. <b>2006</b> , 100, 301-8	20
1823	Structurally similar diazenes exhibit significantly different biological activity. <b>2006</b> , 22, 61-71	8
1822	Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). <b>2006</b> , 57, 376-88	91
1821	Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. <b>2006</b> , 57, 335-42	10
1820	Dibenzocyclooctadiene lignans: a class of novel inhibitors of P-glycoprotein. <b>2006</b> , 58, 99-106	53
1819	Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. <b>2006</b> , 58, 640-53	22

1818	Screening of an annotated compound library for drug activity in a resistant myeloma cell line. <b>2006</b> , 58, 749-58	32
1817	Proteomic analysis of low-abundant integral plasma membrane proteins based on gels. <b>2006</b> , 63, 1790-804	40
1816	Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. <b>2006</b> , 372, 291-9	52
1815	Analysis of oxidized multi-walled carbon nanotubes in single K562 cells by capillary electrophoresis with laser-induced fluorescence. <b>2007</b> , 387, 119-26	14
1814	Convection-enhanced delivery of liposomal doxorubicin in intracranial brain tumor xenografts. <b>2006</b> , 1, 79-85	9
1813	[Expression of multiple-drug resistant proteins in lung cancer]. <b>2006</b> , 79, 46-56	1
1812	[Expression of multidrug resistance (MDR)-associated proteins in solid tumors]. <b>2006</b> , 79, 202-14	1
1811	MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. <b>2006</b> , 100, 239-46	55
1810	Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties. <b>2006</b> , 535, 301-9	18
1809	Reversal of MDR1 gene-dependent multidrug resistance using low concentration of endonuclease-prepared small interference RNA. <b>2006</b> , 536, 93-7	15
1808	Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. <b>2006</b> , 27, 524-32	42
1807	The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). <b>2006</b> , 27, 392-400	172
1806	Suppression of P-glycoprotein expression by antipsychotics trifluoperazine in adriamycin-resistant L1210 mouse leukemia cells. <b>2006</b> , 28, 300-6	33
1805	Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance. <b>2006</b> , 29, 102-10	28
1804	Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. <b>2006</b> , 1766, 184-96	80
1803	Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. <b>2006</b> , 71, 1162-74	63
1802	Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. <b>2006</b> , 71, 1695-704	61
1801	Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. <b>2006</b> , 72, 824-37	75

1800	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. <b>2006</b> , 112, 184-98	151
1799	Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. <b>2006</b> , 6, 183	47
1798	Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. <b>2006</b> , 6, 294	27
1797	Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region. <b>2006</b> , 45, 495-508	17
1796	Inhibitors of mitotic kinesins: next-generation antimetabolites. <b>2006</b> , 1, 293-8	38
1795	Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. <b>2006</b> , 118, 1699-712	120
1794	Development of multidrug resistance due to multiple factors including P-glycoprotein overexpression under K-selection after MYC and HRAS oncogene activation. <b>2006</b> , 118, 2448-54	10
1793	Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. <b>2006</b> , 119, 17-27	52
1792	Role of drug efflux carriers in the healthy and diseased brain. <b>2006</b> , 60, 489-98	56
1791	Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. <b>2006</b> , 5, 39-47	127
1790	EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. <b>2006</b> , 5, 2820-6	56
1789	The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). <b>2006</b> , 7, 893-909	198
1788	Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. <b>2006</b> , 24, 2448-55	53
1787	Brain tumor stem cells: new targets for clinical treatments?. <b>2006</b> , 20, E27	16
1786	Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype: Clinical and Experimental Evidences. <b>2006</b> , 1, 291-309	16
1785	New macrocyclic lathyrane diterpenes, from Euphorbia lagascae, as inhibitors of multidrug resistance of tumour cells. <b>2006</b> , 72, 162-8	52
1784	Pharmacological strategies for overcoming multidrug resistance. <b>2006</b> , 7, 861-79	301
1783	Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs. <b>2006</b> , 67, 1057-62	9

1782	Characterization of gene rearrangements leading to activation of MDR-1. <b>2006</b> , 281, 36501-9	41
1781	Anthracyclines as effective anticancer drugs. <b>2006</b> , 1, 549-68	40
1780	Spectrum of radiopharmaceuticals in nuclear oncology. <b>2006</b> , 6, 181-96	15
1779	Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. <b>2006</b> , 24, 1546-53	135
1778	Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2. <b>2006</b> , 4, 331-344	5
1777	Antibodies and their fragments as anti-cancer agents. <b>2006</b> , 12, 363-78	31
1776	Mechanisms of cellular resistance to camptothecins. <b>2006</b> , 13, 3291-305	64
1775	Recent advances in molecular modeling and medicinal chemistry aspects of phospho-glycoprotein. <b>2006</b> , 7, 205-17	26
1774	MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. <b>2006</b> , 36, 137-41	57
1773	Photochemical internalization of therapeutic macromolecular agents: a novel strategy to kill multidrug-resistant cancer cells. <b>2006</b> , 319, 604-12	50
1772	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1009-1009	
1771	Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models. <b>2006</b> , 12, 3459-69	17
1770	Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis. <b>2006</b> , 12, 4339-49	32
1769	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1009-1009	
1768	Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. <b>2006</b> , 66, 4808-15	148
1767	Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. <b>2006</b> , 12, 6748-57	113
1766	Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance. <b>2006</b> , 69, 1383-8	25
1765	Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. <b>2006</b> , 66, 4263-72	78

1764	The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells. <b>2006</b> , 190, 897-902	43
1763	Drugs Affecting Growth of Tumours. <b>2006</b> ,	1
1762	Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. <b>2006</b> , 176, 5191-8	52
1761	Chemoresistance in solid tumours. <b>2006</b> , 17 Suppl 10, x315-24	127
1760	Molekulare Pharmakologie und Toxikologie. <b>2006</b> ,	
1759	Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. <b>2006</b> , 66, 7195-202	38
1758	Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1). <b>2006</b> , 281, 13906-14	43
1757	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1188-1188	
1756	Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice. <b>2006</b> , 5, 2366-77	41
1755	Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways. <b>2006</b> , 281, 37330-44	18
1754	Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. <b>2006</b> , 70, 287-96	124
1753	Role of ABC transporters in the chemoresistance of human gliomas. <b>2006</b> , 6, 433-45	56
1752	Eradication of leukemia stem cells as a new goal of therapy in leukemia. <b>2006</b> , 12, 340-4	49
1751	From Melanocytes to Melanoma. <b>2006</b> ,	17
1750	Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. <b>2006</b> , 103, 11154-9	646
1749	Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. <b>2006</b> , 66, 445-52	95
1748	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1020-1020	
1747	Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia. <b>2006</b> , 23, 489-94	5

1746	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1204-1208	1
1745	Increased estrogen sulfation of estradiol 17beta-D-glucuronide in metastatic tumor rat livers. <b>2006</b> , 319, 818-31	14
1744	Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. <b>2006</b> , 66, 2338-45	72
1743	The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function. <b>2006</b> , 281, 31152-63	18
1742	Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. <b>2006</b> , 5, 1986-94	57
1741	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1135-1140	1
1740	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1115-1115	
1739	Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). <b>2006</b> , 12, 1547-55	89
1738	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1153-1160	3
1737	Human ABC transporter ABCG2 in xenobiotic protection and redox biology. <b>2006</b> , 38, 371-91	55
1736	DualChip microarray as a new tool in cancer research. <b>2006</b> , 6, 295-306	10
1735	A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. <b>2006</b> , 5, 1710-22	149
1734	Molecular physiology of renal organic anion transporters. <b>2006</b> , 290, F251-61	183
1733	The Role of the Membrane Actions of Phenothiazines and Flavonoids as Functional Modulators. <b>2007</b> , 223-302	6
1732	Targeting hedgehog in cancer stem cells: how a paradigm shift can improve treatment response. <b>2007</b> , 3, 569-74	9
1731	Imaging and modulating antisense microdistribution in solid human xenograft tumor models. <b>2007</b> , 13, 5935-41	5
1730	Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. <b>2007</b> , 25, 411-7	62
1729	Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1. <b>2007</b> , 282, 8821-30	40

1728	Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. <b>2007</b> , 5, 641-53	34
1727	PO(2)-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. <b>2007</b> , 282, 17581-6	28
1726	The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. <b>2007</b> , 13, 2463-70	113
1725	Characterization of human liver cytochrome P-450 enzymes involved in the O-demethylation of a new P-glycoprotein inhibitor HM-30181. <b>2007</b> , 70, 1356-64	5
1724	Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. <b>2007</b> , 6, 3287-96	80
1723	Conformational motion of the ABC transporter MsbA induced by ATP hydrolysis. <b>2007</b> , 5, e271	120
1722	Transporters, enzymes, and enalapril removal in a rat (CC531-induced) liver metastatic model. <b>2007</b> , 293, G1078-88	2
1721	Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy. <b>2007</b> , 13, 463-70	22
1720	Novel mitotic targets and their small-molecule inhibitors. <b>2007</b> , 7, 766-84	9
1719	Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. <b>2007</b> , 8, 787-802	53
1718	Mini review on molecular modeling of P-glycoprotein (Pgp). <b>2007</b> , 7, 1525-9	40
1717	What makes tumors multidrug resistant?. <b>2007</b> , 6, 2782-7	89
1716	Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. <b>2007</b> , 12, 393-401	15
1715	Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter. <b>2007</b> , 6, 397-404	8
1714	Multidrug resistance in lymphoma: is it time for clinical trials?. <b>2007</b> , 48, 643-4	1
1713	Molecular prognostic factors in patients with pancreatic cancer. <b>2007</b> , 11, 1553-69	22
1712	Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes. <b>2007</b> , 73, 212-20	50
1711	Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. <b>2007</b> , 12, 511-7	32



1710	Using attenuated <i>Salmonella typhi</i> as tumor targeting vector for MDR1 siRNA delivery. <b>2007</b> , 6, 555-60	32
1709	Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. <b>2007</b> , 13, 3892-8	63
1708	About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. <b>2007</b> , 6, 13-23	118
1707	Melanoma differentiation associated gene-7/interleukin-24 reverses multidrug resistance in human colorectal cancer cells. <b>2007</b> , 6, 2985-94	26
1706	Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression. <b>2007</b> , 27, 2952-66	42
1705	Ability to acquire drug resistance arises early during the tumorigenesis process. <b>2007</b> , 67, 1130-7	48
1704	Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. <b>2007</b> , 67, 4373-81	54
1703	Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. <b>2007</b> , 13, 6753-60	45
1702	Stem cell-like cancer cells in cancer cell lines. <b>2007</b> , 3, 245-50	62
1701	Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. <b>2007</b> ,	4
1700	Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines. <b>2007</b> , 69, 111-5	10
1699	TC-99m MIBI SPECT imaging in patients with lung carcinoma: is it a functional probe of multidrug resistance genes?. <b>2007</b> , 31, 795-9	4
1698	Mapping ATP-binding cassette transporter gene expression profiles in melanocytes and melanoma cells. <b>2007</b> , 17, 265-73	68
1697	Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data. <b>2007</b> , 18, 389-404	16
1696	Cancer stem cells: implications for cancer treatment and prevention. <b>2007</b> , 13, 271-5	43
1695	Cancer stem cells and oncology therapeutics. <b>2007</b> , 19, 61-4	119
1694	ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. <b>2007</b> , 17, 127-36	34
1693	Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. <b>2007</b> , 18, 111-26	50

1692	Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. <b>2007</b> , 17, 667-78	18
1691	Genetically heterogeneous glioblastoma recurring with disappearance of 1p/19q losses: case report. <b>2007</b> , 61, E168-9; discussion E169	6
1690	Implications of ATP-binding cassette transporters for brain pharmacotherapies. <b>2007</b> , 28, 128-34	55
1689	Dynamics and function in a bacterial ABC transporter: simulation studies of the BtuCDF system and its components. <b>2007</b> , 46, 2767-78	56
1688	Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: Data mining of the NCI-DTP data sets and validation with human tumour xenografts. <b>2007</b> , 43, 791-8	9
1687	Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. <b>2007</b> , 1768, 2698-713	107
1686	Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein. <b>2007</b> , 355, 136-42	23
1685	The yeast Pdr5p multidrug transporter: how does it recognize so many substrates?. <b>2007</b> , 356, 1-5	42
1684	Role of hypoxia-inducible factor-alpha in hepatitis-B-virus X protein-mediated MDR1 activation. <b>2007</b> , 357, 567-73	36
1683	Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. <b>2007</b> , 358, 79-84	79
1682	Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. <b>2007</b> , 361, 549-54	54
1681	Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia/lymphoma. <b>2007</b> , 364, 808-14	19
1680	Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. <b>2007</b> , 246, 300-7	57
1679	Vincristine regulates the phosphorylation of the antiapoptotic protein HSP27 in breast cancer cells. <b>2007</b> , 247, 273-82	33
1678	Resistance to imatinib mesylate in chronic myeloid leukaemia. <b>2007</b> , 249, 121-32	117
1677	The role of membrane transporters in drug delivery to brain tumors. <b>2007</b> , 254, 11-29	49
1676	Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1. <b>2007</b> , 80, 741-8	36
1675	Future directions for drug transporter modelling. <b>2007</b> , 37, 1152-70	54

1674	Cancer stem cells and human malignant melanoma. <b>2008</b> , 21, 39-55	154
1673	Antitumor effects of cytosine deaminase and thymidine kinase fusion suicide gene under the control of mdr1 promoter in mdr1 positive leukemia cells. <b>2007</b> , 48, 1600-9	2
1672	Self-organizing maps for identification of new inhibitors of P-glycoprotein. <b>2007</b> , 50, 1698-702	47
1671	Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. <b>2007</b> , 9, R13	47
1670	Breast Cancer Chemosensitivity. <b>2007</b> ,	2
1669	Microarray Technology and Cancer Gene Profiling. <b>2007</b> ,	4
1668	Silent SNPs: impact on gene function and phenotype. <b>2007</b> , 8, 1075-80	196
1667	A "silent" polymorphism in the MDR1 gene changes substrate specificity. <b>2007</b> , 315, 525-8	1928
1666	Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. <b>2007</b> , 16, 837-47	183
1665	Involvement of MDR1 function in proliferation of tumour cells. <b>2008</b> , 143, 517-24	19
1664	Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. <b>2007</b> , 13, 427-33	165
1663	Structural characterization and biological evaluation of small interfering RNAs containing cyclohexenyl nucleosides. <b>2007</b> , 129, 9340-8	39
1662	Multi-drug resistance and cancer. <b>2007</b> , 17, 511-520	7
1661	Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance. <b>2007</b> , 4, 140-53	18
1660	Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids. <b>2007</b> , 70, 928-31	52
1659	Biological evaluation, structure-activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-beta-agarofuran sesquiterpenes as modulators of P-glycoprotein-dependent multidrug resistance. <b>2007</b> , 50, 4808-17	36
1658	Isomeric N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors. <b>2007</b> , 50, 599-602	16
1657	The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. <b>2007</b> , 6, 3279-86	49

1656	Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP. <b>2007</b> , 46, 13787-99	87
1655	Taxane refractory prostate cancer. <b>2007</b> , 178, S36-41	22
1654	Liver-directed therapies for metastatic neuroendocrine tumors. <b>2007</b> , 21, 545-60; ix-x	6
1653	Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. <b>2007</b> , 18, 821-31	124
1652	Expresi3n de prote3nas relacionadas con resistencia a m3ltiples drogas (MDR-Prote3nas) y su implicaci3n pron3stica en la supervivencia en el c3ncer de pulm3n. <b>2007</b> , 104, 51-63	
1651	Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection?. <b>2007</b> , 258, 84-92	41
1650	Classical PKC isoforms in cancer. <b>2007</b> , 55, 477-86	97
1649	HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. <b>2007</b> , 4, 17	18
1648	The challenges of targeting chronic myeloid leukemia stem cells. <b>2007</b> , 7 Suppl 2, S71-80	16
1647	The Biology and Function of Transporters. <b>2007</b> , 51-85	4
1646	Expression of Proteins Associated With Multidrug Resistance to Chemotherapy in Lung Cancer. <b>2007</b> , 43, 479-484	8
1645	Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. <b>2007</b> , 593, 95-104	35
1644	DNA damage response and development of targeted cancer treatments. <b>2007</b> , 39, 457-64	15
1643	Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells. <b>2007</b> , 20, 465-73	98
1642	Biological Background. <b>2007</b> , 3-18	
1641	The husk fiber of <i>Cocos nucifera</i> L. (Palmae) is a source of anti-neoplastic activity. <b>2007</b> , 40, 1339-43	23
1640	Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells. <b>2007</b> , 21, 243-51	40
1639	Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. <b>2007</b> , 46, 1597-610	255

1638	Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. <b>2007</b> , 46, 1-9	62
1637	Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. <b>2007</b> , 2, 920-42	129
1636	Apoptosis and chemo-resistance in colorectal cancer. <b>2007</b> , 96, 77-88	38
1635	Expression of major vault protein gene in osteosarcoma patients. <b>2007</b> , 25, 958-63	12
1634	Enaminones: Exploring additional therapeutic activities. <b>2007</b> , 96, 2509-31	70
1633	Natural triterpenoids from <i>Cecropia lyratiloba</i> are cytotoxic to both sensitive and multidrug resistant leukemia cell lines. <b>2007</b> , 15, 7355-60	52
1632	Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. <b>2007</b> , 31, 36-100	82
1631	Synthesis and antitumour evaluation of peptidyl-like derivatives containing the 1,3-benzodioxole system. <b>2007</b> , 42, 351-7	29
1630	Conformational mobility of immobilized proteins. <b>2007</b> , 43, 399-406	24
1629	Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. <b>2007</b> , 32, 1054-1082	186
1628	Smart Polymeric Gels: Redefining the Limits of Biomedical Devices. <b>2007</b> , 32, 1083-1122	483
1627	Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. <b>2007</b> , 7, 5	38
1626	Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT <sub>1A</sub> receptor radioligand, [ <sup>11</sup> C](R)-(-)-RWAY. <b>2007</b> , 61, 96-105	58
1625	Modulation of multidrug resistance in cancer cells by the E3 ubiquitin ligase seven-in-absentia homologue 1. <b>2008</b> , 214, 508-14	22
1624	Role of chemotherapy resistance genes in outcome of neuroblastoma. <b>2007</b> , 48, 311-7	39
1623	A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells. <b>2007</b> , 1, 18-31	5
1622	Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. <b>2007</b> , 26, 1357-60	187
1621	Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. <b>2007</b> , 26, 4749-60	107

1620	Nanocarriers as an emerging platform for cancer therapy. <b>2007</b> , 2, 751-60	6530
1619	Waltzing transporters and 'the dance macabre' between humans and bacteria. <b>2007</b> , 6, 56-65	141
1618	The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). <b>2007</b> , 151, 163-74	55
1617	Multiple molecular mechanisms for multidrug resistance transporters. <b>2007</b> , 446, 749-57	678
1616	MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. <b>2007</b> , 17, 347-53	189
1615	Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. <b>2007</b> , 22, 1678-82	22
1614	Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. <b>2007</b> , 274, 6204-14	40
1613	Effect of human WEE1 and stem cell factor on human CD34+ umbilical cord blood cell damage induced by chemotherapeutic agents. <b>2007</b> , 39, 599-607	2
1612	Expresi3n de prote3nas relacionadas con resistencia a m3ltiples f3rmacos y resistencia a la quimioterapia en el c3ncer de pulm3n. <b>2007</b> , 43, 479-484	8
1611	Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. <b>2007</b> , 73, 934-42	20
1610	Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity. <b>2007</b> , 74, 1437-44	32
1609	Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. <b>2007</b> , 16, 262-70	10
1608	Factors determining outcome after third line chemotherapy for metastatic breast cancer. <b>2007</b> , 16, 359-66	27
1607	Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. <b>2007</b> , 173, 1-9	56
1606	The MDR1/ABCB1 regional amplification in large inverted repeats with asymmetric sequences and microhomologies at the junction sites. <b>2007</b> , 178, 120-7	18
1605	Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. <b>2007</b> , 12, 838-43	52
1604	Expression of mdr1 is required for efficient long term regeneration of dystrophic muscle. <b>2007</b> , 313, 2438-50	4
1603	P-Glycoprotein is not present in mitochondrial membranes. <b>2007</b> , 313, 3100-5	28

1602	Functional transcriptomics: an experimental basis for understanding the systems biology for cancer cells. <b>2007</b> , 47, 41-62	
1601	Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. <b>2007</b> , 47, 64-103	63
1600	Anticancer drugs from nature--natural products as a unique source of new microtubule-stabilizing agents. <b>2007</b> , 24, 327-57	205
1599	Inhibition of topoisomerase I activity and efflux drug transporters' expression by xanthohumol. from hops. <b>2007</b> , 30, 1435-9	52
1598	Is MIBG a substrate of P-glycoprotein?. <b>2007</b> , 34, 448-52	7
1597	Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using <sup>99m</sup> Tc-sestamibi. <b>2007</b> , 34, 1793-803	20
1596	Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. <b>2007</b> , 59, 495-505	158
1595	Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. <b>2007</b> , 60, 203-9	23
1594	Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells. <b>2007</b> , 60, 449-57	25
1593	Preclinical antitumor activity of the oral platinum analog satraplatin. <b>2007</b> , 60, 589-600	46
1592	Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. <b>2007</b> , 296, 85-95	171
1591	Genomics and the mechanism of P-glycoprotein (ABCB1). <b>2007</b> , 39, 481-7	61
1590	ABCG2: determining its relevance in clinical drug resistance. <b>2007</b> , 26, 39-57	296
1589	Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. <b>2007</b> , 26, 183-201	102
1588	Characterization of cancer stem-like cells in a novel STI571-resistant chronic myeloid leukemia cell line. <b>2007</b> , 6, 383-388	
1587	The expression and significance of the multidrug resistance-related proteins P-gp, MRP and LRP in human non-small cell lung cancer tissues. <b>2007</b> , 6, 432-436	1
1586	Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor. <b>2007</b> , 166, 447-52	4
1585	Tumour cells resistance in cancer therapy. <b>2007</b> , 9, 13-20	19

1584	ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. <b>2007</b> , 62, 214-26	73
1583	Metalloprobes: synthesis, characterization, and potency of a novel gallium(III) complex in human epidermal carcinoma cells. <b>2007</b> , 101, 1347-53	15
1582	Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. <b>2008</b> , 29, 3856-65	157
1581	Mechanisms of resistance to self-produced toxic secondary metabolites in plants. <b>2008</b> , 7, 467-477	88
1580	Chemoresistance in gliomas. <b>2008</b> , 312, 71-80	108
1579	Expression of ATP-binding cassette multidrug transporters in the giant liver fluke <i>Fasciola gigantica</i> and their possible involvement in the transport of bile salts and anthelmintics. <b>2008</b> , 317, 77-84	25
1578	Cancer stem cells as targets for cancer therapy: selected cancers as examples. <b>2008</b> , 56, 165-80	43
1577	An overview of cancer multidrug resistance: a still unsolved problem. <b>2008</b> , 65, 3145-67	335
1576	Vascular activity of two silicon compounds, ALIS 409 and ALIS 421, novel multidrug-resistance reverting agents in cancer cells. <b>2008</b> , 61, 443-51	10
1575	A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. <b>2008</b> , 61, 453-8	25
1574	A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. <b>2008</b> , 61, 953-63	26
1573	In vitro study of ultrasound on multidrug resistance in MDR human hepatoma HepG2 cells. <b>2008</b> , 5, 165-171	
1572	The Emerging Picture of Human Breast Cancer as a Stem Cell-based Disease. <b>2008</b> , 4, 67-79	25
1571	In search of liver cancer stem cells. <b>2008</b> , 4, 179-92	21
1570	Pharmacogenomics: a tool for improving cancer chemotherapy. <b>2008</b> , 10, 628-37	6
1569	A look at clinical applications and developments of photodynamic therapy. <b>2008</b> , 2, 235-249	25
1568	Chemoprevention and inhibition of P-glycoprotein in cancer cells by Chinese medicinal herbs. <b>2008</b> , 22, 1671-6	14
1567	Synthesis of antiproliferative Cephalotaxus esters and their evaluation against several human hematopoietic and solid tumor cell lines: uncovering differential susceptibilities to multidrug resistance. <b>2008</b> , 14, 4293-306	53



1566	Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells. <b>2008</b> , 112, 1122-30	25
1565	Folate-functionalized polymeric micelles for tumor targeted delivery of a potent multidrug-resistance modulator FG020326. <b>2008</b> , 86, 48-60	65
1564	A subcellular proteomic investigation into vincristine-resistant gastric cancer cell line. <b>2008</b> , 104, 1010-21	35
1563	Synergistic cytotoxic effect of different sized ZnO nanoparticles and daunorubicin against leukemia cancer cells under UV irradiation. <b>2008</b> , 93, 119-26	156
1562	Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells. <b>2008</b> , 16, 474-87	15
1561	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. <b>2008</b> , 16, 362-73	73
1560	Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. <b>2008</b> , 16, 171-80	78
1559	Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells. <b>2008</b> , 16, 3694-703	47
1558	Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells. <b>2008</b> , 16, 9745-56	13
1557	A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins. <b>2008</b> , 18, 4761-3	19
1556	Cytotoxic effects and in vitro reversal of multidrug resistance by therapeutic ultrasound in human hepatocarcinoma cell line (HepG2). <b>2008</b> , 48, 297-302	12
1555	L-histidine-based pH-sensitive anticancer drug carrier micelle: reconstitution and brief evaluation of its systemic toxicity. <b>2008</b> , 358, 177-83	56
1554	Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. <b>2008</b> , 52, 1080-93	79
1553	Therapeutic nanoparticles for drug delivery in cancer. <b>2008</b> , 14, 1310-6	2208
1552	Preparation of hierarchical hollow CaCO <sub>3</sub> particles and the application as anticancer drug carrier. <b>2008</b> , 130, 15808-10	391
1551	Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. <b>2008</b> , 51, 1242-51	133
1550	Multifunctional Polymeric Nanosystems for Tumor-Targeted Delivery. <b>2008</b> , 33-66	2
1549	Multifunctional Water-Soluble Polymers for Drug Delivery. <b>2008</b> , 81-142	8

1548	Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells. <b>2008</b> , 29, 458-64	12
1547	Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas. <b>2008</b> , 116, 791-800	18
1546	In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi. <b>2008</b> , 103, 342-8	19
1545	The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. <b>2008</b> , 22, 1106-16	126
1544	Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. <b>2008</b> , 98, 1515-24	86
1543	Resistance to chemotherapy: new treatments and novel insights into an old problem. <b>2008</b> , 99, 387-91	200
1542	2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. <b>2008</b> , 99, 1842-8	34
1541	Nanoparticle therapeutics: an emerging treatment modality for cancer. <b>2008</b> , 7, 771-82	3332
1540	Drugs and their molecular targets: an updated overview. <b>2008</b> , 22, 1-18	136
1539	Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. <b>2008</b> , 8, 318	58
1538	Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. <b>2008</b> , 8, 375	90
1537	MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. <b>2008</b> , 36, 433-42	76
1536	On the energy-dependence of Hoechst 33342 transport by the ABC transporter LmrA. <b>2008</b> , 75, 866-74	41
1535	Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). <b>2008</b> , 75, 1302-12	129
1534	The complicated copy number alterations in chromosome 7 of a lung cancer cell line is explained by a model based on repeated breakage-fusion-bridge cycles. <b>2008</b> , 185, 11-9	20
1533	Reversal effect of a macrocyclic bisbibenzyl plagiocin E on multidrug resistance in adriamycin-resistant K562/A02 cells. <b>2008</b> , 584, 66-71	46
1532	Computational models for prediction of interactions with ABC-transporters. <b>2008</b> , 13, 311-7	65
1531	Combinatorial library methodology applied to cancer and protease targets. <b>2008</b> , 13, 1107-1108	8

1530	Potential mechanisms of resistance to microtubule inhibitors. <b>2008</b> , 35, S22-7	31
1529	Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. <b>2008</b> , 18, 244-50	175
1528	Multi-functional nanocarriers for targeted delivery of drugs and genes. <b>2008</b> , 130, 121-8	149
1527	Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. <b>2008</b> , 131, 220-7	81
1526	Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. <b>2008</b> , 143, 769-77	75
1525	The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. <b>2008</b> , 57, 114-30	48
1524	Novel insight in structure-activity relationship and bioanalysis of P-glycoprotein targeting highly potent tetrakis-hydroxymethyl substituted 3,9-diazatetraasteranes. <b>2008</b> , 51, 5871-4	22
1523	ATP-binding Cassette (ABC) Transporter Supergene Family: Genetics and Evolution. <b>2008</b> ,	
1522	Human ABC transporters ABCG2 (BCRP) and ABCG4. <b>2008</b> , 38, 863-88	36
1521	Synthesis and biological evaluation of (hetero)arylmethoxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents. <b>2008</b> , 51, 1415-22	15
1520	Resistance to chemotherapy in cancer: a complex and integrated cellular response. <b>2008</b> , 81, 275-300	129
1519	Current status and issues in cancer stem cell study. <b>2008</b> , 26, 741-55	53
1518	ABCG2: structure, function and role in drug response. <b>2008</b> , 4, 1-15	166
1517	Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. <b>2008</b> , 38, 802-32	424
1516	Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity. <b>2008</b> , 51, 3297-303	27
1515	Advanced Dihydropyridines as Novel Multidrug Resistance Modifiers and Reversing Agents. <b>2007</b> , 201-252	13
1514	Molecular mechanisms of adaptation to folate deficiency. <b>2008</b> , 79, 99-143	41
1513	Cytosolic region of TM6 in P-glycoprotein: topographical analysis and functional perturbation by site directed labeling. <b>2008</b> , 47, 3615-24	17

1512	P-glycoprotein: so many ways to turn it on. <b>2008</b> , 48, 365-78	96
1511	Eicosanoids and Resistance of Cancer Cells to Chemotherapeutic Agents. <b>2008</b> , 133-156	
1510	Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. <b>2008</b> ,	2
1509	Drugs That Modulate Resistance to Antitumor Agents. <b>2008</b> , 387-416	1
1508	Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. <b>2008</b> , 383, 281-91	195
1507	Can conception of prostate cancer stem cells influence treatment dedicated to patients with disseminated disease?. <b>2008</b> , 71, 694-9	4
1506	Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. <b>2008</b> , 19, 205-16	160
1505	"Cancer stem cells"-lessons from Hercules to fight the Hydra. <b>2008</b> , 26, 581-9	27
1504	Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats. <b>2008</b> , 71, 1415-29	203
1503	Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. <b>2008</b> , 34, 505-20	89
1502	Role of xenobiotic efflux transporters in resistance to vincristine. <b>2008</b> , 62, 59-64	9
1501	Bypassing cancer drug resistance by activating multiple death pathways--a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. <b>2008</b> , 259, 127-37	68
1500	Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU. <b>2008</b> , 269, 101-10	39
1499	Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. <b>2008</b> , 272, 102-9	62
1498	Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. <b>2008</b> , 11, 110-21	141
1497	Histone deacetylase inhibitor apicidin-mediated drug resistance: involvement of P-glycoprotein. <b>2008</b> , 368, 959-64	29
1496	MDR1 expression identifies human melanoma stem cells. <b>2008</b> , 368, 930-6	104
1495	Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. <b>2008</b> , 34, 378-90	247

1494	Multi-functional nanocarriers to overcome tumor drug resistance. <b>2008</b> , 34, 592-602	335
1493	Histone deacetylase inhibitors from microorganisms: the Astellas experience. <b>2008</b> , 66, 335, 337-59	11
1492	Introduction. <b>2008</b> , 1-8	12
1491	In silico prediction of substrate properties for ABC-multidrug transporters. <b>2008</b> , 4, 1167-80	42
1490	Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro. <b>2008</b> , 38, 1112-21	27
1489	[Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer]. <b>2008</b> , 18 Suppl 7, S365-75	5
1488	Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. <b>2008</b> , 324, 95-102	220
1487	Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. <b>2008</b> , 26, 344-51	32
1486	Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes. <b>2008</b> , 105, 8697-702	317
1485	Individualizing Therapy in Patients With Chronic Kidney Disease. <b>2008</b> , 21, 225-236	
1484	Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. <b>2008</b> , 105, 12128-33	196
1483	Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. <b>2008</b> , 5, 516-26	105
1482	Function-oriented synthesis: biological evaluation of laulimalide analogues derived from a last step cross metathesis diversification strategy. <b>2008</b> , 5, 829-38	24
1481	Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. <b>2008</b> , 51, 6034-43	66
1480	Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania. <b>2008</b> , 51, 7132-43	30
1479	Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing. <b>2008</b> , 7, 4784-91	25
1478	Design, synthesis, and biological evaluation of new-generation taxoids. <b>2008</b> , 51, 3203-21	85
1477	Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. <b>2008</b> , 74, 476-84	53

1476	Drug-Drug Interactions, Second Edition. <b>2008</b> ,	6
1475	Bioactive Heterocycles VI. <b>2008</b> ,	2
1474	Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. <b>2008</b> , 13, 1207-23	65
1473	High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent. <b>2008</b> , 13, 185-93	23
1472	Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. <b>2008</b> , 68, 190-7	433
1471	ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. <b>2008</b> , 14, 4543-9	117
1470	RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. <b>2008</b> , 6, 1607-20	44
1469	Therapeutic nanomedicine: Polymeric nanosystems for drug and gene delivery. <b>2008</b> , 1,	
1468	P-glycoprotein--a clinical target in drug-refractory epilepsy?. <b>2008</b> , 73, 1343-6	43
1467	Future Perspectives for Brain Pharmacotherapies: Implications of Drug Transport Processes at the Blood-brain Barrier. <b>2008</b> , 1, 167-79	3
1466	Effects of the high-affinity Peptide reversin 121 on multidrug resistance proteins in experimental pancreatic cancer. <b>2008</b> , 29, 351-8	6
1465	Dielectrophoretic analysis of changes in cytoplasmic ion levels due to ion channel blocker action reveals underlying differences between drug-sensitive and multidrug-resistant leukaemic cells. <b>2008</b> , 53, N1-7	39
1464	Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. <b>2008</b> , 7, 3081-91	130
1463	Depletion of mitochondrial DNA up-regulates the expression of MDR1 gene via an increase in mRNA stability. <b>2008</b> , 40, 109-17	41
1462	Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy. <b>2008</b> , 283, 5769-79	59
1461	Modulation of drug resistance by artificial transcription factors. <b>2008</b> , 7, 688-97	20
1460	Molecular Drug Targets. <b>2008</b> , 85-105	0
1459	Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif. <b>2008</b> , 295, C807-18	22

1458	Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. <b>2008</b> , 29, 1837-44	90
1457	11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. <b>2008</b> , 49, 649-56	75
1456	Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. <b>2008</b> , 389, 1067-74	36
1455	Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1. <b>2008</b> , 28, 7066-80	102
1454	99mTc-MIBI in the Evaluation of Breast Cancer Biology. <b>2008</b> , 71-81	
1453	Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. <b>2008</b> , 15, 1981-2039	287
1452	Cancer stem cells: how can we target them?. <b>2008</b> , 15, 3171-84	92
1451	Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. <b>2008</b> , 7, 1931-5	49
1450	MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. <b>2008</b> , 7, 1150-5	70
1449	Genetic variations and gene expression of transporters in drug disposition and response. <b>2008</b> , 4, 237-54	20
1448	ABCA2 as a therapeutic target in cancer and nervous system disorders. <b>2008</b> , 12, 491-504	23
1447	Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 Isomers, tetraaisoquinolin derivatives. <b>2008</b> , 31, 1258-64	26
1446	Synthesis and evaluation of novel N-substituted-6-methoxynaphthalene-2-carboxamides as potential chemosensitizing agents for cancer. <b>2008</b> , 56, 894-6	0
1445	Role of the ABC transporters ABCA1 and ABCG1 in foam cell formation and atherosclerosis. <b>2008</b> , 3, 675-687	3
1444	Improved tumour response by laser light treatment. <b>2008</b> ,	
1443	Recent trends in targeted anticancer prodrug and conjugate design. <b>2008</b> , 15, 1802-26	182
1442	Breast cancer, a stem cell disease. <b>2008</b> , 3, 55-65	12
1441	Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. <b>2008</b> , 30, 831-49	47

1440 Cancer Stem Cells and New Therapeutic Approaches. 217-232

1439 . 2008,

1438 Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line. **2008**, 121, 1563-1568 4

1437 New targets of neuroprotection in ischemic stroke. **2008**, 8, 698-712 7

1436 Stem cell biomarkers in chronic myeloid leukemia. **2008**, 24, 201-16 11

1435 Role of Caveolin-1 in Indomethacin-induced Death of Human Hepatocarcinoma SK-Hep1 Cells. **2008**, 12, 143-8 1

1434 Solute Transport, Energy Consumption, and Production in the Kidney. **2008**, 185-209

1433 Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib. **2009**, 2, 83-94 5

1432 . **2009**, 9

1431 Daunorubicin-loaded magnetic nanoparticles of Fe<sub>3</sub>O<sub>4</sub> overcome multidrug resistance and induce apoptosis of K562- $\eta$ /VCR cells in vivo. **2009**, 4, 201-8 26

1430 Hyaluronan $\alpha$ D44 Interactions and Chemoresistance in Cancer Cells. **2009**, 19-35 2

1429 Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro. **2009**, 15, 431-40 15

1428 A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis. **2009**, 4, e6938 40

1427 NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. **2009**, 4, e7415 37

1426 Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. **2009**, 34, 1-9 38

1425 Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. **2009**, 53, 3256-65 77

1424 Targeting multiple kinases in glioblastoma multiforme. **2009**, 18, 277-92 36

1423 Supramolecular assemblies for the active drug targeting to the brain. **2009**, 19, 155-163 2



1422	The secondary multidrug/proton antiporter MdfA tolerates displacements of an essential negatively charged side chain. <b>2009</b> , 284, 6966-71	29
1421	Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. <b>2009</b> , 75, 92-100	86
1420	Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. <b>2009</b> , 27, 4287-92	68
1419	Coadministration of glycolipid-like micelles loading cytotoxic drug with different action site for efficient cancer chemotherapy. <b>2009</b> , 20, 055102	17
1418	Mapping daunorubicin-binding Sites in the ATP-binding cassette transporter MsbA using site-specific quenching by spin labels. <b>2009</b> , 284, 13904-13913	35
1417	Modelling Physiological and Pharmacological Control on Cell Proliferation to Optimise Cancer Treatments. <b>2009</b> , 4, 12-67	28
1416	Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. <b>2009</b> , 21, 793-801	118
1415	Retention of the radiotracers <sup>64</sup> Cu-ATSM and <sup>64</sup> Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression. <b>2009</b> , 50, 1332-9	35
1414	Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. <b>2009</b> , 69, 178-84	105
1413	Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila. <b>2009</b> , 29, 3538-50	129
1412	Oncolytic reovirus effectively targets breast cancer stem cells. <b>2009</b> , 17, 972-9	65
1411	Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins. <b>2009</b> , 8, 655-64	23
1410	Cyclodepsipeptides - potential drugs and lead compounds in the drug development process. <b>2009</b> , 16, 1122-37	70
1409	Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. <b>2009</b> , 69, 7235-42	47
1408	Mechanism of drug sensitivity and resistance in melanoma. <b>2009</b> , 9, 391-7	55
1407	If cancer stem cells are resistant to current therapies, what's next?. <b>2009</b> , 5, 747-50	6
1406	The reversal of drug-resistance in tumors using a drug-carrying nanoparticulate system. <b>2009</b> , 10, 3776-92	38
1405	Role of multidrug transporters in neurotherapeutics. <b>2009</b> , 12, 89-98	11

1404	A dual-fluorescence high-throughput cell line system for probing multidrug resistance. <b>2009</b> , 7, 233-49	45
1403	Combination effects of SC144 and cytotoxic anticancer agents. <b>2009</b> , 20, 312-20	10
1402	A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. <b>2009</b> , 15, 3574-82	81
1401	A combined-cross analysis reveals genes with drug-specific and background-dependent effects on drug sensitivity in <i>Saccharomyces cerevisiae</i> . <b>2009</b> , 183, 1141-51	19
1400	Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. <b>2009</b> , 15, 5811-9	9
1399	Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. <b>2009</b> , 7, 735-44	31
1398	Evolution of vault RNAs. <b>2009</b> , 26, 1975-91	109
1397	Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. <b>2009</b> , 15, 3705-15	95
1396	Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. <b>2009</b> , 69, 4992-8	81
1395	ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. <b>2009</b> , 7, 79-87	94
1394	Drug interactions at the blood-brain barrier: fact or fantasy?. <b>2009</b> , 123, 80-104	145
1393	Metastatic activity and chemotherapy resistance in human pancreatic cancer--influence of cancer stem cells. <b>2009</b> , 146, 430-4	10
1392	Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. <b>2009</b> , 136, 21-9	273
1391	The ABC transporter gene family of <i>Daphnia pulex</i> . <b>2009</b> , 10, 170	93
1390	The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. <b>2009</b> , 9, 356	42
1389	A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. <b>2009</b> , 9, 166-72	12
1388	Cancer research meets evolutionary biology. <b>2009</b> , 2, 62-70	65
1387	7-Diethylamino-3(2'-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimetabolic activity in multidrug resistant cancer cells. <b>2009</b> , 77, 1773-9	43

1386	Nilotinib (AMN107, Tassigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. <b>2009</b> , 78, 153-61	179
1385	Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. <b>2009</b> , 78, 1366-73	49
1384	Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis. <b>2009</b> , 121, 69-75	11
1383	Increased expression of ABC transport proteins is associated with ivermectin resistance in the model nematode Caenorhabditis elegans. <b>2009</b> , 39, 213-20	131
1382	Amplification of the ABCB1 region accompanied by a short sequence of 200bp from chromosome 2 in lung cancer cells. <b>2009</b> , 194, 4-11	1
1381	Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. <b>2009</b> , 609, 34-9	9
1380	The effect of genetic variability on drug response in conventional breast cancer treatment. <b>2009</b> , 625, 122-30	30
1379	Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513. <b>2009</b> , 37, 463-8	9
1378	BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. <b>2010</b> , 126, 1226-34	43
1377	Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. <b>2009</b> , 4, 188-95	47
1376	Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin. <b>2009</b> , 53, 904-20	52
1375	Surfing the wave, cycle, life history, and genes/proteins expressed by testicular germ cells. Part 4: intercellular bridges, mitochondria, nuclear envelope, apoptosis, ubiquitination, membrane/voltage-gated channels, methylation/acetylation, and transcription factors. <b>2010</b> , 73, 364-408	33
1374	MDR1a/1b gene silencing enhances drug sensitivity in rat fibroblast-like synoviocytes. <b>2010</b> , 12, 219-27	8
1373	Identification and targeting of cancer stem cells. <b>2009</b> , 31, 1038-49	123
1372	Predicting ligand interactions with ABC transporters in ADME. <b>2009</b> , 6, 1960-9	36
1371	Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. <b>2009</b> , 135, 181-9	23
1370	ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. <b>2009</b> , 135, 1369-76	55
1369	Hyaluronan substratum induces multidrug resistance in human mesenchymal stem cells via CD44 signaling. <b>2009</b> , 336, 465-75	38

1368	A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. <b>2009</b> , 14, 112-9	27
1367	Design, synthesis and evaluations of acridone derivatives using <i>Candida albicans</i> --search for MDR modulators led to the identification of an anti-candidiasis agent. <b>2009</b> , 17, 3973-9	26
1366	Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. <b>2009</b> , 114, 195-201	72
1365	Impact of novel MDR modulators on human cancer cells: reversal activities and induction studies. <b>2009</b> , 26, 182-8	16
1364	Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. <b>2009</b> , 26, 914-25	66
1363	Pharmacogenomics approach reveals MRP1 (ABCC1)-mediated resistance to geldanamycins. <b>2009</b> , 26, 936-45	12
1362	Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R). <b>2009</b> , 27, 99-110	8
1361	ABC transporters, drug resistance, and cancer stem cells. <b>2009</b> , 14, 3-9	336
1360	Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo. <b>2009</b> , 29, 620-4	4
1359	Proton-Resistant Quantum Dots: Stability in Gastrointestinal Fluids and Implications for Oral Delivery of Nanoparticle Agents. <b>2009</b> , 2, 500-508	39
1358	Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer. <b>2009</b> , 16, 113-20	2
1357	Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. <b>2009</b> , 66, 43-61	161
1356	Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity. <b>2009</b> , 36, 406-12	14
1355	Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. <b>2009</b> , 63, 711-22	116
1354	Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. <b>2009</b> , 64, 53-65	49
1353	The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells. <b>2009</b> , 64, 419-24	27
1352	Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. <b>2009</b> , 5, 2673-7	553
1351	Comparison of Contemporary Feature Selection Algorithms: Application to the Classification of ABC-Transporter Substrates. <b>2009</b> , 28, 1087-1091	5

1350	Synthesis and characterization of thermoresponsive polymers containing reduction-sensitive disulfide linkage. <b>2009</b> , 47, 5989-5997	24
1349	Proteomic approaches for investigation of therapy resistance in cancer. <b>2009</b> , 3, 883-911	4
1348	The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. <b>2009</b> , 69, 1763-73	19
1347	Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. <b>2009</b> , 100, 1701-7	56
1346	Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. <b>2009</b> , 86, 368-77	146
1345	Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. <b>2009</b> , 22, 1312-20	78
1344	Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. <b>2009</b> , 27, 643-51	204
1343	Minicells overcome tumor drug-resistance. <b>2009</b> , 27, 620-1	12
1342	Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. <b>2009</b> , 28, 2358-63	39
1341	Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. <b>2009</b> , 28, 4409-20	61
1340	The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. <b>2009</b> , 28, 2245-56	137
1339	Data-driven homology modelling of P-glycoprotein in the ATP-bound state indicates flexibility of the transmembrane domains. <b>2009</b> , 276, 964-72	32
1338	15-Deoxy-delta 12, 14-prostaglandin J2 induces upregulation of multidrug resistance-associated protein 1 via Nrf2 activation in human breast cancer cells. <b>2009</b> , 1171, 210-6	12
1337	Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts. <b>2009</b> , 50, 1689-96	38
1336	Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. <b>2009</b> , 158, 1153-64	169
1335	Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. <b>2009</b> , 30, 6955-63	207
1334	Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. <b>2009</b> , 33, 1008-19	49
1333	A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. <b>2009</b> , 31, 834-44	140

1332	Synthesis, biological activity and tubulin binding poses of 1-deoxy-9-(R)-dihydrotaxane analogs. <b>2009</b> , 19, 1148-51	7
1331	EmrE, a model for studying evolution and mechanism of ion-coupled transporters. <b>2009</b> , 1794, 748-62	122
1330	In vivo near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes. <b>2009</b> , 3, 3707-13	656
1329	Polymeric Carriers for Anticancer Drugs. <b>2009</b> , 207-243	
1328	Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. <b>2009</b> , 61, 26-33	105
1327	ABCG2: a perspective. <b>2009</b> , 61, 3-13	349
1326	Recent advances in the use of cell-penetrating peptides for medical and biological applications. <b>2009</b> , 61, 953-64	460
1325	Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. <b>2009</b> , 69, 3918-26	231
1324	Botryllamides: natural product inhibitors of ABCG2. <b>2009</b> , 4, 637-47	39
1323	Pharmaceutical Perspectives of Cancer Therapeutics. <b>2009</b> ,	11
1322	The stabilisation of purified, reconstituted P-glycoprotein by freeze drying with disaccharides. <b>2009</b> , 58, 37-44	15
1321	Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. <b>2009</b> , 274, 118-25	40
1320	Naturally-occurring shikonin analogues--a class of necroptotic inducers that circumvent cancer drug resistance. <b>2009</b> , 274, 233-42	101
1319	Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. <b>2009</b> , 274, 327-30	59
1318	Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells. <b>2009</b> , 278, 65-72	72
1317	Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. <b>2009</b> , 279, 13-21	154
1316	Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. <b>2009</b> , 1792, 380-91	52
1315	Emerging new paradigms for ABCG transporters. <b>2009</b> , 1791, 584-93	84

1314	Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. <b>2009</b> , 23, 29-36	36
1313	In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib. <b>2009</b> , 36, 239-46	58
1312	Improved accumulation of ajmalicine and tetrahydroalstonine in Catharanthus cells expressing an ABC transporter. <b>2009</b> , 166, 1405-12	21
1311	Targeting Transglutaminase-2 to Overcome Chemoresistance in Cancer Cells. <b>2009</b> , 95-114	3
1310	Macelignan: a new modulator of P-glycoprotein in multidrug-resistant cancer cells. <b>2009</b> , 61, 538-43	9
1309	C-myc amplification altered the gene expression of ABC- and SLC-transporters in human breast epithelial cells. <b>2009</b> , 6, 627-33	22
1308	Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. <b>2009</b> , 18, 465-73	124
1307	Organic nanoscale drug carriers coupled with ligands for targeted drug delivery in cancer. <b>2009</b> , 19, 5485	76
1306	Drug interactions with lipid membranes. <b>2009</b> , 38, 2509-19	172
1305	iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. <b>2009</b> , 8, 108	61
1304	Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives. <b>2009</b> , 52, 5311-22	68
1303	Transmembrane helix 12 modulates progression of the ATP catalytic cycle in ABCB1. <b>2009</b> , 48, 6249-58	25
1302	Isolation, biology and chemistry of the disorazoles: new anti-cancer macrodiolides. <b>2009</b> , 26, 585-601	39
1301	Potential Molecular Therapeutic Targets in Cancer Stem/Progenitor Cells: Are ATP-Binding Cassette Membrane Transporters Appropriate Targets to Eliminate Cancer-Initiating Cells?. <b>2009</b> , 385-421	
1300	N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors. <b>2009</b> , 52, 807-17	29
1299	The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer. <b>2009</b> , 28, 144	23
1298	Encyclopedia of Cancer. <b>2008</b> , 154-154	
1297	Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. <b>2009</b> , 52, 4524-32	48

1296	Rhodamine inhibitors of P-glycoprotein: an amide/thioamide "switch" for ATPase activity. <b>2009</b> , 52, 3328-41	50
1295	Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. <b>2009</b> , 6, 85-92	20
1294	JWA sensitizes P-glycoprotein-mediated drug-resistant choriocarcinoma cells to etoposide via JNK and mitochondrial-associated signal pathway. <b>2009</b> , 72, 774-81	10
1293	Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. <b>2009</b> , 8, 1716-23	57
1292	Antitumor properties of <i>Gymnosperma glutinosum</i> leaf extracts. <b>2009</b> , 27, 149-55	10
1291	Stimulus-responsive targeted nanomicelles for effective cancer therapy. <b>2009</b> , 4, 657-67	47
1290	A coordinated network of transporters with overlapping specificities provides a robust survival strategy. <b>2009</b> , 106, 9051-6	150
1289	Recent advances in the chemistry and biology of new generation taxoids. <b>2009</b> , 72, 554-65	61
1288	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. <b>2009</b> , 52, 3191-204	125
1287	Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. <b>2009</b> , 22, 740-9	121
1286	Sipholane triterpenoids: chemistry, reversal of ABCB1/P-glycoprotein-mediated multidrug resistance, and pharmacophore modeling. <b>2009</b> , 72, 1291-8	44
1285	Review. Structure and mechanism of ATP-binding cassette transporters. <b>2009</b> , 364, 239-45	283
1284	ABC Proteins and Oncology: Expression, Detection, and Implication of ABC Proteins in Solid Tumors. 143-176	1
1283	Facilitation of drug resistance development by gamma-irradiation in human cancer cells. <b>2009</b> , 22, 921-6	3
1282	Gene expression profiling of adenosine triphosphate-binding cassette transporters in response to K-ras activation and hypoxia in human pancreatic cancer cell cultures. <b>2009</b> , 38, 85-93	4
1281	The P-Glycoprotein 170: Just a Multidrug Resistance Protein or a Protean Molecule?. 15-46	1
1280	Expression of ABC transporters, p53, Bax, Bcl-2 in an archival sample of non-small cell lung cancer bearing a deletion in the EGFR gene. <b>2009</b> , 23, 609-14	3
1279	L1EPO, a novel podophyllotoxin derivative overcomes P-glycoprotein-mediated multidrug resistance in K562/A02 cell line. <b>2009</b> , 32, 609-13	15



1278	ATP11A is a novel predictive marker for metachronous metastasis of colorectal cancer. <b>2009</b> , 23,	4
1277	Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells. <b>2009</b> , 20, 800-6	9
1276	Tumor initiating cells. <b>2009</b> , 10, 192-6	19
1275	Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities. <b>2009</b> , 10, 861-74	41
1274	Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents. <b>2010</b> , 10, 583-92	15
1273	Molecular basis of traditional Chinese medicine in cancer chemoprevention. <b>2010</b> , 7, 67-75	63
1272	Strategies for overcoming chemotherapy resistance in enterohepatic tumours. <b>2010</b> , 10, 467-85	12
1271	Identifying subsets of metastatic breast cancer patients likely to benefit from treatment with the epothilone B analog ixabepilone. <b>2010</b> , 33, 561-7	2
1270	The therapeutic promise of the cancer stem cell concept. <b>2010</b> , 120, 41-50	483
1269	Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. <b>2010</b> , 36, 1513-20	16
1268	Beauvericin and enniatin: emerging toxins and/or remedies?. <b>2010</b> , 3, 415-430	49
1267	A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. <b>2010</b> , 27, 260-73	62
1266	New Concepts on the Critical Functions of Cancer- and Metastasis-Initiating Cells in Treatment Resistance and Disease Relapse: Molecular Mechanisms, Signaling Transduction Elements and Novel Targeting Therapies. <b>2010</b> , 175-207	
1265	Analysis of expression of drug resistance-linked ABC transporters in cancer cells by quantitative RT-PCR. <b>2010</b> , 637, 121-32	7
1264	Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. <b>2010</b> , 89, 653-62	37
1263	Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action. <b>2010</b> , 66, 851-9	15
1262	Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of nitidine. <b>2010</b> , 66, 953-9	12
1261	Papyriferic acid derivatives as reversal agents of multidrug resistance in cancer cells. <b>2010</b> , 18, 2964-75	4

1260	Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. <b>2010</b> , 136, 403-10	9
1259	Tetrandrine prevents acquired drug resistance of K562 cells through inhibition of mdr1 gene transcription. <b>2010</b> , 136, 659-65	31
1258	Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis. <b>2010</b> , 136, 1477-88	25
1257	Prognostic relevance of ALDH1 in breast cancer: a clinicopathological study of 96 cases. <b>2010</b> , 9, 31-35	5
1256	Molecular dynamics simulation of the transmembrane subunit of BtuCD in the lipid bilayer. <b>2010</b> , 53, 620-30	10
1255	Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARgamma activation by troglitazone. <b>2010</b> , 30, 326-31	9
1254	Production of monoclonal antibodies to P-glycoprotein: its application in detection of soluble and surface P-glycoprotein of leukemia patients. <b>2010</b> , 92, 326-33	10
1253	Protein-protein interaction networks suggest different targets have different propensities for triggering drug resistance. <b>2010</b> , 4, 311-22	18
1252	In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy. <b>2010</b> , 97, 195-205	38
1251	Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. <b>2010</b> , 27, 1498-511	57
1250	Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. <b>2010</b> , 142, 89-100	122
1249	Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. <b>2010</b> , 143, 290-301	129
1248	Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. <b>2010</b> , 39, 192-7	31
1247	Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. <b>2010</b> , 35, 36-42	135
1246	Genome-wide identification and evolution of ATP-binding cassette transporters in the ciliate <i>Tetrahymena thermophila</i> : A case of functional divergence in a multigene family. <b>2010</b> , 10, 330	22
1245	Phylogenetic analysis of fungal ABC transporters. <b>2010</b> , 11, 177	141
1244	The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. <b>2010</b> , 10, 204	14
1243	TTFIELDS alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. <b>2010</b> , 10, 229	43

1242	Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. <b>2010</b> , 10, 55	123
1241	Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. <b>2010</b> , 627, 92-8	60
1240	Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein's cellular localization. <b>2010</b> , 41, 53-9	14
1239	The stem cell code in oral epithelial tumorigenesis: 'the cancer stem cell shift hypothesis'. <b>2010</b> , 1806, 146-62	19
1238	Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. <b>2010</b> , 79, 154-61	71
1237	Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. <b>2010</b> , 79, 817-24	272
1236	Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. <b>2010</b> , 79, 1108-17	83
1235	Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. <b>2010</b> , 80, 72-9	25
1234	A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. <b>2010</b> , 80, 1754-61	56
1233	ABC transporter gene expression in benign and malignant ovarian tissue. <b>2010</b> , 117, 198-201	39
1232	Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. <b>2010</b> , 84, 310-5	7
1231	Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells. <b>2010</b> , 116, 5544-54	31
1230	Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. <b>2010</b> , 94, 730-43	24
1229	Analysis of chemoresistance in lung cancer with a simple microfluidic device. <b>2010</b> , 31, 3763-70	12
1228	A novel calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in drug-resistant MCF-7/ADR breast carcinoma cells. <b>2010</b> , 99, 3266-75	22
1227	Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. <b>2010</b> , 225, 822-8	26
1226	Ensemble Rule-Based Classification of Substrates of the Human ABC-Transporter ABCB1 Using Simple Physicochemical Descriptors. <b>2010</b> , 29, 233-42	15
1225	Impact of the Recent Mouse P-Glycoprotein Structure for Structure-Based Ligand Design. <b>2010</b> , 29, 276-86	19

1224	Molecular mechanism of suppression of MDR1 by puerarin from <i>Pueraria lobata</i> via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. <b>2010</b> , 54, 918-28	56
1223	Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. <b>2010</b> , 54, 1574-84	33
1222	Radiosynthesis of [2-(11)C-carbonyl]dantrolene using [(11)C]phosgene for PET. <b>2010</b> , 68, 1715-20	23
1221	Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. <b>2010</b> , 34, 757-62	42
1220	Enhancement of doxorubicin concentration in the M5076 ovarian sarcoma cells by cucurbitacin E co-treatment. <b>2010</b> , 383, 186-91	21
1219	Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. <b>2010</b> , 395, 114-21	29
1218	The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. <b>2010</b> , 31, 358-65	258
1217	Livin gene plays a role in drug resistance of colon cancer cells. <b>2010</b> , 43, 655-60	40
1216	A self-organized 3-diethylaminopropyl-bearing glycol chitosan nanogel for tumor acidic pH targeting: in vitro evaluation. <b>2010</b> , 78, 120-6	69
1215	Radiosynthesis and in vivo evaluation of [(11)C]MC80 for P-glycoprotein imaging. <b>2010</b> , 18, 6489-95	6
1214	How to overcome multidrug resistance in chemotherapy for advanced hepatocellular carcinoma. <b>2010</b> , 30, 496-8	4
1213	Induction of apoptosis by A3 adenosine receptor agonist N-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide in human leukaemia cells: a possible involvement of intracellular mechanism. <b>2010</b> , 199, 171-9	13
1212	Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene. <b>2010</b> , 101, 1493-500	23
1211	Quantitative analysis of cisplatin sensitivity of human esophageal squamous cancer cell lines using in-air micro-PIXE. <b>2010</b> , 101, 1487-92	15
1210	Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. <b>2010</b> , 101, 1447-53	90
1209	PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer. <b>2010</b> , 102, 361-8	30
1208	Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. <b>2010</b> , 103, 560-6	28
1207	How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. <b>2010</b> , 103, 1139-43	312

1206	Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. <b>2010</b> , 87, 126-9	37
1205	Dissecting variability in responses to cancer chemotherapy through systems pharmacology. <b>2010</b> , 88, 34-8	46
1204	Amplification of LAPT4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. <b>2010</b> , 16, 214-8	262
1203	ABC transporters in cancer: more than just drug efflux pumps. <i>Nature Reviews Cancer</i> , <b>2010</b> , 10, 147-56	313 769
1202	Multidrug resistance-associated proteins and implications in drug development. <b>2010</b> , 37, 115-20	40
1201	Transporter-mediated multidrug resistance and its modulation by Chinese medicines and other herbal products. <b>2010</b> , 7, 54-66	10
1200	Molecular mechanism of ochratoxin a transport in the kidney. <b>2010</b> , 2, 1381-98	42
1199	CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. <b>2010</b> , 5, e15183	61
1198	Evaluation of the Reversal of Multidrug Resistance by MDR1 Ribonucleic Acid Interference in a Human Colon Cancer Model Using a Renilla Luciferase Reporter Gene and Coelenterazine. <b>2010</b> , 9, 7290.2010.00021	6
1197	Clinical trials and progress with paclitaxel in ovarian cancer. <b>2010</b> , 2, 411-27	74
1196	Traditional Chinese medicines (TCMs) for molecular targeted therapies of tumours. <b>2010</b> , 7, 37-45	32
1195	Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. <b>2010</b> , 15, 857-70	44
1194	Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. <b>2010</b> , 70, 4499-508	56
1193	Influence of a time-restricted feeding schedule on the daily rhythm of abcb1a gene expression and its function in rat intestine. <b>2010</b> , 335, 418-23	17
1192	N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. <b>2010</b> , 38, 917-22	35
1191	Arsenic-specific stem cell selection during malignant transformation. <b>2010</b> , 102, 638-49	79
1190	Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells. <b>2010</b> , 23, 1469-75	41
1189	Separation and identification of mouse liver membrane proteins using a gel-based approach in combination with 2DnanoLC-Q-TOF-MS/MS. <b>2010</b> , 1, 015015	0

1188	Increased ubiquitination of multidrug resistance 1 by ginsenoside Rd. <b>2010</b> , 62, 252-9	23
1187	Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. <b>2010</b> , 285, 19532-43	71
1186	Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer. <b>2010</b> , 38, 34-42	35
1185	Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer. <b>2010</b> , 78, 675-84	16
1184	Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay. <b>2010</b> , 15, 287-96	27
1183	Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. <b>2010</b> , 78, 855-64	67
1182	Drug Management of Prostate Cancer. <b>2010</b> ,	3
1181	Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. <b>2010</b> , 334, 147-55	191
1180	Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma. <b>2010</b> , 16, 6104-10	15
1179	Molecular mechanism of chemoresistance by astrocyte elevated gene-1. <b>2010</b> , 70, 3249-58	174
1178	Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products. <b>2010</b> , 76, 1143-54	26
1177	Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. <b>2010</b> , 10, 496-508	47
1176	ABC transporters: unvalidated therapeutic targets in cancer and the CNS. <b>2010</b> , 10, 625-33	71
1175	Intrinsic resistance to chemotherapy in breast cancer. <b>2010</b> , 6, 821-30	22
1174	Reversion of multidrug resistance in tumor by biocompatible nanomaterials. <b>2010</b> , 10, 737-45	9
1173	N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR). <b>2010</b> , 10, 1715-31	5
1172	Using structural and mechanistic information to design novel inhibitors/substrates of P-glycoprotein. <b>2010</b> , 10, 1769-74	7
1171	Probing multidrug resistance P-glycoprotein transporter activity with SPECT radiopharmaceuticals. <b>2010</b> , 10, 1834-45	8

1170	Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases. <b>2010</b> , 10, 1732-56	21
1169	Tumor initiation in human malignant melanoma and potential cancer therapies. <b>2010</b> , 10, 131-6	14
1168	In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. <b>2010</b> , 4, 6874-82	278
1167	Novel 4 beta-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents. <b>2010</b> , 6, 410-20	20
1166	ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. <b>2010</b> , 6, 1161-74	51
1165	Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. <b>2010</b> , 53, 1755-62	22
1164	Drug resistance is affected by colocalization of P-glycoproteins in raft-like structures unexpected in eggshells of the nematode <i>Haemonchus contortus</i> . <b>2010</b> , 88, 459-67	9
1163	TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. <b>2010</b> , 9, 199	40
1162	Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols. <b>2010</b> , 9, 99	48
1161	In vivo evaluation of limiting brain penetration of probes for $\beta(2C)$ -adrenoceptor using small-animal positron emission tomography. <b>2010</b> , 1, 520-8	7
1160	Polycationic nanodrug covered with hyaluronic acid for treatment of P-glycoprotein overexpressing cancer cells. <b>2010</b> , 11, 2387-93	28
1159	Synthesis, characterization, and thermodynamic study of a polyvalent lytic peptide-polymer conjugate as novel anticancer agent. <b>2010</b> , 21, 2055-64	8
1158	[Clinicopathological and genomics predictors of response to neoadjuvant chemotherapy in breast cancer]. <b>2010</b> , 38, 475-80	1
1157	The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. <b>2010</b> , 64, 58-62	21
1156	Cell ATP level of <i>Saccharomyces cerevisiae</i> sensitively responds to culture growth and drug-inflicted variations in membrane integrity and PDR pump activity. <b>2010</b> , 395, 51-5	15
1155	Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. <b>2010</b> , 395, 104-10	65
1154	In vivo evaluation of [123I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine, an iodinated SPECT tracer for imaging the P-gp transporter. <b>2010</b> , 37, 469-77	6
1153	Glucosylceramide in humans. <b>2010</b> , 688, 156-64	52

1152	Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain. <b>2010</b> , 3, ra72	38
1151	Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors. <b>2010</b> , 62, 1704-10	7
1150	Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. <b>2010</b> , 53, 1883-97	94
1149	Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. <b>2010</b> , 62, 919-30	357
1148	Receptor-targeted nanocarriers for therapeutic delivery to cancer. <b>2010</b> , 27, 286-98	212
1147	Targeted chemotherapy in drug-resistant tumors, noninvasive imaging of P-glycoprotein-mediated functional transport in cancer, and emerging role of Pgp in neurodegenerative diseases. <b>2010</b> , 596, 141-81	9
1146	Membrane Transporters in Drug Discovery and Development. <b>2010</b> ,	2
1145	Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. <b>2010</b> , 102, 1637-52	208
1144	Stem Cell Biology in Health and Disease. <b>2010</b> ,	
1143	Sphingolipids as Signaling and Regulatory Molecules. <b>2010</b> ,	14
1142	Highly sensitive identification of cancer cells by combining the new tetrathiafulvalene derivative with a $\beta$ -cyclodextrin/multi-walled carbon nanotubes modified GCE. <b>2010</b> , 135, 2965-9	16
1141	Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods. <b>2010</b> , 29, 115	15
1140	Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. <b>2010</b> , 70, 4850-8	153
1139	Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione S-transferase-pi correlated in colorectal adenocarcinoma. <b>2010</b> , 45, 925-34	8
1138	ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies. <b>2010</b> , 6, 571-89	18
1137	Multidrug resistance in the chronic lymphoproliferative disorders. <b>2010</b> , 51, 1793-804	9
1136	Synthesis and MDR inhibitory activity evaluation of derivatives of schizandrin A. <b>2010</b> , 12, 549-56	3
1135	Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. <b>2011</b> , 10, 1252-63	38



1134	Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. <b>2011</b> , 439, 141-9	52
1133	Bioengineering approaches to study multidrug resistance in tumor cells. <b>2011</b> , 3, 529-39	17
1132	Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. <b>2011</b> , 14, 192-205	50
1131	COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. <b>2011</b> , 32, 667-75	63
1130	Enhanced invasiveness in multidrug resistant leukemic cells is associated with overexpression of P-glycoprotein and cellular inhibitor of apoptosis protein. <b>2011</b> , 52, 1302-11	16
1129	Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. <b>2011</b> , 54, 4987-97	32
1128	Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer. <b>2011</b> , 8, 260-9	38
1127	Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. <b>2011</b> , 63, 435-43	25
1126	Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity. <b>2011</b> , 2, 494-7	58
1125	A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. <b>2011</b> , 5, 6184-94	115
1124	Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites. <b>2011</b> , 50, 3724-35	12
1123	A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. <b>2011</b> , 17, 569-80	122
1122	Peptide-chlorambucil conjugates combat pgp-dependent drug efflux. <b>2011</b> , 2, 419-23	18
1121	Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. <b>2011</b> , 5, 9788-98	324
1120	Ha-ras Oncogene and Anticancer Drug Resistance. <b>2011</b> , 3, 39-48	2
1119	Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. <b>2011</b> , 140, 344-55	114
1118	Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. <b>2011</b> , 8, 185-203	117
1117	Nanoscale delivery systems for multiple drug combinations in cancer. <b>2011</b> , 7, 1347-57	11

- 1116 Encyclopedia of Cancer. **2011**, 324-325
- 1115 Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals. **2011**, 40, 3005-18 207
- 1114 Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis. **2011**, 7, 1701-12 33
- 1113 Biological and Biochemical Aspects of Tellurium Derivatives. **2011**,
- 1112 Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. **2011**, 71, 191-8 41
- 1111 Multidrug resistance-associated protein 1 mediates 15-deoxy- $\Delta^{12,14}$ -prostaglandin J2-induced expression of glutamate cysteine ligase expression via Nrf2 signaling in human breast cancer cells. **2011**, 24, 1231-41 20
- 1110 Drug resistance in metastatic castration-resistant prostate cancer. **2011**, 8, 12-23 243
- 1109 Probing the stereoselectivity of P-glycoprotein-synthesis, biological activity and ligand docking studies of a set of enantiopure benzopyrano[3,4-b][1,4]oxazines. **2011**, 47, 2586-8 16
- 1108 Encyclopedia of Cancer. **2011**, 187-187
- 1107 Encyclopedia of Cancer. **2011**, 174-178
- 1106 Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. **2011**, 5, 5729-45 224
- 1105 Encyclopedia of Cancer. **2011**, 115-115
- 1104 The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). **2011**, 2, 82-9 129
- 1103 Emerging Therapeutic Targets in Ovarian Cancer. **2011**, 1 1
- 1102 The novel potent multidrug resistance inhibitors N,N-bis(cyclohexanol)amine aryl esters are devoid of vascular effects. **2011**, 88, 137-41 2
- 1101 Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates. **2011**, 5, 6962-70 100
- 1100 Oleanolic acid derivative methyl 3,11-dioxolean-12-en-28-olate targets multidrug resistance related to ABCB1. **2011**, 63, 1500-17 11
- 1099 Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. **2011**, 178, 838-52 109

1098	Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. <b>2011</b> , 65, 85-9	38
1097	The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines. <b>2011</b> , 65, 345-53	46
1096	PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. <b>2011</b> , 300, 48-56	62
1095	Retrovirus-mediated multidrug resistance gene (MDR1) overexpression inhibits chemotherapy-induced toxicity of granulosa cells. <b>2011</b> , 95, 1390-6.e1-6	8
1094	Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. <b>2011</b> , 14, 191-201	426
1093	Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. <b>2011</b> , 1812, 796-805	28
1092	Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane. <b>2011</b> , 1808, 154-63	27
1091	In vitro and in vivo activity of 4-thio-uridylyate against JY cells, a model for human acute lymphoid leukemia. <b>2011</b> , 410, 682-7	1
1090	Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression. <b>2011</b> , 412, 207-13	49
1089	Oroidin inhibits the activity of the multidrug resistance target Pdr5p from yeast plasma membranes. <b>2011</b> , 74, 279-82	13
1088	The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. <b>2011</b> , 8, 1996-2011	159
1087	A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells. <b>2011</b> , 83, 1466-71	18
1086	Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GST activity. <b>2011</b> , 25, 937-43	17
1085	Epothilones in prostate cancer. <b>2011</b> , 29, 358-65	4
1084	Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. <b>2011</b> , 54, 3606-23	162
1083	Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. <b>2011</b> , 2, e179	234
1082	Glutathione in cancer cell death. <b>2011</b> , 3, 1285-310	196
1081	Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. <b>2011</b> , 152, 418-25	106

1080	3'-O, 4'-O-aromatic acyl substituted 7,8-pyrano-coumarins: a new class of P-glycoprotein modulators. <b>2012</b> , 64, 90-100	14
1079	Nanoparticles in cancer chemotherapy. <b>2011</b> , 104, 489-507	24
1078	Quinoline as a privileged scaffold in cancer drug discovery. <b>2011</b> , 18, 1488-508	410
1077	ABCB1 protects kidney proximal tubule cells against cadmium-induced apoptosis: roles of cadmium and ceramide transport. <b>2011</b> , 121, 343-56	43
1076	ATP-binding cassette transporters and their roles in protecting the brain. <b>2011</b> , 17, 423-36	29
1075	Radiobiology goes 3D: how ECM and cell morphology impact on cell survival after irradiation. <b>2011</b> , 99, 271-8	89
1074	ATP-Binding Cassette Transporters Modulate Both Coelenterazine- and D-Luciferin-Based Bioluminescence Imaging. <b>2011</b> , 10, 7290.2010.00045	9
1073	Smart Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems. <b>2011</b> , 1, 67-84	
1072	Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. <b>2011</b> , 4, 11-33	25
1071	EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. <b>2011</b> , 16, 1811-23	14
1070	Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. <b>2011</b> , 6, 1027-34	11
1069	Multidrug Resistance Transporters Roles in maintaining Cancer Stem-Like Cells. <b>2011</b> ,	1
1068	Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. <b>2011</b> , 28, 1-45	86
1067	Encyclopedia of Cancer. <b>2011</b> , 178-184	
1066	Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. <b>2011</b> , 16, 368-92	47
1065	Piceatannol, an Antitumor Compound from Euphorbia lagascae Seeds. <b>2011</b> , 453-460	
1064	Molecular evolutionary analysis of ABCB5: the ancestral gene is a full transporter with potentially deleterious single nucleotide polymorphisms. <b>2011</b> , 6, e16318	21
1063	Inhibition of multidrug resistance by SV40 pseudovirion delivery of an antigene peptide nucleic acid (PNA) in cultured cells. <b>2011</b> , 6, e17981	14

1062	The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. <b>2011</b> , 6, e19329	62
1061	Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters. <b>2011</b> , 6, e22429	66
1060	Killing them with kindness? In-hive medications may inhibit xenobiotic efflux transporters and endanger honey bees. <b>2011</b> , 6, e26796	65
1059	Drug transport and transporters. 90-102	
1058	Microwave-Assisted Synthesis and Evaluation of Substituted Aryl Propyl Acridone-4-Carboxamides as Potential Chemosensitizing Agents for Cancer. <b>2011</b> , 8, 268-275	1
1057	The impact of folate status on the efficacy of colorectal cancer treatment. <b>2011</b> , 12, 975-84	15
1056	Nanotechnology platforms; an innovative approach to brain tumor therapy. <b>2011</b> , 7, 488-503	8
1055	Synthesis and Comparison of the Antitumor Activities of Steroids on ABCB1-transfected Mouse Lymphoma and Human Ovary Carcinoma. <b>2011</b> , 8, 138-147	
1054	P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. <b>2011</b> , 39, 925-33	18
1053	PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. <b>2011</b> , 12, 774-92	57
1052	Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma. <b>2011</b> , 39, 425-31	40
1051	Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8 $\beta$ <sup>+</sup> semi-invariant T cells. <b>2011</b> , 118, 2752-62	90
1050	Improving cancer chemotherapy with modulators of ABC drug transporters. <b>2011</b> , 12, 621-30	169
1049	Evolution of Vault RNAs. <b>2011</b> ,	
1048	Tryptanthrin-loaded nanoparticles for delivery into cultured human breast cancer cells, MCF7: the effects of solid lipid/liquid lipid ratios in the inner core. <b>2011</b> , 59, 266-71	44
1047	Cancer stem cells and markers: new model of tumorigenesis with therapeutic implications. <b>2010</b> , 9, 65-99	10
1046	A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. <b>2011</b> , 6, 2123-31	18
1045	Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. <b>2011</b> , 12, 609-20	126

1044	Functional expression and characterization in <i>Xenopus laevis</i> oocytes of the ABCG2 transporter derived from A549 human lung adenocarcinoma cells. <b>2012</b> , 27, 499-503	
1043	HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. <b>2011</b> , 38, 807-12	30
1042	Metformin inhibits P-glycoprotein expression via the NF- $\kappa$ B pathway and CRE transcriptional activity through AMPK activation. <b>2011</b> , 162, 1096-108	131
1041	Phenotype prediction of non-synonymous single-nucleotide polymorphisms in human ATP-binding cassette transporter genes. <b>2011</b> , 108, 94-114	10
1040	In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. <b>2011</b> , 108, 177-84	17
1039	A yeast cell-based system for screening <i>Candida glabrata</i> multidrug resistance reversal agents and selection of loss-of-function pdr1 mutants. <b>2011</b> , 11, 155-9	1
1038	The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. <b>2011</b> , 10, 389-97	838
1037	Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. <b>2011</b> , 30, 482-93	94
1036	ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. <b>2011</b> , 30, 4874-86	135
1035	Melanoma stem cells: not rare, but well done. <b>2011</b> , 91, 647-64	66
1034	Rapid detection of ABC transporter interaction: potential utility in pharmacology. <b>2011</b> , 63, 217-22	31
1033	Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. <b>2011</b> , 152, 76-83	227
1032	Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. <b>2011</b> , 155, 237-47	99
1031	Expression of multidrug resistance-associated P-glycoprotein in feline tumours. <b>2011</b> , 144, 164-9	6
1030	Platelet activating factor induces blood brain barrier permeability alteration in vitro. <b>2011</b> , 230, 42-7	12
1029	Reversal effect of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU. <b>2011</b> , 18, 1086-92	30
1028	Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo. <b>2011</b> , 18, 1096-101	23
1027	ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. <b>2011</b> , 6, 90	35

1026	Characterisation of antimony-resistant <i>Leishmania donovani</i> isolates: biochemical and biophysical studies and interaction with host cells. <b>2011</b> , 41, 1311-21	72
1025	Reversal effect of Dioscin on multidrug resistance in human hepatoma HepG2/adriamycin cells. <b>2011</b> , 654, 129-34	39
1024	A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells. <b>2011</b> , 669, 38-44	16
1023	Upregulation of <i>mdr1</i> gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. <b>2011</b> , 39, 558-69	56
1022	Synthesis and biological evaluation of RON-neoglycosides as tumor cytotoxins. <b>2011</b> , 346, 2663-76	22
1021	Synthesis and structure-activity evaluation of isatin- $\beta$ -thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. <b>2011</b> , 54, 5878-89	86
1020	Role of MicroRNAs in Anti-cancer Drug Resistance. <b>2011</b> , 449-483	3
1019	Nanoparticles: a promising modality in the treatment of sarcomas. <b>2011</b> , 28, 260-72	12
1018	Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. <b>2011</b> , 28, 3091-100	95
1017	Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro. <b>2011</b> , 36, 1397-406	31
1016	Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. <b>2011</b> , 67, 823-8	65
1015	Over-expression of MDR1 in amrubicinol-resistant lung cancer cells. <b>2011</b> , 68, 669-76	9
1014	A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. <b>2011</b> , 68, 1033-44	13
1013	Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein. <b>2011</b> , 68, 1179-90	29
1012	Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases. <b>2011</b> , 68, 1325-30	24
1011	Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. <b>2011</b> , 68, 1093-8	7
1010	In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. <b>2011</b> , 85, 315-26	42
1009	Assay for determination of daunorubicin in cancer cells with multidrug resistance phenotype. <b>2011</b> , 879, 1875-80	13

1008	Theoretical optimization of Irinotecan-based anticancer strategies in the case of drug-induced efflux. <b>2011</b> , 24, 1251-1256	9
1007	Effects of Ganoderic acid Me on inhibiting multidrug resistance and inducing apoptosis in multidrug resistant colon cancer cells. <b>2011</b> , 46, 1307-1314	15
1006	Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. <b>2011</b> , 34, 33-44	30
1005	Formulation strategy to overcome multi-drug resistance (MDR). <b>2011</b> , 34, 511-3	3
1004	Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. <b>2011</b> , 34, 607-13	132
1003	Cancer stem cells and cancer therapy. <b>2011</b> , 32, 425-40	108
1002	Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells. <b>2011</b> , 31, 488	14
1001	Proliferation-inhibiting and apoptosis-inducing effects of ursolic acid and oleanolic acid on multi-drug resistance cancer cells in vitro. <b>2011</b> , 17, 607-11	61
1000	Colorectal Cancer Stem Cells: Biology and Therapeutic Implications. <b>2011</b> , 7, 128-135	34
999	P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. <b>2011</b> , 11, 254	13
998	In silico quantitative structure-activity relationship studies on P-gp modulators of tetrahydroisoquinoline-ethyl-phenylamine series. <b>2011</b> , 11, 5	14
997	Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. <b>2011</b> , 11, 3	89
996	Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. <b>2011</b> , 10, 80	33
995	An integrative approach to identifying cancer chemoresistance-associated pathways. <b>2011</b> , 4, 23	16
994	Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. <b>2011</b> , 4, 21	54
993	Genome-wide identification and characterization of ATP-binding cassette transporters in the silkworm, <i>Bombyx mori</i> . <b>2011</b> , 12, 491	89
992	Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. <b>2011</b> , 29, 32-45	338
991	Impact of lipid substitution on assembly and delivery of siRNA by cationic polymers. <b>2011</b> , 11, 662-72	68



990	Pegylated phosphatidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. <b>2011</b> , 100, 2267-77	27
989	MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. <b>2011</b> , 33, 786-91	58
988	Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. <b>2011</b> , 33, 959-68	18
987	Cytometric assessment of mitochondria using fluorescent probes. <b>2011</b> , 79, 405-25	245
986	ABCG2 is required to control the sonic hedgehog pathway in side population cells with stem-like properties. <b>2011</b> , 79, 672-83	14
985	IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathway. <b>2011</b> , 128, 1966-80	4
984	Multifunctional Gold Nanoshells on Silica Nanorattles: A Platform for the Combination of Photothermal Therapy and Chemotherapy with Low Systemic Toxicity. <b>2011</b> , 123, 921-925	84
983	Multifunctional gold nanoshells on silica nanorattles: a platform for the combination of photothermal therapy and chemotherapy with low systemic toxicity. <b>2011</b> , 50, 891-5	430
982	Micellar electrokinetic chromatographic analysis for in vitro accumulation of anthracyclines enhanced by inhibitors of cell membrane transporter-proteins in cancer cells. <b>2011</b> , 25, 1168-74	5
981	Effects of a moderate-intensity static magnetic field and adriamycin on K562 cells. <b>2011</b> , 32, 191-9	21
980	The two faces of FBW7 in cancer drug resistance. <b>2011</b> , 33, 851-9	32
979	Rapid determination of multidrug resistance-associated protein in cancer cells by capillary electrophoresis immunoassay. <b>2011</b> , 1218, 3923-7	14
978	Rapid diagnosis of multidrug resistance in cancer by electrochemical sensor based on carbon nanotubes-drug supramolecular nanocomposites. <b>2011</b> , 26, 3361-6	37
977	Synthesis and in vivo evaluation of $^{18}\text{F}$ -fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters. <b>2011</b> , 19, 861-70	23
976	Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. <b>2011</b> , 19, 4782-95	50
975	Inhibition of P-glycoprotein-mediated Multidrug Resistance (MDR) by N,N-bis(cyclohexanol)amine aryl esters: further restriction of molecular flexibility maintains high potency and efficacy. <b>2011</b> , 21, 106-9	12
974	Polymeric micelles for nano-scale drug delivery. <b>2011</b> , 71, 227-234	338
973	Ultrasound reverses multidrug resistance in human cancer cells by altering gene expression of ABC transporter proteins and Bax protein. <b>2011</b> , 37, 151-9	30

972	The tau-path test for monotone association in an unspecified subpopulation: Application to chemogenomic data mining. <b>2011</b> , 8, 97-111	9
971	The medicinal chemistry of novel iron chelators for the treatment of cancer. <b>2011</b> , 11, 483-99	66
970	Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). <b>2011</b> , 18, 439-81	89
969	Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. <b>2011</b> , 12, 732-41	61
968	Central neurotoxicity in cancer chemotherapy: pharmacogenetic insights. <b>2011</b> , 12, 379-95	21
967	Comparative proteomic analysis of advanced serous epithelial ovarian carcinoma: possible predictors of chemoresistant disease. <b>2011</b> , 15, 281-92	9
966	Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. <b>2011</b> , 39, 729-35	56
965	Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. <b>2011</b> , 108, 2593-8	45
964	The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model. <b>2011</b> , 16, 10556-69	40
963	Regulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a chinese medicinal formula, in vitro and in vivo. <b>2011</b> , 10, 58-69	14
962	Expression of ABC transporters is an unfavorable prognostic factor in laryngeal squamous cell carcinoma. <b>2011</b> , 120, 820-7	23
961	2-(Naphthalene-1-yl)-6-pyrrolidinyl-4-quinazolinone inhibits skin cancer M21 cell proliferation through aberrant expression of microtubules and the cell cycle. <b>2011</b> , 338, 942-51	7
960	Long-chain polyunsaturated fatty acids promote paclitaxel cytotoxicity via inhibition of the MDR1 gene in the human colon cancer Caco-2 cell line. <b>2011</b> , 30, 265-73	54
959	Reversal of multidrug resistance by guggulsterone in drug-resistant MCF-7 cell lines. <b>2011</b> , 57, 62-70	20
958	Current and emerging therapies for advanced adrenocortical carcinoma. <b>2011</b> , 16, 36-48	27
957	Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. <b>2011</b> , 108, 20778-83	70
956	Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. <b>2011</b> , 10, 761-9	91
955	Encyclopedia of Cancer. <b>2011</b> , 29-32	

954	A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma. <b>2011</b> , 38, 1653-61	9
953	Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. <b>2012</b> , 27, 265-9	29
952	Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. <b>2011</b> , 301, G347-55	24
951	ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. <b>2011</b> , 12, 600-20	123
950	Passive and active tumour targeting with nanocarriers. <b>2011</b> , 8, 188-96	121
949	Active-targeted nanotherapy strategies for prostate cancer. <b>2011</b> , 11, 954-65	18
948	P-glycoprotein retains drug-stimulated ATPase activity upon covalent linkage of the two nucleotide binding domains at their C-terminal ends. <b>2011</b> , 286, 10476-82	35
947	The Study of Apoptosis Induced by Allicin in HT-9/HL-60 and its Transfection Cell. <b>2011</b> , 340, 409-415	2
946	Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells. <b>2011</b> , 105, 513-22	10
945	Toward a new age of cellular pharmacokinetics in drug discovery. <b>2011</b> , 43, 335-45	38
944	Effect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells. <b>2011</b> , 27, 553-9	12
943	Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. <b>2011</b> , 10, 1378-84	367
942	A new tool to enhance the efficacy of chemoembolization to treat primary and metastatic hepatic tumors. <b>2011</b> , 8, 409-13	3
941	Revisiting the ABCs of multidrug resistance in cancer chemotherapy. <b>2011</b> , 12, 570-94	155
940	Quantitative structure- $\beta$ -cytotoxicity relationships (QSCR) for semi-synthetic Taxoteres against cancer cell lines. <b>2011</b> , 37, 1122-1130	
939	Peloruside- and laulimalide-resistant human ovarian carcinoma cells have $\beta$ tubulin mutations and altered expression of $\beta$ - and $\beta$ -tubulin isotypes. <b>2011</b> , 10, 1419-29	36
938	Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. <b>2011</b> , 10, 1490-9	24
937	Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. <b>2011</b> , 16, 1487-97	21

- 936 New substrates on the block: clinically relevant resistances for EmrE and homologues. **2012**, 194, 6766-70 11
- 935 The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia. **2012**, 2012, 671702 16
- 934 Herbal Compound "Songyou Yin" Renders Hepatocellular Carcinoma Sensitive to Oxaliplatin through Inhibition of Stemness. **2012**, 2012, 908601 23
- 933 The Hedgehog receptor patched functions in multidrug transport and chemotherapy resistance. **2012**, 10, 1496-508 30
- 932 miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. **2012**, 446, 291-300 70
- 931 Reversion of p-glycoprotein-mediated multidrug resistance in human leukemic cell line by diallyl trisulfide. **2012**, 2012, 719805 12
- 930 Effects of 3-acetyl tormentic acid (3ATA) on ABC proteins activity. **2012**, 13, 6757-71 13
- 929 PPAR Medicines and Human Disease: The ABCs of It All. **2012**, 2012, 504918 13
- 928 Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. **2012**, 30, 119-25 20
- 927 Functionalization of single-walled carbon nanotubes and their binding to cancer cells. **2012**, 7, 905-14 42
- 926 Three decades of P-gp inhibitors: skimming through several generations and scaffolds. **2012**, 19, 1946-2025 332
- 925 Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia. **2012**, 8, 249-258 8
- 924 Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. **2012**, 12, 962-86 46
- 923 Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEP-2 cells. **2012**, 13, 1307-18 18
- 922 Stem-like cells and therapy resistance in squamous cell carcinomas. **2012**, 65, 235-65 26
- 921 Single molecule tracking of P-glycoprotein in live cells reveals dynamic heterogeneity. **2012**, 2012, 3159-62 41
- 920 Canonical and noncanonical Hedgehog/GLI signaling in hematological malignancies. **2012**, 88, 25-54 41
- 919 The role of ABC transporters in progression and clinical outcome of colorectal cancer. **2012**, 27, 187-96 150

918	Recent advances in pharmacogenomics of ABC transporters involved in breast cancer therapy. <b>2012</b> , 13, 633-6	6
917	Advances in Cancer Stem Cell Biology. <b>2012</b> ,	2
916	Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers. <b>2012</b> , 3, e293	68
915	Localization and substrate selectivity of sea urchin multidrug (MDR) efflux transporters. <b>2012</b> , 287, 43876-83	47
914	Dynamic ligand-induced conformational rearrangements in P-glycoprotein as probed by fluorescence resonance energy transfer spectroscopy. <b>2012</b> , 287, 1112-27	71
913	MEDICINAL RADIOPHARMACEUTICAL CHEMISTRY OF METAL RADIOPHARMACEUTICALS. <b>2012</b> , 08, 11-81	3
912	ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. <b>2012</b> , 83, 218-27	18
911	Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. <b>2012</b> , 13, 615-24	24
910	Doxorubicin and chloroquine coencapsulated liposomes: preparation and improved cytotoxicity on human breast cancer cells. <b>2012</b> , 22, 245-53	15
909	Hyaluronan regulates cell behavior: a potential niche matrix for stem cells. <b>2012</b> , 2012, 346972	136
908	The frequency and clinical relevance of multidrug resistance protein expression in patients with lymphoma. <b>2012</b> , 29, 120-9	1
907	Overcoming drug resistance and treating advanced prostate cancer. <b>2012</b> , 13, 1308-23	76
906	Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. <b>2012</b> , 13, 1799-819	83
905	Colon adenocarcinoma multidrug resistance reverted by Euphorbia diterpenes: structure-activity relationships and pharmacophore modeling. <b>2012</b> , 12, 1015-24	21
904	Nanocarriers to solid tumors: considerations on tumor penetration and exposure of tumor cells to therapeutic agents. <b>2012</b> , 13, 1306-16	13
903	miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. <b>2012</b> , 44, 269-77	45
902	Effect of NF- $\kappa$ B inhibitors on the chemotherapy-induced apoptosis of the colon cancer cell line HT-29. <b>2012</b> , 4, 716-722	16
901	Special AT-rich sequence binding protein 1 regulates the multidrug resistance and invasion of human gastric cancer cells. <b>2012</b> , 4, 156-162	28

900	YB-1 Protein and Multidrug Resistance of Tumor Cells. <b>2012</b> , 7, 237-246	7
899	SPECT and PET Imaging of Multidrug Resistance. <b>2012</b> , 315-339	
898	PET and SPECT in Cancer Theragnostics. <b>2012</b> , 979-1014	
897	Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. <b>2012</b> , 23, 865-73	21
896	Genomics and cancer drug resistance. <b>2012</b> , 13, 651-73	33
895	Tumor stem cells: A new approach for tumor therapy (Review). <b>2012</b> , 4, 187-193	4
894	Network systems biology for targeted cancer therapies. <b>2012</b> , 31, 134-41	20
893	Modulation of P-glycoprotein expression by triptolide in adriamycin-resistant K562/A02 cells. <b>2012</b> , 3, 485-489	18
892	The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. <b>2012</b> , 27, 1703-9	25
891	Oral Chemotherapeutic Agents. <b>2012</b> , 1	1
890	Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1. <b>2012</b> , 3, 135-140	12
889	Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. <b>2012</b> , 40, 2122-30	30
888	Mesoporous Silica Nanoparticles in Nanomedicine. <b>2012</b> , 135-182	
887	Effects of Kampo medicines on MDR-1-mediated multidrug resistance in human hepatocellular carcinoma HuH-7/PTX cells. <b>2012</b> , 35, 1729-39	14
886	Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113. <b>2012</b> , 39, 1219-25	15
885	Recent advances in drug delivery strategies for treatment of ovarian cancer. <b>2012</b> , 9, 567-83	29
884	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. <b>2012</b> , 19, 977-87	71
883	Preparation, characterization and cytotoxicity of carbon nanotube-chitosan-phycoerythrin complex. <b>2012</b> , 23, 035101	29

882	Identification of docetaxel resistance genes in castration-resistant prostate cancer. <b>2012</b> , 11, 329-39	74
881	Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis. <b>2012</b> , 29, 3040-52	36
880	Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF- $\kappa$ B pathways. <b>2012</b> , 326, 135-42	26
879	Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. <b>2012</b> , 33, 8613-24	118
878	Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site. <b>2012</b> , 81, 431-9	18
877	Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the anti-tumor effect of metformin in prostate cancer cells. <b>2012</b> , 7, 493-506	38
876	Investigational ABC transporter inhibitors. <b>2012</b> , 21, 657-66	88
875	Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. <b>2012</b> , 13, 1979-88	31
874	Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. <b>2012</b> , 436, 127-34	54
873	Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. <b>2012</b> , 2, 3-44	629
872	Stem Cells and Cancer Stem Cells: New Insights. <b>2012</b> , 17-31	
871	A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines. <b>2012</b> , 30, 880-8	17
870	Effects of pharmaceuticals on the expression of genes involved in detoxification in a carp primary hepatocyte model. <b>2012</b> , 46, 6306-14	29
869	Synthesis, characterization and anticancer activity of 3-aza-analogues of DP-7. <b>2012</b> , 21, 4002-4009	9
868	Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. <b>2012</b> , 138, 1449-62	36
867	Protein kinase C $\beta$ protects against multidrug resistance in human colon cancer cells. <b>2012</b> , 34, 61-9	25
866	Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. <b>2012</b> , 135, 737-47	73
865	Acquired resistance to peloruside A and laulimalide is associated with downregulation of vimentin in human ovarian carcinoma cells. <b>2012</b> , 29, 3022-32	11

864	Statins and cancer: current and future prospects. <b>2012</b> , 324, 1-12	134
863	Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. <b>2012</b> , 22, 373-88	316
862	Chemistry of DNA minor groove binding agents. <b>2012</b> , 115, 105-18	77
861	Different roles of TM5, TM6, and ECL3 in the oligomerization and function of human ABCG2. <b>2012</b> , 51, 3634-41	8
860	CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. <b>2012</b> , 64, 751-7	27
859	Multiplex analysis of tumor multidrug-resistance genes expression with photonic suspension array. <b>2012</b> , 137, 3343-8	14
858	Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. <b>2012</b> , 82, 47-58	79
857	Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer. <b>2012</b> , 55, 3113-21	35
856	Partial synthesis and biological evaluation of bisbenzylisoquinoline alkaloids derivatives: potential modulators of multidrug resistance in cancer. <b>2012</b> , 14, 564-76	14
855	The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier. <b>2012</b> , 39, 121-5	17
854	Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine. <b>2012</b> , 54, 483-98	19
853	Flow cytometric techniques for detection of candidate cancer stem cell subpopulations in canine tumour models. <b>2012</b> , 10, 252-73	13
852	Nontoxic concentrations of PEGylated graphene nanoribbons for selective cancer cell imaging and photothermal therapy. <b>2012</b> , 22, 20626	176
851	Role of ABC transporters in the pathogenesis of Alzheimer's disease. <b>2012</b> , 3, 820-31	94
850	Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. <b>2012</b> , 180, 2490-503	191
849	cDNA cloning and expression profile analysis of an ATP-binding cassette transporter in the hepatopancreas and intestine of shrimp <i>Fenneropenaeus chinensis</i> . <b>2012</b> , 356-357, 250-255	9
848	Fabrication of magnetic nanoparticles with controllable drug loading and release through a simple assembly approach. <b>2012</b> , 162, 233-41	73
847	Epigenetic loss of CDH1 correlates with multidrug resistance in human hepatocellular carcinoma cells. <b>2012</b> , 422, 739-44	10



846	Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells. <b>2012</b> , 50, 1060-5	32
845	Simultaneous nuclear imaging and intranuclear drug delivery by nuclear-targeted multifunctional upconversion nanoprobe. <b>2012</b> , 33, 7282-90	128
844	Reversal effect of Tween-20 on multidrug resistance in tumor cells in vitro. <b>2012</b> , 66, 187-94	13
843	Thiorhodamines containing amide and thioamide functionality as inhibitors of the ATP-binding cassette drug transporter P-glycoprotein (ABCB1). <b>2012</b> , 20, 4290-302	8
842	ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells. <b>2012</b> , 315, 153-60	30
841	Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. <b>2012</b> , 315, 198-205	77
840	Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell detachment and reattachment. <b>2012</b> , 321, 36-44	14
839	Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/ $\beta$ -catenin pathway. <b>2012</b> , 323, 106-113	90
838	Cell-derived microvesicles and antitumoral multidrug resistance. <b>2012</b> , 335, 103-6	7
837	Molecular cloning and characterisation of a novel P-glycoprotein in the salmon louse <i>Lepeophtheirus salmonis</i> . <b>2012</b> , 155, 198-205	21
836	Starvation, detoxification, and multidrug resistance in cancer therapy. <b>2012</b> , 15, 114-22	44
835	Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. <b>2012</b> , 15, 70-80	128
834	Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. <b>2012</b> , 15, 50-61	151
833	Collateral sensitivity as a strategy against cancer multidrug resistance. <b>2012</b> , 15, 98-105	215
832	Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers. <b>2012</b> , 81, 33-42	32
831	PXR and NF- $\kappa$ B correlate with the inducing effects of IL-1 $\beta$ and TNF- $\alpha$ on ABCG2 expression in breast cancer cell lines. <b>2012</b> , 47, 474-80	20
830	Design, synthesis and pharmacophoric model building of novel substituted nicotinic acid hydrazones with potential antiproliferative activity. <b>2012</b> , 35, 1543-52	23
829	Effect of dietary polyphenols on K562 leukemia cells: a Foodomics approach. <b>2012</b> , 33, 2314-27	46

828	Annotating Human P-Glycoprotein Bioassay Data. <b>2012</b> , 31, 599-609	27
827	Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells. <b>2012</b> , 30, 2175-87	33
826	Dual regulation of P-glycoprotein expression by trichostatin A in cancer cell lines. <b>2012</b> , 13, 25	12
825	Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. <b>2012</b> , 12, 139	78
824	Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments. <b>2012</b> , 12, 522	28
823	Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. <b>2012</b> , 5, 47	22
822	The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. <i>Nature Reviews Cancer</i> , <b>2012</b> , 12, 587-98	313 415
821	Magnetoliposomes and their potential in the intelligent drug-delivery field. <b>2012</b> , 3, 1469-82	14
820	Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. <b>2012</b> , 132, 2440-2450	63
819	Transporter Proteins. <b>2012</b> , 129-174	
818	8.8 Molecular Aspects of the Translocation Process by ABC Proteins. <b>2012</b> , 145-173	6
817	Asperjinone, a nor-neolignan, and terrein, a suppressor of ABCG2-expressing breast cancer cells, from thermophilic <i>Aspergillus terreus</i> . <b>2012</b> , 75, 630-5	76
816	An Overview of the Current Development of Phytoremedies for Breast Cancer. <b>2012</b> , 47-67	2
815	Drug Delivery Using Nanocarriers: Indian Perspective. <b>2012</b> , 82, 167-206	11
814	Strategic Incorporation of Fluorine into Taxoid Anticancer Agents. <b>2012</b> , 209-240	
813	Uptake and transport of a novel anticancer drug-delivery system: lactosyl-norcantharidin-associated N-trimethyl chitosan nanoparticles across intestinal Caco-2 cell monolayers. <b>2012</b> , 7, 1921-30	25
812	Enhanced expression of membrane transporter and drug resistance in keloid fibroblasts. <b>2012</b> , 43, 2024-32	10
811	miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. <b>2012</b> , 181, 1823-35	131

810	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. <b>2012</b> , 84, 766-74	20
809	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. <b>2012</b> , 20, 5388-95	55
808	Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. <b>2012</b> , 38, 890-903	176
807	Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. <b>2012</b> , 15, 183-210	291
806	A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18F]pentafluoropropyl)-acetamide ([18F]EF5). <b>2012</b> , 39, 1012-8	8
805	Graphene oxide used as a carrier for adriamycin can reverse drug resistance in breast cancer cells. <b>2012</b> , 23, 355101	82
804	Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. <b>2012</b> , 7, e51764	71
803	Significant activity of ecdysteroids on the resistance to doxorubicin in mammalian cancer cells expressing the human ABCB1 transporter. <b>2012</b> , 55, 5034-43	39
802	Development of classification models for identifying "true" P-glycoprotein (P-gp) inhibitors through inhibition, ATPase activation and monolayer efflux assays. <b>2012</b> , 13, 6924-43	9
801	Downregulation of mdr1 and abcg2 genes is a mechanism of inhibition of efflux pumps mediated by polymeric amphiphiles. <b>2012</b> , 22, 6577-9	39
800	Reversing ABCB1-mediated multi-drug resistance from within cells using translocating immune conjugates. <b>2012</b> , 20, 445-52	5
799	Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. <b>2012</b> , 70, 883-90	20
798	Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. <b>2012</b> , 3, 1429-45	35
797	Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells. <b>2012</b> , 13, 1144-51	93
796	Targeting the cancer initiating cell: the ultimate target for cancer therapy. <b>2012</b> , 18, 1784-95	36
795	Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin. <b>2012</b> , 53, 1399-405	19
794	The conformational transition pathways of ATP-binding cassette transporter BtuCD revealed by targeted molecular dynamics simulation. <b>2012</b> , 7, e30465	28
793	Effects of $\beta$ -adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport. <b>2012</b> , 7, e30697	6

792	Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics. <b>2012</b> , 7, e35487	39
791	Basic residues R260 and K357 affect the conformational dynamics of the major facilitator superfamily multidrug transporter LmrP. <b>2012</b> , 7, e38715	9
790	Correlation between multi-drug resistance-associated membrane transport in clonal cancer cells and the cell cycle phase. <b>2012</b> , 7, e41368	14
789	Ionizing radiation induces stemness in cancer cells. <b>2012</b> , 7, e43628	124
788	Discovering associations in biomedical datasets by link-based associative classifier (LAC). <b>2012</b> , 7, e51018	7
787	A-Subclass ATP-Binding Cassette Proteins in Brain Lipid Homeostasis and Neurodegeneration. <b>2012</b> , 3, 17	32
786	Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. <b>2012</b> , 15, 568-82	37
785	Secondary metabolites from two species of Tolpis and their biological activities. <b>2012</b> , 17, 12895-909	4
784	Multidrug resistance associated proteins in multidrug resistance. <b>2012</b> , 31, 58-72	165
783	Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. <b>2012</b> , 11, 899-906	18
782	Multidrug resistance reversal effects of aminated thioxanthenes and interaction with cytochrome P450 3A4. <b>2012</b> , 15, 31-45	9
781	Isocorydine targets the drug-resistant cellular side population through PDCD4-related apoptosis in hepatocellular carcinoma. <b>2012</b> , 18, 1136-46	34
780	Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. <b>2012</b> , 31, 100-9	94
779	The New Model of Carcinogenesis: The Cancer Stem Cell Hypothesis. <b>2012</b> ,	
778	Apoptosis as a Therapeutic Target in Cancer and Cancer Stem Cells: Novel Strategies and Futures Perspectives. <b>2012</b> ,	1
777	Arsenic trioxide induces depolymerization of microtubules in an acute promyelocytic leukemia cell line. <b>2012</b> , 47, 105-12	6
776	Synthesis of 5-oxyquinoline derivatives for reversal of multidrug resistance. <b>2012</b> , 8, 1700-4	4
775	HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. <b>2012</b> , 12, 4	104

774	Jasmonates: Plant Stress Hormones as Anticancer Agents. <b>2012</b> , 303-322	
773	Circumventing cancer drug resistance in the era of personalized medicine. <b>2012</b> , 2, 214-26	348
772	Chalcogenopyrylium compounds as modulators of the ATP-binding cassette transporters P-glycoprotein (P-gp/ABCB1) and multidrug resistance protein 1 (MRP1/ABCC1). <b>2012</b> , 55, 4683-99	38
771	The use of a glucose-reduced graphene oxide suspension for photothermal cancer therapy. <b>2012</b> , 22, 13773	353
770	The Effect of Environment on the Structure of a Membrane Protein: P-Glycoprotein under Physiological Conditions. <b>2012</b> , 8, 3964-76	40
769	Molecular dynamics simulations of membrane proteins. <b>2012</b> , 4, 271-282	9
768	Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. <b>2012</b> , 41, 2971-3010	1286
767	FHL3 Contributes to EMT and Chemotherapy Resistance Through Up-Regulation of Slug and Activation of TGF/Smad-Independent Pathways in Gastric Cancer. <b>2021</b> , 11, 649029	3
766	Determinants of Unresponsiveness to Treatment in Cutaneous Leishmaniasis: A Focus on Anthroponotic Form Due to. <b>2021</b> , 12, 638957	5
765	Impact of Poly (Styrene-Acrylic Acid) Latex Nanoparticles on Colorectal and Cervical Cancer Cells. <b>2021</b> , 13,	2
764	Dual-labeled visual tracer system for topical drug delivery by nanoparticle-triggered P-glycoprotein silencing. <b>2021</b> ,	0
763	Drug resistance reversal by intervening cancer bioenergetics with spherical helical polypeptide-potented gene silencing. <b>2021</b> , 414, 128545	4
762	Cell-Penetrating Peptides: Applications in Tumor Diagnosis and Therapeutics. <b>2021</b> , 13,	4
761	Histone deacetylase 10, a potential epigenetic target for therapy. <b>2021</b> , 41,	2
760	Advances in cancer theranostics using organic-inorganic hybrid nanotechnology. <b>2021</b> , 23, 101003	11
759	Green synthesis and characterization of gold nanoparticles from Moringa oleifera leaves and assessment of antioxidant, antidiabetic and anticancer properties. <b>2021</b> , 33, 100714	5
758	Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center. <b>2021</b> , 38, 119-125	2
757	Thermodynamic genome-scale metabolic modeling of metallodrug resistance in colorectal cancer.	0

756	Differential Action of Silver Nanoparticles on ABCB1 (MDR1) and ABCC1 (MRP1) Activity in Mammalian Cell Lines. <b>2021</b> , 14,	4
755	Acquired ABC-transporter overexpression in cancer cells: transcriptional induction or Darwinian selection?. <b>2021</b> , 394, 1621-1632	3
754	Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism. <b>2021</b> , 12, 4376	8
753	A tumor-penetrable drug nanococktail made from human histones for interventional nucleus-targeted chemophotothermal therapy of drug-resistant tumors. <b>2022</b> , 9, 554-565	2
752	A Personalized Therapeutics Approach Using an Reveals Optimal Chemo- and Targeted Therapy Combinations for Colorectal Cancer. <b>2021</b> , 11, 692592	1
751	Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. <b>2021</b> , 26,	8
750	LncRNA as a multifunctional regulator in cancer multi-drug resistance. <b>2021</b> , 48, 1-15	5
749	Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways. <b>2021</b> , 139, 111632	7
748	TWIST1-mediated transcriptional activation of PDGFR $\alpha$ in breast cancer stem cells promotes tumorigenesis and metastasis. <b>2021</b> , 1867, 166141	3
747	The role of CD44 in cancer chemoresistance: A concise review. <b>2021</b> , 903, 174147	14
746	TPGS and chondroitin sulfate dual-modified lipid-albumin nanosystem for targeted delivery of chemotherapeutic agent against multidrug-resistant cancer. <b>2021</b> , 183, 1270-1282	3
745	ATP-Binding Cassette (ABC) Transporter Proteins, Multidrug Resistance and Novel Flavonoid Dimers as Potent, Nontoxic and Selective Inhibitors.	0
744	Solute carriers as potential oncodrivers or suppressors: their key functions in malignant tumor formation. <b>2021</b> , 26, 1689-1701	2
743	Overexpression of glycosyltransferase 8 domain containing 2 confers ovarian cancer to CDDP resistance by activating FGFR/PI3K signalling axis. <b>2021</b> , 10, 55	1
742	Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective Platinum Prodrug Against Triple Negative Breast Cancer. <b>2021</b> , 16, 2276-2279	3
741	Hypermonones A $\beta$ New Polyprenylated Acylphloroglucinols from <i>Hypericum monogynum</i> with Multidrug Resistance Reversal Activity. <b>2021</b> , 39, 2422-2432	1
740	Synergistic Therapy of Doxorubicin with Cationic Anticancer Peptide L-K6 Reverses Multidrug Resistance in MCF-7/ADR Cancer Cells In Vitro via P-glycoprotein Inhibition. 1	3
739	A metal-free salalen ligand with anti-tumor and synergistic activity in resistant leukemia and solid tumor cells via mitochondrial pathway. <b>2021</b> , 147, 2591-2607	2

738	Use of photoimmunoconjugates to characterize ABCB1 in cancer cells.. <b>2021</b> , 10, 3049-3061	1
737	Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer. <b>2021</b> , 129, 258-268	5
736	Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. <b>2021</b> , 9, 699571	0
735	Identification and Characterization of Multiple Myeloma Stem Cell-Like Cells. <b>2021</b> , 13,	3
734	Thermodynamic Genome-Scale Metabolic Modeling of Metallodrug Resistance in Colorectal Cancer. <b>2021</b> , 13,	0
733	Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems. <b>2021</b> , 14,	5
732	Stress-activated kinases as therapeutic targets in pancreatic cancer. <b>2021</b> , 27, 4963-4984	1
731 <sup>1</sup>	Engineering Exosomes Endowed with Targeted Delivery of Triptolide for Malignant Melanoma Therapy. <b>2021</b> , 13, 42411-42428	8
730	Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL. <b>2021</b> , 5, 3497-3510	2
729	Comparative in silico prediction of P-glycoprotein-mediated transport for 2010-2020 US FDA-approved drugs using six Web-tools. <b>2021</b> , 42, 393-398	0
728	Small molecule photocatalysis enables drug target identification via energy transfer.	6
727	Ingenane and jatrophane-type diterpenoids from Euphorbia kansui with multidrug resistance reversal activity. <b>2021</b> , 188, 112775	1
726	Principles of Alternating Access in Multidrug and Toxin Extrusion (MATE) Transporters. <b>2021</b> , 433, 166959	5
725	Anticarcinogenic Effects of Capsaicin-Loaded Nanoparticles on In vitro Hepatocellular Carcinoma. <b>2021</b> , 15, 188-201	2
724	FAK inhibitors as promising anticancer targets: present and future directions. <b>2021</b> , 13, 1559-1590	3
723	Improvement of cytotoxicity of mitoxantrone and daunorubicin by candidone, tephrosin, and bavachinin. <b>2021</b> , 48, 7105-7111	1
722	Research updates on the clinical implication of long noncoding RNA in digestive system cancers and chemoresistance. <b>2021</b> , 11, 423	
721	New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. <b>2021</b> , 22,	3

720	Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy. <b>2021</b> , 121, 13454-13619	90
719	Effect of the Force Field on Molecular Dynamics Simulations of the Multidrug Efflux Protein P-Glycoprotein. <b>2021</b> , 17, 6491-6508	3
718	Recent advances in ruthenium(II) and iridium(III) complexes containing nanosystems for cancer treatment and bioimaging. <b>2021</b> , 443, 214016	14
717	Protein Based Biomaterials for Therapeutic and Diagnostic Applications.. <b>2022</b> , 4,	1
716	Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs. <b>2021</b> , 84, 2544-2553	2
715	Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. <b>2021</b> , 9, 694363	8
714	Rational design of phenyl thiophene (pyridine) derivatives that overcome P-glycoprotein mediated MDR in MCF-7/ADR cell. <b>2021</b> , 114, 105075	0
713	Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. <b>2021</b> , 23, 106	1
712	Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer. <b>2021</b> , 13,	0
711	Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. <b>2021</b> ,	3
710	Di-2-pyridylketone 4, 4-dimethyl-3-thiosemicarbazone effectively induces human colorectal carcinoma cell apoptosis via mTOR pathway. <b>2021</b> , 3, 56-62	1
709	A glutathione-responsive polyphenol - Constructed nanodevice for double roles in apoptosis and ferroptosis. <b>2021</b> , 205, 111902	2
708	Drug resistance: from bacteria to cancer.. <b>2021</b> , 2, 27	2
707	Application of smart nanoparticles as a potential platform for effective colorectal cancer therapy. <b>2021</b> , 442, 213949	9
706	Supply and demand: Cellular nutrient uptake and exchange in cancer. <b>2021</b> , 81, 3731-3748	5
705	Chemoreversal Agents from Taiwanofungus Genus and Their More Potent Methyl Derivatives Targeting Signal Transducer and Activator of Transcription 3 (STAT3) Phosphorylation. <b>2021</b> , 14,	
704	Mechanistic Insights into Photodynamic Regulation of Adenosine 5'-Triphosphate-Binding Cassette Drug Transporters.	1
703	Multifunctional PLGA nanoparticles combining transferrin-targetability and pH-stimuli sensitivity enhanced doxorubicin intracellular delivery and in vitro antineoplastic activity in MDR tumor cells. <b>2021</b> , 75, 105192	3



702	Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells. <b>2021</b> , 155, 112381	5
701	Role of the bone marrow microenvironment in drug resistance of hematological malignances. <b>2021</b> ,	0
700	MicroRNAs as a clue to overcome breast cancer treatment resistance. <b>2021</b> , 1	5
699	Thiophene-2-carboxamide derivatives of anthraquinone: A new potent antitumor chemotype. <b>2021</b> , 221, 113521	4
698	Genome-wide analyses of ATP-Binding Cassette (ABC) transporter gene family and its expression profile related to deltamethrin tolerance in non-biting midge <i>Propisilocerus akamusi</i> . <b>2021</b> , 239, 105940	1
697	Acid-sensitive and L61-crosslinked hyaluronic acid nanogels for overcoming tumor drug-resistance. <b>2021</b> , 188, 11-23	2
696	The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. <b>2021</b> , 11, 713530	8
695	Vitamin E-tocopheryl polyethylene glycol succinate decorated drug delivery system with synergistic antitumor effects to reverse drug resistance and immunosuppression. <b>2021</b> , 628, 127387	0
694	Evaluation of diffusion coefficient of P-glycoprotein molecules labeled with green fluorescent protein in living cell membrane. <b>2021</b> , 1863, 183721	
693	LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan. <b>2021</b> , 143, 112091	1
692	Anticancer effects of asiatic acid against doxorubicin-resistant breast cancer cells via an AMPK-dependent pathway in vitro. <b>2021</b> , 92, 153737	4
691	SH003 overcomes drug resistance and immune checkpoints by inhibiting JAK-STAT3 signaling in MCF7/ADR cells. <b>2021</b> , 1, 100111	0
690	Structural insight into the binding pattern and interaction mechanism of chemotherapeutic agents with Sorcin by docking and molecular dynamic simulation. <b>2021</b> , 208, 112098	7
689	TRPC5 mediates TMZ resistance in TMZ-resistant glioblastoma cells via NFATc3-P-gp pathway. <b>2021</b> , 14, 101214	1
688	Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer. <b>2021</b> , 225, 113775	2
687	The hallmarks of cancer and immunology. <b>2022</b> , 1-17	
686	Molecular modeling approaches to address drug-metabolizing enzymes (DMEs) mediated chemoresistance: a review. <b>2021</b> , 53, 45-75	0
685	Human ES and iPS cells display less drug resistance than differentiated cells, and naïve-state induction further decreases drug resistance. <b>2021</b> , 46, 131-142	

684	Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance. <b>2021</b> , 28, 670-679	5
683	A plasmon-enhanced theranostic nanoplatfrom for synergistic chemo-phototherapy of hypoxic tumors in the NIR-II window. <b>2021</b> , 12, 10848-10854	8
682	The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors.. <b>2021</b> , 4, 784-804	3
681	Neurological Disorders: Biochemistry of Drug Resistance and Future Challenges. <b>2021</b> , 255-277	
680	The Breast Cancer Stem Cells Traits and Drug Resistance. <b>2020</b> , 11, 599965	11
679	Unprecedented collateral sensitivity for cisplatin-resistant lung cancer cells presented by new ruthenium organometallic compounds. <b>2021</b> , 8, 1983-1996	6
678	Repressing PDCD4 activates JNK/ABCG2 pathway to induce chemoresistance to fluorouracil in colorectal cancer cells. <b>2021</b> , 9, 114	2
677	Carbonic anhydrase XII inhibition overcomes P-glycoprotein-mediated drug resistance: a potential new combination therapy in cancer.. <b>2021</b> , 4, 343-355	2
676	Increasing the accumulation of aptamer AS1411 and verapamil conjugated silver nanoparticles in tumor cells to enhance the radiosensitivity of glioma. <b>2021</b> , 32, 145102	9
675	A chameleonic macrocyclic peptide with drug delivery applications. <b>2021</b> , 12, 6670-6683	3
674	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. <b>2021</b> , 13, 17588359211038478	
673	Electrospun Nanofibers for Cancer Therapy. <b>2021</b> , 1295, 163-190	5
672	Optimization of Mesoporous Silica Nanoparticles through Statistical Design of Experiment and the Application for the Anticancer Drug. <b>2021</b> , 13,	7
671	Self-delivery nanomedicine to overcome drug resistance for synergistic chemotherapy. <b>2021</b> , 9, 3445-3452	7
670	Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer. <b>2021</b> , 12, 2377-2388	3
669	Therapeutic potential of cannabinoids in combination cancer therapy. <b>2021</b> , 79, 100774	9
668	Drug Delivery Strategies for Combating Multiple Drug Resistance. 1	2
667	The ABC Transporters: Structural Insights into Drug Transport. <b>2009</b> , 1-48	2

666	ABC Transporters [From Targets to Antitargets?. <b>2009</b> , 349-362	2
665	Role of Tumour Microenvironment in Chemoresistance. <b>2005</b> , 285-321	7
664	Targeting Cancer Lysosomes with Good Old Cationic Amphiphilic Drugs. <b>2021</b> , 1	4
663	Novel approaches for chemosensitization of breast cancer cells: the E1A story. <b>2007</b> , 608, 144-69	17
662	Multidrug Resistance in Solid Tumor and Its Reversal. <b>2009</b> , 121-148	6
661	In Silico Approaches to Predict DDIs. <b>2010</b> , 151-168	2
660	Cancer Stem Cell and ATP-Binding Cassette: Which Role in Chemoresistance?. <b>2012</b> , 267-288	1
659	p53-Reactivating Molecules as Research Tools and Anticancer Drugs. <b>2013</b> , 231-255	2
658	Molecular Pathways of Drug Resistance. <b>2004</b> , 463-489	1
657	ABC Transporter Proteins and Cellular Drug Resistance. <b>2004</b> , 129-162	2
656	How Melanoma Cells Evade Chemotherapy. <b>2006</b> , 591-603	1
655	Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors. <b>2006</b> , 241-260	2
654	Resistance To Taxanes. <b>2006</b> , 329-358	9
653	Cancer Stem Cells Implications for Development of More Effective Therapies. <b>2006</b> , 125-136	3
652	Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. <b>2008</b> , 448, 63-76	33
651	Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells. <b>2009</b> , 83-88	3
650	Drug-Cytokine Interactions. <b>2011</b> , 167-201	2
649	Chemoresistance in Glioma. <b>2013</b> , 243-270	2

648	Cancer Nanomedicine: Special Focus on Cancer Immunotherapy. <b>2021</b> , 465-508	1
647	Cancer Stem Cells and Chemoresistance: Strategies to Overcome Therapeutic Resistance. <b>2015</b> , 477-518	2
646	Drug-Cytokine Interactions. <b>2018</b> , 163-204	2
645	Multidrug Resistance. <b>2010</b> , 121-133	1
644	Toxicology of cadmium and its damage to mammalian organs. <b>2013</b> , 11, 415-90	104
643	Preventive and Therapeutic Effect of Ganoderma (Lingzhi) on Liver Injury. <b>2019</b> , 1182, 217-242	5
642	Anticancer drugs. <b>2012</b> , 673-688	2
641	Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study. <b>2020</b> , 28, 115553	7
640	Pyrimidine: A promising scaffold for optimization to develop the inhibitors of ABC transporters. <b>2020</b> , 200, 112458	17
639	Fabrication of functionalized layered double hydroxide/chitosan nanocomposite with dual responsive drug release for the targeted therapy of breast cancer. <b>2020</b> , 139, 109993	9
638	Anthracyclines. <b>2005</b> , 19-33	1
637	ATP-dependent thermostabilization of human P-glycoprotein (ABCB1) is blocked by modulators. <b>2019</b> , 476, 3737-3750	13
636	Engineered gene networks enable non-genetic drug resistance and enhanced cellular robustness. <b>2019</b> , 3, 72-79	3
635	The impact of competition between cancer cells and healthy cells on optimal drug delivery. <b>2020</b> , 15, 42	2
634	Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells. <b>2020</b> , 111, 2872-2882	18
633	MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review. <b>2020</b> , 111, 3122-3131	10
632	Inhibitory effects of gallic acid ester derivatives on <i>Saccharomyces cerevisiae</i> multidrug resistance protein Pdr5p. <b>2010</b> , 10, 244-251	15
631	Inhibitory effects of gallic acid ester derivatives on <i>Saccharomyces cerevisiae</i> multidrug resistance protein Pdr5p. <b>2010</b> , 10, 244-51	7

630	Periplasmic ABC Transporters. 287-303	2
629	Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer. <b>2016</b> , 1,	11
628	CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. <b>2018</b> , 3,	62
627	Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. <b>2020</b> , 130, 3287-3298 <sub>13</sub>	
626	P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. <b>2005</b> , 115, 3285-90	459
625	Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. <b>2006</b> , 116, 1994-2004	105
624	Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. <b>2018</b> , 128, 4098-4114	17
623	Nanocapsules as Carriers for the Transport and Targeted Delivery of Bioactive Molecules. <b>2011</b> , 45-67	4
622	Impact of Bionanointeractions of Engineered Nanoparticles for Nanomedicine. <b>2014</b> , 21-36	3
621	Association between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer. <b>2011</b> , 17, BR354-63	10
620	Olmudinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells. <b>2020</b> , 26, e924922	1
619	Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. <b>2020</b> , 9,	11
618	A double blinded, placebo-controlled pilot study to examine reduction of CD34 /CD117 /CD133 lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. <b>2015</b> , 4, 42	4
617	A double blinded, placebo-controlled pilot study to examine reduction of CD34+/CD117+/CD133+ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. 4, 42	1
616	How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient. <b>2017</b> , 15, e2001110	72
615	A multidrug ABC transporter with a taste for salt. <b>2009</b> , 4, e6137	30
614	Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate. <b>2010</b> , 5, e11253	37
613	Pre-clinical drug prioritization via prognosis-guided genetic interaction networks. <b>2010</b> , 5, e13937	8

612	Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance. <b>2011</b> , 6, e16007	69
611	Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. <b>2012</b> , 7, e36762	82
610	Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. <b>2013</b> , 8, e60975	46
609	Pathway-based analysis using genome-wide association data from a Korean non-small cell lung cancer study. <b>2013</b> , 8, e65396	20
608	An antimetabolic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells. <b>2013</b> , 8, e65686	16
607	The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder. <b>2013</b> , 8, e75681	26
606	BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. <b>2013</b> , 8, e83627	53
605	MicroRNA-dependent regulation of transcription in non-small cell lung cancer. <b>2014</b> , 9, e90524	53
604	ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. <b>2014</b> , 9, e91555	33
603	Tissue-specific transcript profiling for ABC transporters in the sequestering larvae of the phytophagous leaf beetle <i>Chrysomela populi</i> . <b>2014</b> , 9, e98637	29
602	Transcriptome-based identification of ABC transporters in the western tarnished plant bug <i>Lygus hesperus</i> . <b>2014</b> , 9, e113046	39
601	Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells. <b>2014</b> , 9, e114787	28
600	HZ08 reverse P-glycoprotein mediated multidrug resistance in vitro and in vivo. <b>2015</b> , 10, e0116886	6
599	18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY. <b>2015</b> , 10, e0121342	9
598	An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. <b>2015</b> , 10, e0126159	21
597	Identification of a Cryptic Bacterial Promoter in Mouse ( <i>mdr1a</i> ) P-Glycoprotein cDNA. <b>2015</b> , 10, e0136396	5
596	A Survey of the ATP-Binding Cassette (ABC) Gene Superfamily in the Salmon Louse ( <i>Lepeophtheirus salmonis</i> ). <b>2015</b> , 10, e0137394	15
595	Genome-Wide Identification, Characterization and Phylogenetic Analysis of ATP-Binding Cassette (ABC) Transporter Genes in Common Carp ( <i>Cyprinus carpio</i> ). <b>2016</b> , 11, e0153246	7

594	Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2. <b>2017</b> , 12, e0184578	6
593	Genetic variation in Dip5, an amino acid permease, and Pdr5, a multiple drug transporter, regulates glyphosate resistance in <i>S. cerevisiae</i> . <b>2017</b> , 12, e0187522	12
592	Salubrinal-Mediated Upregulation of eIF2 $\beta$ Phosphorylation Increases Doxorubicin Sensitivity in MCF-7/ADR Cells. <b>2016</b> , 39, 129-35	21
591	The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. <b>2018</b> , 25, R663-R685	38
590	Reversal Effect of Docosahexaenoic Acid on Taxol Resistance in Human Ovarian Carcinoma A2780/T Cells. <b>2014</b> , 1,	1
589	Early Differentiating Mouse Astroglial Progenitors Share Common Protein Signatures with GL261 Glioma Cells. <b>2016</b> , 2, 1-15	1
588	Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy. <b>2014</b> , 19, 143-76	20
587	RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF- $\kappa$ B/Snail/YY1/RKIP resistance-driver loop. <b>2014</b> , 19, 431-45	25
586	Classification of P-glycoprotein-interacting compounds using machine learning methods. <b>2015</b> , 14, 958-70	9
585	[Molecular mechanisms of niclosamide antitumor activity]. <b>2015</b> , 61, 680-93	10
584	Expression of multidrug resistance proteins in retinoblastoma. <b>2017</b> , 10, 1655-1661	11
583	Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action. <b>2020</b> , 12, 3713-3729	5
582	TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation. <b>2016</b> , 7, 46203-46218	15
581	Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization. <b>2016</b> , 7, 49848-49858	15
580	Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. <b>2013</b> , 4, 1230-40	32
579	Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma. <b>2016</b> , 7, 68585-68596	34
578	DCTPP1 attenuates the sensitivity of human gastric cancer cells to 5-fluorouracil by up-regulating MDR1 expression epigenetically. <b>2016</b> , 7, 68623-68637	19
577	Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance. <b>2016</b> , 7, 70832-70844	8

- 576 The role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance. **2016**, 7, 73101-73113<sup>11</sup>
- 575 The CEA-/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells. **2016**, 7, 80700-80715 19
- 574 Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance. **2016**, 7, 83502-83513 52
- 573 Disruption of the association between drug transporter and actin cytoskeleton abolishes drug resistance in hypertrophic scar. **2017**, 8, 2617-2627 3
- 572 Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. **2017**, 8, 8622-8632 28
- 571 P-glycoprotein attenuates DNA repair activity in multidrug-resistant cells by acting through the Cbp-Csk-Src cascade. **2017**, 8, 45072-45087 1
- 570 PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses. **2017**, 8, 24046-24062 5
- 569 Pygopus2 inhibits the efficacy of paclitaxel-induced apoptosis and induces multidrug resistance in human glioma cells. **2017**, 8, 27915-27928 7
- 568 Evidence of drug-response heterogeneity rapidly generated from a single cancer cell. **2017**, 8, 41113-41124 7
- 567 TUBB3 overexpression has a negligible effect on the sensitivity to taxol in cultured cell lines. **2017**, 8, 71536-71547 11
- 566 Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. **2014**, 5, 4529-42 37
- 565 Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: and studies. **2017**, 8, 93785-93799 21
- 564 Bioenergetics of acquired cisplatin resistant H1299 non-small cell lung cancer and P31 mesothelioma cells. **2017**, 8, 94711-94725 7
- 563 Long noncoding RNA TUG1 is a diagnostic factor in lung adenocarcinoma and suppresses apoptosis via epigenetic silencing of BAX. **2017**, 8, 101899-101910 45
- 562 Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals. **2017**, 8, 111144-111160 19
- 561 Distinct histone modifications denote early stress-induced drug tolerance in cancer. **2018**, 9, 8206-8222 39
- 560 Chemopreventive activity of celastrol in drug-resistant human colon carcinoma cell cultures. **2018**, 9, 21211-21223 19
- 559 MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts. **2014**, 5, 11957-70 18



558	Co-treatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression. <b>2018</b> , 9, 36585-36602	16
557	The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. <b>2015</b> , 6, 510-21	26
556	Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma. <b>2020</b> , 11, 671-686	2
555	ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF- $\kappa$ B. <b>2015</b> , 6, 1049-63	25
554	Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. <b>2011</b> , 2, 538-50	69
553	Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. <b>2015</b> , 6, 9313-26	82
552	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. <b>2015</b> , 6, 29833-46	25
551	Extracellular galectin-3 programs multidrug resistance through Na <sup>+</sup> /K <sup>+</sup> -ATPase and P-glycoprotein signaling. <b>2015</b> , 6, 19592-604	17
550	An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. <b>2015</b> , 6, 25149-60	26
549	Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid. <b>2015</b> , 6, 25076-92	44
548	Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor. <b>2015</b> , 6, 27065-82	14
547	Cell-based high-throughput screens for the discovery of chemotherapeutic agents. <b>2012</b> , 3, 581-5	8
546	A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. <b>2012</b> , 3, 640-50	67
545	Liposome armed with herpes virus-derived gH625 peptide to overcome doxorubicin resistance in lung adenocarcinoma cell lines. <b>2016</b> , 7, 4077-92	21
544	Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. <b>2016</b> , 7, 5877-91	21
543	p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. <b>2016</b> , 7, 8184-99	36
542	Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. <b>2016</b> , 7, 20753-72	28
541	ATP7B expression confers multidrug resistance through drug sequestration. <b>2016</b> , 7, 22779-90	7

540	Storkhead box 2 and melanoma inhibitory activity promote oral squamous cell carcinoma progression. <b>2016</b> , 7, 26751-64	10
539	Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation. <b>2016</b> , 7, 34395-419	24
538	Cabazitaxel operates anti-metastatic and cytotoxic via apoptosis induction and stalls brain tumor angiogenesis. <b>2016</b> , 7, 38306-38318	14
537	Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer.. <b>2019</b> , 2, 297-312	5
536	Resistance to anti-tubulin agents: From vinca alkaloids to epothilones.. <b>2019</b> , 2, 82-106	6
535	Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs' involvement in cancer drug resistance.. <b>2019</b> , 2, 897-911	3
534	Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators.. <b>2019</b> , 2, 710-743	3
533	MicroRNAs and cancer drug resistance: over two thousand characters in search of a role.. <b>2019</b> , 2, 618-633	1
532	Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies.. <b>2019</b> , 2, 490-515	2
531	Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance. <b>2017</b> , 5, 377	11
530	A new era of cancer treatment: carbon nanotubes as drug delivery tools. <b>2011</b> , 6, 2963-79	179
529	Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer. <b>2019</b> , 26, 7059-7080	15
528	Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy. <b>2020</b> , 27, 2118-2132	17
527	Flavonoids as P-gp Inhibitors: A Systematic Review of SARs. <b>2019</b> , 26, 4799-4831	12
526	The Role of NIR Fluorescence in MDR Cancer Treatment: From Targeted Imaging to Phototherapy. <b>2020</b> , 27, 5510-5529	2
525	Targeting Mitochondria through the Use of Mitocans as Emerging Anticancer Agents. <b>2020</b> , 27, 5730-5757	5
524	ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. <b>2014</b> , 20, 793-807	304
523	Advances in Nanoparticles as Anticancer Drug Delivery Vector: Need of this Century. <b>2020</b> , 26, 1637-1649	8

522	Curcumin Based Drug Delivery Systems for Cancer Therapy. <b>2020</b> , 26, 5430-5440	1
521	Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities. <b>2019</b> , 20, 1114-1131	14
520	Anti-Cancer Phytometabolites Targeting Cancer Stem Cells. <b>2017</b> , 18, 156-174	19
519	Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery. <b>2012</b> , 13, 994-1003	62
518	An Overview of Privileged Scaffold: Quinolines and Isoquinolines in Medicinal Chemistry as Anticancer Agents. <b>2020</b> , 20, 2599-2633	5
517	The Delicate Equilibrium between Oxidants and Antioxidants in Brain Glioma. <b>2019</b> , 17, 342-351	17
516	Prospects of Wedelolactone as a Chemotherapeutic Agent in Gynecological Cancers; Clue From its In Vitro and In Silico Investigation. <b>2020</b> , 16, 365-375	2
515	Nanoparticle-assisted Therapeutic Strategies for Effective Cancer Management. <b>2020</b> , 16, 42-50	4
514	Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis. <b>2020</b> , 13, 150-172	5
513	The Impact of Opioid Analgesics and the Pharmacogenomics of ABCB1 in Opioid Dependence and Pharmacotherapies: A Short Review. <b>2020</b> , 13, 7-21	6
512	Reversal of Multidrug Resistance in an Epirubicin-Resistant Gastric Cancer Cell Subline. <b>2018</b> , 19, 1237-1242	2
511	Alterations of The Stem-Like Properties in The Breast Cancer Cell Line MDA-MB-231 Induced by Single Pulsed Doxorubicin Treatment. <b>2019</b> , 73, 89-99	3
510	Differential Expression of ADP/ATP Carriers as a Biomarker of Metabolic Remodeling and Survival in Kidney Cancers. <b>2020</b> , 11,	3
509	Targeting the Roots of Recurrence: New Strategies for Eliminating Therapy-Resistant Breast Cancer Stem Cells. <b>2020</b> , 13,	1
508	Silencing of Taxol-Sensitizer Genes in Cancer Cells: Lack of Sensitization Effects. <b>2015</b> , 7, 1052-71	7
507	Doxorubicin Inhibits Phosphatidylserine Decarboxylase and Modifies Mitochondrial Membrane Composition in HeLa Cells. <b>2020</b> , 21,	3
506	Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. <b>2020</b> , 12,	47
505	Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. <b>2005</b> , 11, 2748-53	70

504	Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells. <b>2006</b> , 12, 3332-7	19
503	Cellular reprogramming and hepatocellular carcinoma development. <b>2013</b> , 19, 8850-60	24
502	ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?. <b>2018</b> , 24, 3222-3238	45
501	MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. <b>2017</b> , 38, 1383-1392	48
500	Cytotoxic Effect of Biosynthesized Silver Nanoparticles on Ehrlich Ascites Tumor Cells in Mice. <b>2017</b> , 13, 134-144	16
499	Targeting Multidrug Resistance with Small Molecules for Cancer Therapy. <b>2010</b> , 18, 375-385	6
498	A Novel Submicron Emulsion System Loaded with Doxorubicin Overcome Multi-Drug Resistance in MCF-7/ADR Cells. <b>2015</b> , 77, 499-504	2
497	knockout promotes paclitaxel sensitivity in drug-resistant cells induction of necrotic cell death. <b>2020</b> , 24, 233-240	2
496	Efflux Pumps Modulation in Colorectal Adenocarcinoma Cell Lines: The Role of Nuclear Medicine. <b>2011</b> , 02, 408-417	16
495	Natural Products Modulate the Multifactorial Multidrug Resistance of Cancer. <b>2015</b> , 06, 146-176	26
494	Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. <b>2010</b> , 9, 34-40	43
493	Non-coding RNA in drug resistance of gastric cancer. <b>2019</b> , 11, 957-970	11
492	Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive system. <b>2016</b> , 8, 735-744	19
491	variants C3435T and T129C are not associated with colorectal cancer risk. <b>2019</b> , 19, 2476-2483	1
490	Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma. <b>2019</b> , 13, 342-348	16
489	Various Partial Charge Schemes on 3D-QSAR Models for P-gp Inhibiting Adamantyl Derivatives. <b>2011</b> , 32, 1604-1612	2
488	Prediction Models of P-Glycoprotein Substrates Using Simple 2D and 3D Descriptors by a Recursive Partitioning Approach. <b>2012</b> , 33, 1123-1127	6
487	In silico Study on the Interaction between P-glycoprotein and Its Inhibitors at the Drug Binding Pocket. <b>2014</b> , 35, 2317-2325	8

486	Solid lipid nanoparticles in cancer therapy.. <b>2010</b> , 2, 192-199	20
485	The relationship of cancer stem cells in urological cancers. <b>2013</b> , 66, 273-80	11
484	Volasertib (BI 6727), a novel polo-like kinase inhibitor, reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cells. <b>2013</b> , 2, 13	4
483	Multidrug resistance-associated protein 1 predicts relapse in Iranian childhood acute lymphoblastic leukemia. <b>2012</b> , 13, 2285-9	8
482	Cytotoxicity, toxicity, and anticancer activity of Zingiber officinale Roscoe against cholangiocarcinoma. <b>2012</b> , 13, 4597-606	29
481	Associations of ABCB1 and XPC genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis in a Chinese population. <b>2013</b> , 14, 3085-91	19
480	Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. <b>2013</b> , 14, 4801-4	18
479	Establishment and partial characterization of an epirubicin-resistant gastric cancer cell line with upregulated ABCB1. <b>2014</b> , 15, 6849-53	5
478	Enhancing Activity of Anticancer Drugs in Multidrug Resistant Tumors by Modulating P-Glycoprotein through Dietary Nutraceuticals. <b>2015</b> , 16, 6831-9	25
477	Reversal of Multidrug Resistance in Mouse Lymphoma Cells by Extracts and Flavonoids from Pistacia integerrima. <b>2016</b> , 17, 51-5	10
476	Isolation and Structure Elucidation, Molecular Docking Studies of Screlotiumol from Soil Borne Fungi Screlotium rolfsii and their Reversal of Multidrug Resistance in Mouse Lymphoma Cells. <b>2016</b> , 17, 2083-7	3
475	Co-expression of HIF-1 $\beta$ , MDR1 and LPTM4B in peripheral blood of solid tumors. <b>2019</b> , 7, e6309	7
474	Isolation of Bioactive Compounds from Pistacia integerrima with Promising Effects on Reverse Cancer Multidrug Resistance. <b>2021</b> , 47, 997-1003	1
473	Cycloruthenated Self-Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers. <b>2021</b> , 34, e2100245	1
472	Flavonoid Monomers as Potent, Nontoxic, and Selective Modulators of the Breast Cancer Resistance Protein (ABCG2). <b>2021</b> , 64, 14311-14331	3
471	GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway. <b>2021</b> ,	4
470	Innovative nanochemotherapy for overcoming cancer multidrug resistance. <b>2021</b> , 33,	1
469	An Aptamer-Modified DNA Tetrahedron-Based Nanogel for Combined Chemo/Gene Therapy of Multidrug-Resistant Tumors.. <b>2021</b> , 4, 7701-7707	4

- 468 Synthesis of Highly Stabilized AuNPs Using 3,5-Dinitrobenzoic Acid and Sodium Acetate as Capping Agents in an Aqueous Solution and their Bioactivity. 70, 67-79 0
- 467 Polymeric Silver Nanoparticles: Potential for Folate-Targeted Delivery of Cisplatin In Vitro.
- 466 P-glycoprotein suppression by photothermal-responsive nitric oxide releasing nanoplatform for triple-combination therapy of multidrug resistant cancer. **2021**, 211, 110160 1
- 465 Estrogen- and estrogen receptor (ER)-mediated cisplatin chemoresistance in cancer. **2021**, 286, 120029 1
- 464 Cancer gene therapy. **2003**, 583-613 1
- 463 Gene Expression and Detection. **2003**, 413-480
- 462 Clinical Pharmacology Overview. **2004**, 111-127 1
- 461 ABC Transporters. **2004**, 267-288
- 460 Drug Transporters. **2004**, 122-142
- 459 Drug Transporters. **2004**, 111-136
- 458 PET and SPECT as Platforms for Molecular Imaging. **2005**, 59-93
- 457 ATP-Binding Cassette (ABC) Transporter Supergene Family: Genetics and Evolution.
- 456 Cancer chemotherapy. **2007**, 718-735 1
- 455 Chemotherapeutic Drug Resistant Cancer Stem-like Cells of Glioma. **2007**, 17, 1039-1045
- 454 DNA Polymorphisms Affecting Chemosensitivity Toward Drugs. **2008**, 365-387
- 453 Chemotherapy for Metastatic Clear-Cell Renal Cell Carcinoma. **2008**, 385-397
- 452 Destabilizing Agents. **2008**, 227-258
- 451 Making of glioma-initiating cells. **2008**, 28, 537-542

- 450 Natural Agents That Can Sensitize Tumor Cells to Chemotherapy and Radiation Therapy. **2008**, 211-240 3
- 449 Drug Transport in Living Systems. 1
- 448 Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. **2008**, 080808065201770-21
- 447 Screening of Chemosensitizer Candidates Using Natural Extracts. **2008**, 18, 1244-1248
- 446 Toward Understanding P-Glycoprotein Structure-Activity Relationships. **2008**, 497-519 1
- 445 Transporters in the Gastrointestinal Tract. **2008**, 221-276
- 444 Cancer Stem Cell Theory and Head & Neck Cancer. **2009**, 102, 403-410
- 443 The leukemia stem cell. **2010**, 145, 1-17 4
- 442 Drug Accumulation and Efflux Do not Contribute to Acquired Gefitinib Resistance. **2009**, 127-131
- 441 Breast Cancer Stem Cells. **2009**, 167-192
- 440 Cancer Stem Cells and Skin Cancer. **2009**, 251-267
- 439 Functional Imaging of Multidrug Resistance and Its Applications. **2009**, 601-643
- 438 Effects of Morin on the Bioavailability of Doxorubicin for Oral Delivery in Rats. **2009**, 39, 243-248 0
- 437 QSAR Studies on ABC Transporter [How to Deal with Polyspecificity. **2009**, 195-214
- 436 Nitric Oxide: Monotherapy or Sensitiser to Conventional Cancer Treatments?. **2010**, 387-417
- 435 Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer. **2010**, 163-177
- 434 Chinese Herbal Medicines as Reversal Agents for P-glycoprotein-mediated Multidrug Resistance in Tumors. **2010**, 7, 465-475 1
- 433 Gene Expression Profiles as Preclinical and Clinical Cancer Biomarkers of Prognosis, Drug Response, and Drug Toxicity. 1

- 432 Ovarian Cancer Progenitor/Stem Cells: Therapeutic Potential. **2011**, 223-244
- 431 Melanoma Stem Cells. **2011**, 255-279
- 430 Encyclopedia of Cancer. **2011**, 10-13
- 429 Targeting Tumor Associated Fibroblasts Tumor Associated Fibroblasts and Chemotherapy. **2011**, 403-418
- 428 Outward-Directed Transport. **2011**, 385-393 1
- 427 Pharmacogenomics and Personalized Medicine. **2011**, 1359-1382
- 426 Tumorigenesis of Glioma-Initiating Cells: Role of Sox11. **2012**, 93-98
- 425 Photodynamic Drug Delivery. **2012**, 1529-1540
- 424 Drug Transport in Living Systems. 115-132
- 423 Pegylated Zinc Protoporphyrin: A Micelle-Forming Polymeric Drug for Cancer Therapy. **2012**, 181-212
- 422 Vemurafenib (PLX4032, Zelboraf<sup>®</sup>), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance.
- 421 Molecular markers of glioma initiating cells. **2013**, 33, 181-189
- 420 Industrial Evaluation of Drug Transporters in ADME. **2013**, 285-307
- 419 TGF- $\beta$  in Cancer Stem Cells. **2013**, 93-112
- 418 The Reciprocal Interaction of Small Molecule Protein Kinase Inhibitors and ATP-Binding Cassette Transporters in Targeted Cancer Therapy.
- 417 Action of free and polymer carrier encapsulated doxorubicin towards HCT116 cells of human colorectal carcinoma. **2013**, 85, 33-44
- 416 Cellular Signals like MAPK/NF- $\kappa$ B/m-TOR Mediated Drug Resistance: A Promising Concept in Cancer Research. **2013**, 4, 414-427
- 415 Emerging Potential of Nanoparticles for the Treatment of Solid Tumors and Metastasis. **2013**, 1-28



414 Anticancer Clinical Pharmacology Overview. **2014**, 141-157

1

413 Encyclopedia of Cancer. **2014**, 17-21

412 PET Imaging of ABC Transporters in the BBB. **2014**, 625-652

411 MicroRNAs in Cancer Drug Resistance and Drug Sensitivity. **2014**, 251-293

410 Structure and Mechanism of a Eukaryotic ABC Multidrug Transporter. **2014**, 56, 224-229

409 Encyclopedia of Cancer. **2014**, 1431-1434

408 Sphingosine-1-Phosphate in Hypoxic Signaling. **2014**, 199-217

407 ABC Transporters: Maintenance of the Cancer Stem Cell Phenotype.

406 Encyclopedia of Cancer. **2014**, 1-5

405 Encyclopedia of Cancer. **2014**, 1-4

404 Case Study: Systems Biology of Chemotherapy Resistance in Hypoxic Cancer. **2014**, 49-61

403 Epithelial to Mesenchymal Transition (EMT) and Intestinal Tumorigenesis. **2015**, 309-364

402 Nanomedicine. **2015**, 64-89

401 Natūralus imunitetas atavistiniam endotoksinui eksperimentinėje onkologijoje ir ėnogaus vėio profilaktikoje (naujos koncepcijos apġalga). **2015**, 21, 430-437

400 Isoreserpine Reverses Multidrug Resistance Mediated by ABCB1. **2015**, 4, 188-194

399 Immunotherapy and Vaccines. **2016**, 441-464

398 Mitochondria do not play a major role in landomycin E-induced ROS burst and circumvention of multiple drug resistance in HL-60 leukemia cells. **2016**, 32, 190-202

397 Novel Carriers for Targeted Delivery of Herbal Medicines. **2016**, 523-537

- 396 Transcriptional study of the ABC transporter-encoding genes in response to fungicide treatment and during plant infection in the phytopathogenic fungus *Botrytis cinerea*. 0
- 395 Melanoma Stem Cells. **2017**, 311-337
- 394 Nanomedicine. **2017**, 1258-1285
- 393 Cell Proliferation and Differentiation. **2017**, 11-35
- 392 Drug Resistance in Leishmaniasis. **2017**, 1293-1304
- 391 Cancer Stem Cells and Multi-drug Resistance by Flow Cytometry. **2017**, 253-266
- 390 A double blinded, placebo-controlled pilot study to examine reduction of CD34+/CD117+/CD133+ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. **2015**, 4, 42 3
- 389 Nanoimaging of Biomolecules Using Near-Field Scanning Optical Microscopy. **2017**, 127-142
- 388 Integrated in Vitro and in Silico Modelling Delineates the Molecular Effects of a Symbiotic Regimen on Colorectal Cancer-Derived Cells.
- 387 Genomic amplification of chromosome 7 in the Doxorubicin resistant K562 cell line. **2018**, 14, 587-593 1
- 386 The effects of aranose, cisplatin or paclitaxel in monotherapy and in combination on the expression of Pd $\alpha$ 1 and Pd $\alpha$ 2 in melanoma cells. **2019**, 17, 71-80 1
- 385 [Study on colorectal cancer using air-liquid interface organoid culture method]. **2019**, 154, 50-55
- 384 Mesenchymal stem cells (MSCs) offer a drug tolerant and immune-privileged niche to *Mycobacterium tuberculosis*.
- 383 Stromal Barriers Within the Tumor Microenvironment and Obstacles to Nanomedicine. **2019**, 57-89 0
- 382 Design, synthesis and biological evaluation of selective survivin inhibitors. **2019**, 33, 82-100 1
- 381 Observation of live cells' attachment, spreading, and drug interactions using metasurface-enhanced infrared reflection spectroscopy. **2019**,
- 380 Electric charge conversable drug liposomes enable to enhance treatment efficacy of breast cancer. **2019**, 2, 317-343 0
- 379 Multicellular tumor spheroids- an effective in vitro model for understanding drug resistance in head and neck cancer.

- 378 Metabolic wastes are extracellularly disposed by excretosomes, nanotubes and exophers in mouse HT22 cells through an autophagic vesicle clustering mechanism. 1
- 377 Synthesis of Oridonin Derivatives via Mizoroki-Heck Reaction and Click Chemistry for Cytotoxic Activity. **2019**, 19, 935-947 1
- 376 The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2receptor subtype.
- 375 The significance of microRNA genes expression in ovarian cancer cell lines resistant to cytotoxic drugs.
- 374 An engineered Abcb4 expressing model reveals the central role of NF- $\kappa$ B in the regulation of drug resistance in zebrafish.
- 373 Oncogenic Ras downregulates expression through generation of reactive oxygen species. **2020**, 24, 267-276
- 372 Knock-down of the TIM/TIPIN complex promotes apoptosis in melanoma cells. **2020**, 11, 1846-1861 1
- 371 Effect of sodium butyrate on ABC transporters in lung cancer A549 and colorectal cancer HCT116 cells. **2020**, 20, 148 8
- 370 Human ES and iPS Cells Display Less Drug Resistance Than Differentiated Cells, and Na<sup>+</sup> State Induction Further Decreases Drug Resistance.
- 369 Molecular Mechanisms Behind Nano-Cancer Therapeutics. **2021**, 167-186
- 368 Double-Coated Poly(butyl Cyanoacrylate) Nanoparticles as a Potential Carrier for Overcoming P-Gp- and BCRP-Mediated Multidrug Resistance in Cancer Cells. **2021**, 3, 0
- 367 Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers. **2021**, 13, 1
- 366 Circumventing Drug Resistance Pathways with a Nanoparticle-Based Photodynamic Method. **2021**, 21, 9115-9123 1
- 365 Discovery of the Triazolo[1,5-]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. **2021**, 64, 16187-16204 5
- 364 Phytochemicals Plus Nanomaterials on Colorectal Cancer. **2020**, 171-191
- 363 Metabolic Changes and Their Characterization. **2020**, 35-70
- 362 Do Multiple Drug Resistance Transporters Interfere with Cell Functioning under Normal Conditions?. **2020**, 85, 1560-1569 1
- 361   **2020**, 85, 1837-1848

- 360 Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. **2020**, 9, 2599-2617 0
- 359 A Marine Natural Products as Modulators of Multidrug Resistance. 9, 96-101
- 358 Application of nanocarriers for paclitaxel delivery and chemotherapy of cancer. **2022**, 73-127
- 357 Cancer biology and other disorders: beneficial role of camptothecin and novel derivatives. **2020**, 1-46
- 356 Mecanismos moleculares emergentes y células madre leucémicas en la quimiorresistencia de tumores hematológicos. **2020**, 52, 129-144
- 355 Antineoplastic activity of free 4-nitrochalcone and encapsulated in poly(thioether-ester) nanoparticles obtained by thiol-ene polymerization in two human leukemia cell lines (Jurkat and K562). **2021**, 67, 102924
- 354 Ferroptosis-Related Gene Signature Predicts the Prognosis of Skin Cutaneous Melanoma and Response to Immunotherapy. **2021**, 12, 758981 2
- 353 Context Matters-Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. **2021**, 9, 760705 1
- 352 A polyplex human saliva peptide histatin 5-grafted methoxy PEG-b-polycaprolactone polymersome for intelligent stimuli-oriented doxorubicin delivery. **2021**, 67, 102958 1
- 351 Chemotherapie. **2006**, 560-577
- 350 Tubulin interacting agents. **2006**, 101-131
- 349 CAM-DR: HANGING ON FOR CELL SURVIVAL. **2006**, 163-177
- 348 Targeting Signaling Pathways In the Search of Melanoma's Achilles Heel. **2008**, 27-42
- 347 Molekulare Mechanismen der Pharmakokinetik. **2006**, 19-49
- 346 In silico Drosophila Patient Model Reveals Optimal Combinatorial Therapies for Colorectal Cancer.
- 345 Advance in Pancreatic Cancer Diagnosis and Therapy.
- 344 New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. **2009**, 1, 44-60 2
- 343 Cytotoxic Activities of Silver Nanoparticles and Silver Ions in Parent and Tamoxifen-Resistant T47D Human Breast Cancer Cells and Their Combination Effects with Tamoxifen against Resistant Cells. **2010**, 2, 187-96 35

342	UMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter. <b>2014</b> , 4, 148-60	5
341	Preparation and characterization of stable nanoliposomal formulation of fluoxetine as a potential adjuvant therapy for drug-resistant tumors. <b>2014</b> , 13, 3-14	12
340	ATP-binding cassette transporters modulate both coelenterazine- and D-luciferin-based bioluminescence imaging. <b>2011</b> , 10, 215-26	10
339	The role of ATP-binding cassette transporter A2 in childhood acute lymphoblastic leukemia multidrug resistance. <b>2014</b> , 4, 118-26	7
338	Impact of mitochondrial telomerase over-expression on drug resistance of hepatocellular carcinoma. <b>2015</b> , 7, 88-99	4
337	Errestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression. <b>2015</b> , 8, 1354-63	14
336	Two SNPs of ATP-binding cassette B1 gene on the risk and prognosis of colorectal cancer. <b>2015</b> , 8, 3083-9	9
335	Formononetin sensitizes glioma cells to doxorubicin through preventing EMT via inhibition of histone deacetylase 5. <b>2015</b> , 8, 6434-41	18
334	MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. <b>2015</b> , 5, 3015-29	24
333	Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistance. <b>2015</b> , 8, 17308-20	12
332	Elevated expression of MDR1 associated with Line-1 hypomethylation in esophageal squamous cell carcinoma. <b>2015</b> , 8, 14392-400	8
331	Multidrug resistance P-glycoprotein dampens SR-BI cholesteryl ester uptake from high density lipoproteins in human leukemia cells. <b>2016</b> , 6, 615-27	5
330	Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. <b>2016</b> , 7, 27-47	6
329	Inhibition of Akt phosphorylation attenuates resistance to TNF- $\alpha$ cytotoxic effects in MCF-7 cells, but not in their doxorubicin resistant derivatives. <b>2016</b> , 19, 1363-1367	1
328	Scrophularia Atropatana Extract Reverses TP53 Gene Promoter Hypermethylation and Decreases Survivin Antiapoptotic Gene Expression in Breast Cancer Cells. <b>2018</b> , 19, 2599-2605	3
327	Babaodan inhibits cell growth by inducing autophagy through the PI3K/AKT/mTOR pathway and enhances antitumor effects of cisplatin in NSCLC cells. <b>2019</b> , 11, 5272-5283	3
326	Overexpression of Rad51 predicts poor prognosis and silencing of Rad51 increases chemo-sensitivity to doxorubicin in neuroblastoma. <b>2019</b> , 11, 5788-5799	3
325	Pattern of Transporter Gene Expression in Pediatric Patients with Relapsed Acute Lymphoblastic Leukemia. <b>2019</b> , 8, 184-193	

- 324 MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. **2020**, 10, 164-178 4
- 323 KD025, an anti-adipocyte differentiation drug, enhances the efficacy of conventional chemotherapeutic drugs in ABCG2-overexpressing leukemia cells. **2020**, 20, 309 1
- 322 KCNN4 induces multiple chemoresistance in breast cancer by regulating BCL2A1. **2020**, 10, 3302-3315 2
- 321 Effect of Menadione and Combination of Gemcitabine and Cisplatin on Cancer Stem Cells in Human Non-small Cell Lung Cancer (NSCLC) Cell Line A549. **2021**, 20, 105-117
- 320 AML-derived Extracellular Vesicles Confer Chemoresistance to Leukemic Myeloblast Cells by Promoting Drug Export Genes Expression and ROS Inhibition. **2021**, 20, 384-397 1
- 319 Long-term glucocorticoid treatment induces glucocorticoid resistance in canine mast cell tumors. **2021**, 85, 302-308
- 318 Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein. **2021**, 175, 105975 3
- 317 A genetically encoded fluorescent biosensor for monitoring ATP in living cells with heterobifunctional aptamers. **2021**, 198, 113827 3
- 316 Porous FeO@COF-Immobilized gold nanoparticles with excellent catalytic performance for sensitive electrochemical detection of ATP. **2022**, 197, 113758 10
- 315 Ad-Aoptin-hTERTp-E1a Regulates Autophagy Through the AMPK-mTOR-eIF4F Signaling Axis to Reduce Drug Resistance of MCF-7/ADR Cells. **2021**, 8, 763500 0
- 314 Exploring silver nanoparticles for cancer therapy and diagnosis.. **2021**, 210, 112254 4
- 313 A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo. **2021**, 22, 0
- 312 Heterostructures Made of Upconversion Nanoparticles and Metal-Organic Frameworks for Biomedical Applications. **2021**, e2103911 10
- 311 Current developments in modelling the tumour microenvironment in vitro: Incorporation of biochemical and physical gradients. **2021**, 3, 100012 1
- 310 Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer. **2021**, 12, 759146 0
- 309 Impact of Dietary Interventions on Cancer Stem Cells. **2021**, 89-97
- 308 The Intricacy of ROS in Cancer Therapy Resistance. **2021**, 1-22
- 307 Potentiating VβVβ T cell proliferation and assessing their cytotoxicity towards adherent cancer cells at the single cell level.. **2022**, 0

306	Multidrug resistance crisis during COVID-19 pandemic: Role of anti-microbial peptides as next-generation therapeutics.. <b>2021</b> , 211, 112303	2
305	EGFR-targeted photosensitizer for enhanced photodynamic therapy and imaging therapeutic effect by monitoring GSH decline. <b>2022</b> , 355, 131275	1
304	KD025, an anti-adipocyte differentiation drug, enhances the efficacy of conventional chemotherapeutic drugs in ABCG2-overexpressing leukemia cells. <b>2020</b> , 20, 1-1	2
303	Metal-Phenolic Networks-Encapsulated Cascade Amplification Delivery Nanoparticles Overcoming Cancer Drug Resistance Via Combined Starvation/Chemodynamic/Chemo Therapy.	
302	Emerging Significance of Ginsenosides as Potentially Reversal Agents of Chemoresistance in Cancer Therapy.. <b>2021</b> , 12, 720474	1
301	Interactions of Environmental Chemicals and Natural Products With ABC and SLC Transporters in the Digestive System of Aquatic Organisms.. <b>2021</b> , 12, 767766	
300	Exosomal Long Non-Coding RNA ANCR Mediates Drug Resistance in Osteosarcoma.. <b>2021</b> , 11, 735254	0
299	Systemic Mobilization of Breast Cancer Resistance Protein in Response to Oncogenic Stress.. <b>2022</b> , 14,	0
298	Human skin-resident host T cells can persist long term after allogeneic stem cell transplantation and maintain recirculation potential.. <b>2022</b> , 7, eabe2634	4
297	SUMOylation of METTL3 facilitates CRC progression by promoting circ_0000677 to regulate ABCC1 in an m6A-dependent manner.. <b>2022</b> ,	1
296	Nanomedicine-enabled chemotherapy-based synergetic cancer treatments.. <b>2022</b> , 20, 4	5
295	Interaction of A adenosine receptor ligands with the human multidrug transporter ABCG2.. <b>2022</b> , 231, 114103	0
294	S-20, a steroidal saponin from the berries of black nightshade, exerts anti-multidrug resistance activity in K562/ADR cells through autophagic cell death and ERK activation.. <b>2022</b> ,	0
293	Targeted disruption of mitochondria potently reverses multidrug resistance in cancer therapy.. <b>2022</b> ,	1
292	Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies.. <b>2022</b> , 27,	22
291	Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.. <b>2022</b> , 61, 100805	4
290	B-nor-methylene Colchicinoid PT-100 Selectively Induces Apoptosis in Multidrug-Resistant Human Cancer Cells via an Intrinsic Pathway in a Caspase-Independent Manner.. <b>2022</b> , 7, 2591-2603	2
289	Tumor-Acidity and Bioorthogonal Chemistry-Mediated On-Site Size Transformation Clustered Nanosystem to Overcome Hypoxic Resistance and Enhance Chemoimmunotherapy.. <b>2022</b> ,	11

288	The Intricacy of ROS in Cancer Therapy Resistance. <b>2022</b> , 1217-1238	
287	Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors.. <b>2022</b> , 14,	0
286	Research advances in the role and pharmaceuticals of ATP-binding cassette transporters in autoimmune diseases.. <b>2022</b> , 1	0
285	Molecular mechanism of therapeutic approaches for human gastric cancer stem cells.. <b>2022</b> , 14, 76-91	2
284	Salidroside Promotes Sensitization to Doxorubicin in Human Cancer Cells by Affecting the PI3K/Akt/HIF Signal Pathway and Inhibiting the Expression of Tumor-Resistance-Related Proteins.. <b>2022</b> ,	0
283	Targeted Self-Emulsifying Drug Delivery Systems to Restore Docetaxel Sensitivity in Resistant Tumors.. <b>2022</b> , 14,	1
282	Synthesis of Multifunctional Organic Nanoparticles Combining Photodynamic Therapy and Chemotherapeutic Drug Release. <b>2022</b> , 30, 61-69	2
281	Dependence of ABCB1 transporter expression and function on distinct sphingolipids generated by ceramide synthases-2 and -6 in chemoresistant renal cancer.. <b>2021</b> , 101492	1
280	Closed loop fractional order drug delivery control scheme for chemotherapy. <b>2022</b> , 6, 100097	0
279	Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization.. <b>2022</b> , 530, 45-45	6
278	Advances in smart mesoporous carbon nanoplatfoms for photothermal-enhanced synergistic cancer therapy. <b>2022</b> , 435, 134886	9
277	DOT1L is a novel cancer stem cell target for triple negative breast cancer.. <b>2022</b> ,	4
276	Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.. <b>2022</b> , 23,	0
275	: phytochemistry and pharmacological potential of a gifted species.. <b>2022</b> , 1-30	0
274	Anticancer drug resistance: An update and perspective.. <b>2021</b> , 100796	17
273	Emerging Nano-Based Strategies Against Drug Resistance in Tumor Chemotherapy.. <b>2021</b> , 9, 798882	4
272	Recent advances of SIRT1 and implications in chemotherapeutics resistance in cancer. <b>2021</b> , 11, 5233-5248	1
271	The Effects of Drugs of Abuse on ABC Transporters. <b>2022</b> , 1-26	



- 270 Stimuli-responsive cyclodextrin-based supramolecular assemblies as drug carriers.. **2022**, 4
- 269 Nanoparticles in dentistry. **2022**, 335-358
- 268 An injectable thermosensitive hydrogel loaded with a theranostic nanoprobe for synergistic chemo-photothermal therapy for multidrug-resistant hepatocellular carcinoma.. **2022**, 0
- 267 Lemon-Derived Extracellular Vesicles Nanodrugs Enable to Efficiently Overcome Cancer Multidrug Resistance by Endocytosis-Triggered Energy Dissipation and Energy Production Reduction.. **2022**, e2105274 9
- 266 Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes.. **2022**, 14, 729-738
- 265 Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4 T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.. **2022**, 13, 796349 1
- 264 Gold Nanorods for Doxorubicin Delivery: Numerical Analysis of Electric Field Enhancement, Optical Properties and Drug Loading/Releasing Efficiency.. **2022**, 15, 2
- 263 Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells.. **2022**, 13, 843829 1
- 262 The Roles of microRNAs in Cancer Multidrug Resistance.. **2022**, 14, 1
- 261 Development and molecular characterization of doxorubicin-resistant canine mammary gland tumour cells. **2022**, 50, 125-145
- 260 Double-acting anticancer drugs to overcome the acquired resistance of malignant cells to chemotherapy. **2022**, 64-73
- 259 An engineered abcb4 expression model reveals the central role of NF- $\kappa$ B in the regulation of drug resistance in zebrafish.. **2022**, 1
- 258 Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells i, , and .. **2022**, 24, 636-649 0
- 257 Chemotherapy as a regulator of extracellular matrix-cell communication: implications in therapy resistance.. **2022**, 3
- 256 Utilization of Photoaffinity Labeling to Investigate Binding of Microtubule Stabilizing Agents to P-Glycoprotein and  $\beta$ Tubulin.. **2022**,
- 255 Liposome-Based Nanoencapsulation of a Mitochondria-Targeting Photosensitizer for Efficient Photodynamic Therapy.. **2022**, 1
- 254 Discovery of Proteins Responsible for Resistance to Three Chemotherapy Drugs in Breast Cancer Cells Using Proteomics and Bioinformatics Analysis.. **2022**, 27, 0
- 253 Blockade of integrin signaling reduces chemotherapy-induced premature senescence in collagen cultured bladder cancer cells. 0

252	Putative probiotics decrease cell viability and enhance chemotherapy effectiveness in human cancer cells: role of butyrate and secreted proteins.. <b>2022</b> , 260, 127012	1
251	Cobalt (III) complex exerts anti-cancer effects on T cell lymphoma through induction of cell cycle arrest and promotion of apoptosis.. <b>2022</b> , 1	0
250	Construction of Intelligent Responsive Drug Delivery System and Multi-Mode Imaging Based on Gold Nanodots.. <b>2022</b> , e2200034	0
249	Conquering multidrug resistant lung cancer by upconversion nanoparticles-mediated photodynamic therapy and gene silencing.	
248	Enzyme-Instructed Self-Assembly of Peptides: From Concept to Representative Applications.. <b>2022</b> ,	0
247	Bacteria-Mediated Intracellular Click Reaction for Drug Enrichment and Selective Apoptosis of Drug-Resistant Tumor Cells.. <b>2022</b> ,	1
246	Phytol and Heptacosane Are Possible Tools to Overcome Multidrug Resistance in an In Vitro Model of Acute Myeloid Leukemia.. <b>2022</b> , 15,	1
245	LncRNA SNHG11 enhances bevacizumab resistance in colorectal cancer by mediating miR-1207-5p/ABCC1 axis.. <b>2022</b> ,	3
244	Xanthohumol: An underestimated, while potent and promising chemotherapeutic agent in cancer treatment.. <b>2022</b> ,	4
243	Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. <b>2022</b> ,	1
242	Applications of Nanotechnology-Based Approaches to Overcome Multi-Drug Resistance in Cancer.. <b>2022</b> ,	0
241	Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.. <b>2022</b> , 1-14	0
240	Co-administration of tariquidar using functionalized nanostructured lipid carriers overcomes resistance to docetaxel in multidrug resistant MCF7/ADR cells. <b>2022</b> , 103323	1
239	Metal-phenolic networks-encapsulated cascade amplification delivery nanoparticles overcoming cancer drug resistance via combined starvation/chemodynamic/chemo therapy. <b>2022</b> , 442, 136221	1
238	Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma.. <b>2021</b> , 13,	1
237	Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter.. <b>2021</b> , 11, 24150	1
236	The Role of Chloride Channels in the Multidrug Resistance.. <b>2021</b> , 12,	0
235	Bioinformatic Prediction of Novel Signaling Pathways of Apoptosis-inducing Factor, Mitochondrion-associated 3 (AIFM3) and Their Roles in Metastasis of Cholangiocarcinoma Cells.. <b>2022</b> , 19, 35-49	0

- 234 Adaptor SH3BGRL drives autophagy-mediated chemoresistance through promoting PIK3C3 translation and ATG12 stability in breast cancers. **2021**, 1-19 2
- 233 Overcoming prostate cancer drug resistance with a novel organosilicon small molecule. **2021**, 23, 1261-1274 0
- 232 A double-decker cage for allosteric encapsulation of ATP.. **2022**,
- 231 Overcoming multidrug resistance (MDR): design, biological evaluation and molecular modelling studies of 2,4-substituted quinazoline derivatives.. **2022**, 0
- 230 Ferroptosis Biology and Implication in Cancers.. **2022**, 9, 892957 1
- 229 Cervical cancer therapies: current challenges and future perspectives.. **2022**, 200238 4
- 228 Identification and Validation of ATP-Binding Cassette Transporters Involved in the Detoxification of Abamectin in Rice Stem Borer, .. **2022**, 2
- 227 AIEgens Based on 9,10-Distyrylanthracene (DSA). **2022**, 23-52 0
- 226 Cancer Pharmacogenomics. **2005**, 339-357
- 225 Data\_Sheet\_1.pdf. **2020**,
- 224 Data\_Sheet\_1.docx. **2021**,
- 223 Presentation\_1.pptx. **2020**,
- 222 Image\_1.TIF. **2019**,
- 221 Image\_1.tif. **2020**,
- 220 Image\_2.tif. **2020**,
- 219 Image\_1.TIFF. **2018**,
- 218 Table\_1.XLSX. **2018**,
- 217 Table\_2.xlsx. **2018**,

216	DataSheet_1.pdf. <b>2020,</b>	
215	Data_Sheet_1.ZIP. <b>2018,</b>	
214	Image_1.JPEG. <b>2018,</b>	
213	Image_2.JPEG. <b>2018,</b>	
212	Image_3.JPEG. <b>2018,</b>	
211	Image_4.JPEG. <b>2018,</b>	
210	Tailored protein-conjugated DNA nanoplatform for synergistic cancer therapy.. <b>2022,</b>	1
209	Folic Acid-Functionalized Carbon Dot-Enabled Starvation Therapy in Synergism with Paclitaxel against Breast Cancer.. <b>2022,</b>	0
208	Recent patents on plant derived nanoparticles and their potential application towards various cancer therapeutics.. <b>2022,</b>	
207	anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting.. <b>2021,</b> 24, 1515-1522	1
206	Cancer drug resistance related microRNAs: recent advances in detection methods.	0
205	Supramolecular Assembly Hydrogel for Programmable Delivery of Therapeutic Agents to Combat Multidrug- Resistant Cancer.	
204	The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer.. <b>2022,</b> 14,	0
203	The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment.. <b>2022,</b> 11,	2
202	Current trends of targeted therapy for oral squamous cell carcinoma.. <b>2022,</b>	2
201	ST08 Altered NF- $\kappa$ B Pathway in Breast Cancer Cells In Vitro as Revealed by miRNA-mRNA Analysis and Enhanced the Effect of Cisplatin on Tumour Reduction in EAC Mouse Model. <b>2022,</b> 12,	0
200	A DFT investigation on theranostic potential of alkaline earth metal doped phosphorenes for ifosfamide anti-cancer drug. <b>2022,</b> 153618	0
199	Gambogic Acid and Piperine Synergistically Induce Apoptosis in Human Cholangiocarcinoma Cell via Caspase and Mitochondria-Mediated Pathway. <b>2022,</b> 2022, 1-12	

198	Rationally Screened and Designed ABCG2-Binding Aptamers for Targeting Cancer Stem Cells and Reversing Multidrug Resistance.. <b>2022,</b>	1
197	The gut efflux pump MRP-1 exports oxidized glutathione as a danger signal that stimulates behavioral immunity and aversive learning.. <b>2022, 5, 422</b>	
196	P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells.. <b>2022, 14,</b>	2
195	Ordered micropattern arrays fabricated by lung-derived dECM hydrogels for chemotherapeutic drug screening. <b>2022, 15, 100274</b>	1
194	Oxidative stress-amplified nanomedicine for intensified ferroptosis-apoptosis combined tumor therapy.. <b>2022, 347, 104-114</b>	1
193	An ester derivative of tenacigenin B from Marsdenia tenacissima (Roxb.) Wight et Arn reversed paclitaxel-induced MDR in vitro and in vivo by inhibiting both P-gp and MRP2.. <b>2022, 294, 115353</b>	0
192	Photoinduced free radical-releasing systems and their anticancer properties.. <b>2022,</b>	0
191	Dose-response assessment of cerebral P-glycoprotein inhibition in vivo with [F]MC225 and PET.. <b>2022,</b>	0
190	Molecular-engineered highly photosensitive triarylphosphine oxide compounds for apoptosis imaging and selectively inducing apoptosis of tumor cells by photodynamic therapy.	
189	GSTs, MRP and Apoptototic Markers in DLD-1 Human Colon Cancer Cell Line Before and After 5-FU Treatment. <b>2022, 6, 25-40</b>	
188	Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment. <b>2022, 151, 113116</b>	1
187	Cancer Stem Cells: The Greatest Menace in Conquering Cancer Management.	
186	Mitochondrial Targeting Peptide-based Nanodelivery for Cancer Treatment. <b>2022, 23,</b>	
185	The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. <b>2022, 104787</b>	4
184	StructureActivity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer.	3
183	Genetically encoded fluorescent sensing probes. <b>2022,</b>	
182	Nkx2.8 promotes chemosensitivity in bladder urothelial carcinoma via transcriptional repression of MDR1. <b>2022, 13,</b>	
181	The Human ATP-Binding Cassette (ABC) Transporter Superfamily.	2

180	A new twist in ABC transporter mediated multidrug resistance Pdr5 is a drug/proton co-transporter. <b>2022</b> , 167669	1
179	Introduction to MicroRNAs. <b>2022</b> , 1-12	
178	Role of MicroRNAs in Cancer Drug Resistance. <b>2022</b> , 133-148	0
177	The Role of ABC Transporters in the Actions of Drugs of Abuse. <b>2022</b> , 1-18	
176	A red-light activatable and mitochondrion-targeting PtIV complex to overcome drug resistance.	0
175	On-target inhibition of <i>Cryptosporidium parvum</i> by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify on/off-target rates.	
174	In silico screening of c-Met tyrosine kinase inhibitors targeting nucleotide and drug-substrate binding sites of ABCB1 as potential MDR reversal agents. 1-13	0
173	Self-cascade nanohybrids boost cell ferroptosis stress for tumor radiosensitization therapy. <b>2022</b> , 101558	1
172	High drug loading polymer micelle@ZIF-8 hybrid core-shell nanoparticles through donor-acceptor coordination interaction for pH/H <sub>2</sub> O <sub>2</sub> -responsive drug release. <b>2022</b> , 16,	0
171	Association Between microRNAs and Chemoresistance in Pancreatic Cancer; Current Knowledge, New Insights, and Forthcoming Perspectives. <b>2022</b> , 153982	
170	Loading Drugs in Natural Phospholipid Bilayers of Cell Membrane Shells to Construct Biomimetic Nanocomposites for Enhanced Tumor Therapy.	2
169	Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. 12,	5
168	Ferrous ions doped calcium carbonate nanoparticles potentiate chemotherapy by inducing ferroptosis. <b>2022</b> , 348, 346-356	2
167	A011, a novel small-molecule ligand of $\mu$ receptor, potently suppresses breast cancer progression via endoplasmic reticulum stress and autophagy. <b>2022</b> , 152, 113232	0
166	Recent progress in two-dimensional nanomaterials for cancer theranostics. <b>2022</b> , 469, 214654	2
165	Nitric Oxide Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells by Inhibiting the Drug Efflux. <b>2005</b> , 65, 516-525	139
164	Cancer Prevention Strategies That Address the Evolutionary Dynamics of Neoplastic Cells: Simulating Benign Cell Boosters and Selection for Chemosensitivity. <b>2004</b> , 13, 1375-1384	32
163	Influence of <i>Padina gymnospora</i> on Apoptotic Proteins of Oral Cancer Cells—Proteome-Wide Analysis.	0

162	Spatio-Temporal Controlled Gene-Chemo Drug Delivery in a DNA Nanocomplex to Overcome Multidrug Resistance of Cancer Cells.	1
161	Immunohistochemical expression of PD-L1 and MDR1 in breast tumors: association with clinico-pathological parameters and treatment outcome.	0
160	Co-delivery of Cisplatin and Chlorin e6 by Poly(phosphotyrosine) for Synergistic Chemotherapy and Photodynamic Therapy.	0
159	Long non-coding RNA mediated drug resistance in breast cancer. <b>2022</b> , 63, 100851	2
158	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. <b>2022</b> , 15,	0
157	Mannosylated poly(acrylic acid)-coated mesoporous silica nanoparticles for anticancer therapy. <b>2022</b> , 349, 241-253	2
156	RLIP76 Transports Vinorelbine and Mediates Drug Resistance in Non-small Cell Lung Cancer. <b>2005</b> , 65, 991-998	29
155	Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. <b>2004</b> , 3, 633-640	31
154	Neuronal-associated microtubule proteins class III $\beta$ -tubulin and MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs. <b>2004</b> , 3, 1137-1146	8
153	Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in $\beta$ -tubulin. <b>2004</b> , 3, 1319-1327	8
152	Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. <b>2004</b> , 3, 1577-1584	14
151	Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma. <b>2022</b> , 14, 3705	2
150	Thiosemicarbazones Can Act Synergistically with Anthracyclines to Downregulate CHEK1 Expression and Induce DNA Damage in Cell Lines Derived from Pediatric Solid Tumors. <b>2022</b> , 23, 8549	0
149	Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival. 13,	0
148	Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies. 13,	1
147	Small molecule photocatalysis enables drug target identification via energy transfer. <b>2022</b> , 119,	1
146	Roles of ABCA1 in cancer (Review). <b>2022</b> , 24,	0
145	Different costs of therapeutic resistance in cancer: Short- and long-term impact of population heterogeneity. <b>2022</b> , 108891	

144	FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3.	1
143	Mining the multifunction of mucosal-associated invariant T cells in hematological malignancies and transplantation immunity: A promising hexagon soldier in immunomodulatory. 13,	
142	Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer. <b>2022</b> , 41,	1
141	Disulfiram: A Food and Drug Administration-approved multifunctional role in synergistically drug delivery systems for tumor treatment. <b>2022</b> , 122130	2
140	LncRNA RP11-59J16.2 aggravates apoptosis and increases tau phosphorylation by targeting MCM2 in AD. 13,	1
139	P-Glycoprotein Activity at Diagnosis Does Not Predict Therapy Outcome and Survival in Canine B-Cell Lymphoma. <b>2022</b> , 14, 3919	
138	Folic acid-decorated PEGylated magnetite nanoparticles as efficient drug carriers to tumor cells overexpressing folic acid receptor. <b>2022</b> , 625, 122064	1
137	Intelligent poly(L-histidine)-based nanovehicles for controlled drug delivery. <b>2022</b> , 349, 963-982	3
136	Deciphering the enigmatic crosstalk between prostate cancer and Alzheimer's disease: A current update on molecular mechanisms and combination therapy. <b>2022</b> , 1868, 166524	
135	Development of fullerene nanospherical miRNA and application in overcoming resistant breast cancer. <b>2022</b> , 26, 101019	
134	Cyclodextrin-based supramolecular nanoparticles break the redox balance in chemodynamic therapy-enhanced chemotherapy. <b>2022</b> , 628, 864-876	
133	Erythrocyte membrane camouflaged siRNA/chemodrugs nanoassemblies for cancer combination therapy.	0
132	An Examination of Mechanisms by which Synonymous Mutations may Alter Protein Levels, Structure and Functions. <b>2022</b> , 99-132	0
131	ABCG2/BCRP transport mechanism revealed through kinetically excited targeted molecular dynamics simulations. <b>2022</b> , 20, 4195-4205	0
130	A multifunctional theranostics nanosystem featuring self-assembly of alcohol-abuse drug and photosensitizers for synergistic cancer therapy.	0
129	A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence. <b>2022</b> , 14, 4128	1
128	Functional Phosphoproteomics in Cancer Chemoresistance Using CRISPR-Mediated Base Editors. 2200717	1
127	Nanogels as target drug delivery systems in cancer therapy: A review of the last decade. 13,	1



- 126 Nuclear morphology and functional characteristics that enable survival of cells in the polyan euploid cancer cell state following cytotoxic chemotherapy. ○
- 125 P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure. **2022**, 15, 1124 ○
- 124 Molecular design, synthesis and biological evaluation of novel 1,2,5-trisubstituted benzimidazole derivatives as cytotoxic agents endowed with ABCB1 inhibitory action to overcome multidrug resistance in cancer cells. **2022**, 37, 2710-2724 ○
- 123 Alginate-Based Nanosystems for Therapeutic Applications. **2022**, 2022, 1-11 ○
- 122 Enzymatic Nanosphere-to-Nanofiber Transition and Autophagy Inducer Release Promote Tumor Chemotherapy. 2201916 ○
- 121 Inorganic nanoparticle-based advanced cancer therapies: Promising combination strategies. **2022**, 103386 ○
- 120 Colistin Crosslinked Gemcitabine Micelles to Eliminate Tumor Drug Resistance Caused by Intratumoral Microorganisms. ○
- 119 Inhibition of insulin-like growth factor 2 mRNA -binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics. ○
- 118 TrkC-mediated inhibition of DJ-1 degradation is essential for direct regulation of pathogenesis of hepatocellular carcinoma. **2022**, 13, ○
- 117 The Role of ABC Transporters in the Actions of Drugs of Abuse. **2022**, 635-652 ○
- 116 Small molecule induces mitochondrial impairment in colon cancer cells. ○
- 115 The Effects of Drugs of Abuse on ABC Transporters. **2022**, 609-634 ○
- 114 Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance. **2022**, 11, 3305 ○
- 113 Natural killer cell-mimicking nanomaterial for overcoming the multidrug resistance of tumor via cascade catalysis. ○
- 112 PRMT7 Inhibitor SGC8158 Enhances Doxorubicin-Induced DNA Damage and Its Cytotoxicity. **2022**, 23, 12323 ○
- 111 Modified Aerotaxy for the Plug-in Manufacture of Cell-Penetrating Fenton Nanoagents for Reinforcing Chemodynamic Cancer Therapy. 2
- 110 Genomic Data Mining Reveals Abundant Uncharacterized Transporters in *Coccidioides immitis* and *Coccidioides posadasii*. **2022**, 8, 1064 ○
- 109 Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)2, in Reversing Multidrug Resistance Mediated by Breast Cancer Resistance Protein (BCRP/ABCG2). **2022**, 23, 13261 ○

108	Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings. <b>2022</b> , 23, 12893	3
107	USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1. <b>2022</b> , 11, 3294	0
106	Potential of zinc carbide 2D monolayers as a new drug delivery system for nitrosourea (NU) anti-cancer drug. <b>2022</b> , 113927	0
105	New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells.	1
104	Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review. <b>2022</b> , 27, 6608	0
103	P-glycoprotein and cancer: what do we currently know?. <b>2022</b> , 8, e11171	0
102	Dual tumor- and subcellular-targeted photodynamic therapy using glucose-functionalized MoS <sub>2</sub> nanoflakes for multidrug-resistant tumor ablation. <b>2022</b> , 290, 121844	1
101	Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways. <b>2022</b> , 86, 1186-1202	1
100	Redox-responsive waterborne polyurethane nanocarriers for targeted doxorubicin delivery. <b>2022</b> , 628, 122275	0
99	Recent progress in nitric oxide-generating nanomedicine for cancer therapy. <b>2022</b> , 352, 179-198	1
98	Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy. <b>2022</b> , 291, 121880	0
97	Synergistic effect of anticancer drug resistance and Wnt3a on primary ciliogenesis in A549 cell-derived anticancer drug-resistant subcell lines. <b>2022</b> , 635, 1-11	0
96	STRATEGIE WALKI ZE ZJAWISKIEM OPORNOŚCI WIELOLEKOWEJ NOWOTWORŃ. <b>2012</b> , 10, 1-8	0
95	Natural quinazolinones: From a treasure house to promising anticancer leads. <b>2023</b> , 245, 114915	0
94	Wnt/ $\beta$ Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma. <b>2022</b> , 14, 5468	0
93	The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance. <b>2022</b> , 23, 13577	0
92	Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin. <b>2022</b> , 62,	0
91	Enhanced cytotoxic effect of doxorubicin conjugated gold nanoparticles on breast cancer model. <b>2022</b> , 16,	1

- 90 Epigenetic Regulation of Drug Transporters in Cancer. **2022**, 573-603 ○
- 89 CCT251545 enhances drug delivery and potentiates chemotherapy in multidrug-resistant cancers by Rac1-mediated macropinocytosis. **2023**, 66, 100906 ○
- 88 CRISPR/Cas9 targeting liposomes knocked down multidrug resistance proteins in brain endothelial cells as a model to predict potential pharmacoresistance. **2023**, 222, 113103 ○
- 87 Nanoelectropulse delivery for cell membrane perturbation and oxidation in human colon adenocarcinoma cells with drug resistance. **2023**, 150, 108356 ○
- 86 Polymeric Nanoparticles to Target Glioblastoma Tumors. **2022**, 329-349 ○
- 85 Blockade of c-Met-Mediated Signaling Pathways by E7050 Suppresses Growth and Promotes Apoptosis in Multidrug-Resistant Human Uterine Sarcoma Cells. **2022**, 23, 14884 ○
- 84 Bioavailability of Schisandrin B and its effect on 5-Fluorouracil metabolism in a xenograft mouse model of colorectal cancer. ○
- 83 Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma. **2022**, 23, 14474 ○
- 82 Does the primary treatment sequence affect post-relapse survival in recurrent epithelial ovarian cancer? A real-world multicentre retrospective study. **2022**, 129, 70-78 ○
- 81 Screening of Endophytes for Anticancer Compounds. **2023**, 255-268 ○
- 80 Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide. **2022**, 14, 5689 ○
- 79 Metal-organic framework for biomimetic nitric oxide generation and anticancer drug delivery. **2022**, 213268 1
- 78 Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells. **2022**, 121320 ○
- 77 Nanoliposomes for doxorubicin delivery: Reversing drug resistance, stimuli-responsive carriers and clinical translation. **2022**, 104112 1
- 76 Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain. **2022**, 14, 6054 1
- 75 Establishment and Characterization of Single and Triple-Agent Resistant Osteosarcoma Cell Lines. 2200194 ○
- 74 Structural insights into human ABCC4 mediated transport of platelet agonist and inhibitor. ○
- 73 Integration of Manganese Dioxide-Based Nanomaterials for Biomedical Applications. 2200093 ○

- 72 Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel. **2022**, 23, 15299 ○
- 71 Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets. **2022**, 14, 6246 ○
- 70 A pilot study of chemotherapy combinations in rats: Focus on mammary cancer treatment in female dogs. **2023**, ○
- 69 Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to imatinib mesylate, in Iranian chronic myeloid leukemia patients. **2023**, 24, ○
- 68 Peptide Drug Conjugates and Their Role in Cancer Therapy. **2023**, 24, 829 2
- 67 The More the Better Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors. **2023**, 15, 241 ○
- 66 Organoids of patient-derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogs. ○
- 65 Innovative nanotheranostics: Smart nanoparticles based approach to overcome breast cancer stem cells mediated chemo- and radioresistances. 1
- 64 Green Tea Catechin Potentiating Doxorubicine Effects against BE(2)C Neuroblastoma Cells In Vitro. **2023**, In Press, ○
- 63 Analysis of Changes in the Expression of Selected Genes from the ABC Family in Patients with Triple-Negative Breast Cancer. **2023**, 24, 1257 ○
- 62 Fluorescent inosine analogues: Synthesis, cytotoxicity activity and self-assembly nanoparticle for live cell image. **2023**, 131, 133230 ○
- 61 Polymorphic renal transporters and cisplatin toxicity in urinary bladder cancer patients: current perspectives and future directions. **2023**, 40, ○
- 60 Herbal Medicine: Prejudice to Realm of Reality Against TNBC. **2023**, 123-144 ○
- 59 The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells. **2023**, 23, ○
- 58 Supramolecular hydrogel for programmable delivery of therapeutics to cancer multidrug resistance. **2023**, 146, 213282 ○
- 57 Functionalized liposomes for targeted breast cancer drug delivery. **2023**, 24, 401-437 1
- 56 CANCER STEM CELLS: THE GREATEST MENACE IN CONQUERING CANCER MANAGEMENT. 954-975 ○
- 55 Investigating Key Targets of Dajianzhong Decoction for Treating Crohn Disease Using Weighted Gene Co-Expression Network. **2023**, 11, 112 ○

- 54 Metal Complexes of a 5-Nitro-8-Hydroxyquinoline-Proline Hybrid with Enhanced Water Solubility Targeting Multidrug Resistant Cancer Cells. **2023**, 24, 593 ○
- 53 In Silico Identification and In Vitro Evaluation of New ABCG2 Transporter Inhibitors as Potential Anticancer Agents. **2023**, 24, 725 ○
- 52 Nanoenabled Tumor Energy Metabolism Disorder via Sonodynamic Therapy for Multidrug Resistance Reversal and Metastasis Inhibition. **2023**, 15, 309-326 ○
- 51 The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in Cancer. **2023**, 22, 153303382311552 ○
- 50 Correlation between the Warburg effect and progression of triple-negative breast cancer. 12, ○
- 49 Smart Metabolism Nanovalve Reprograms Cancer Energy Homeostasis for Maximizing Photometabolism Therapy. **2023**, 15, 6456-6472 ○
- 48 Nanomedicine-based multimodal therapies: Recent progress and perspectives in colon cancer. 29, 670-681 ○
- 47 Porous Carbon Materials Enhanced the Therapeutic Efficacy of Anticancer Drugs. **2023**, 939-954 ○
- 46 Dual regulation of Akt and glutathione caused by isovalantolactone effectively triggers human ovarian cancer cell apoptosis. **2023**, ○
- 45 On-target inhibition of *Cryptosporidium parvum* by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target. **2023**, 17, e0011217 ○
- 44 ATP-binding cassette efflux transporters and MDR in cancer. **2023**, 28, 103537 1
- 43 Application of zinc carbide nanosheet as a promising material for 5-fluorouracil drug delivery. **2023**, 152, 110630 ○
- 42 Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. **2023**, 162, 114643 ○
- 41 Effects of antimony exposure on DNA damage and genome-wide variation in zebrafish (*Danio rerio*) liver. **2023**, 259, 106524 ○
- 40 Cancer stem cell-derived exosome-induced metastatic cancer: An orchestra within the tumor microenvironment. **2023**, 212, 1-11 ○
- 39 Ratiometric fluorescence biosensing of silver NanoCluster Beacons for ATP detection based on ligation-triggered rolling cycle amplification. **2023**, 190, 108663 ○
- 38 Remodeling of the Gut Microbiota in Colorectal Cancer and its Association with Obesity. **2023**, 29, 256-271 ○
- 37 Nanomedicine based strategies for oligonucleotide transversion across the blood-brain barrier. **2023**, 354, 554-571 1

- 36 Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis. **2023**, 24, 2242 ○
- 35 Effect of Cellular and Microenvironmental Multidrug Resistance on Tumor-Targeted Drug Delivery in Triple-Negative Breast cancer. **2023**, 354, 784-793 ○
- 34 Autolysosomal activation combined with lysosomal destabilization efficiently targets myeloid leukemia cells for cell death. 13, ○
- 33 Association between adjuvant therapy and survival in colorectal cancer patients according to metabolic Warburg-subtypes. ○
- 32 Hypoxia-Driven TGF $\beta$  Modulation of Side Population Cells in Breast Cancer: The Potential Role of ER $\beta$ . **2023**, 15, 1108 ○
- 31 Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines. **2023**, 24, 3553 ○
- 30 Imidazo[1,2-a]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance. **2023**, 66, 2804-2831 ○
- 29 Targeted degradation of ABCG2 for reversing multidrug resistance by hypervalent bispecific gold nanoparticle-anchored aptamer chimeras. **2023**, 59, 3118-3121 ○
- 28 Natural Inhibitors of P-glycoprotein in Acute Myeloid Leukemia. **2023**, 24, 4140 ○
- 27 Breast cancer patient-derived explant cultures recapitulate in vivo drug responses. 13, ○
- 26 What Is the Significance of Lysosomal-Mediated Resistance to Imatinib?. **2023**, 12, 709 ○
- 25 Induction of Drug-Resistance and Production of a Culture Medium Able to Induce Drug-Resistance in Vinblastine Untreated Murine Myeloma Cells. **2023**, 28, 2051 ○
- 24 The Multidrug Resistance Transporter P-glycoprotein Confers Resistance to Ferroptosis Inducers. ○
- 23 Functionalized Lipid Nanocarriers for Simultaneous Delivery of Docetaxel and Tariquidar to Chemoresistant Cancer Cells. **2023**, 16, 349 ○
- 22 Chemical Constituents of the Endophytic Fungus Pestalotiopsis microspora Derived from Artemisia argyi and their P-Glycoprotein Inhibitory Activity. ○
- 21 Total steroidal saponins from black nightshade ( *Solanum nigrum* L.) overcome tumor multidrug resistance by inducing autophagy-mediated cell death in vivo and in vitro. ○
- 20 Role of Carbon Nanostructures as Nano-Theranostics Against Breast and Brain Cancer. **2023**, 1151-1172 ○
- 19 Porous Carbon Materials and Their Applications in Biosensing, Medical Diagnostics, and Drug Delivery. **2023**, 885-906 ○

- 18 Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. 29, 1395-1426 ○
- 17 The Molecular Mechanisms of Oleanane Aldehyde-Ketone Cytotoxicity against Doxorubicin-Resistant Cancer Cells. **2023**, 12, 415 ○
- 16 Simplified Derivatives of Tetrandrine as Potent and Specific P-gp Inhibitors to Reverse Multidrug Resistance in Cancer Chemotherapy. **2023**, 66, 4086-4105 ○
- 15 Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment. 14, ○
- 14 ABC transporters linked to multiple herbicide resistance in blackgrass (*Alopecurus myosuroides*). 14, ○
- 13 Development of a Novel Tool to Demystify Drug Distribution at Tissue-Blood Barriers. ○
- 12 Inorganic nanosystems for imaging diagnostics. **2023**, 549-588 ○
- 11 Epothilones as Natural Compounds for Novel Anticancer Drugs Development. **2023**, 24, 6063 ○
- 10 2-Carboranylquinazoline: The Path to an ABCG2 Inhibitor. ○
- 9 Levistolide A and periplogenin inhibit the growth of gastric cancer cells in vitro and in vivo. **2023**, 1, 64-76 ○
- 8 Modifying superparamagnetic iron oxides nanoparticles for doxorubicin delivery carriers: a review. **2023**, 25, ○
- 7 ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines. **2023**, 12, 1056 ○
- 6 HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies. ○
- 5 Redox and pH Dual-Responsive Polypeptide Micelles for Doxorubicin Delivery with Enhanced Anticancer Efficacy. ○
- 4 Nanoparticle-Based Combination Therapy for Ovarian Cancer. Volume 18, 1965-1987 ○
- 3 Characterization of Potent ABCG2 Inhibitor Derived from Chromone: From the Mechanism of Inhibition to Human Extracellular Vesicles for Drug Delivery. **2023**, 15, 1259 ○
- 2 APC Loss Prevents Doxorubicin-Induced Cell Death by Increasing Drug Efflux and a Chemoresistant Cell Population in Breast Cancer. **2023**, 24, 7621 ○
- 1 General aspects of cancer therapy. **2023**, 1-35 ○

